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ABSTRACT		 The	goal	of	my	dissertation	was	to	compare	and	contrast	the	function	of	all	three	major	isoforms	of	Myosin	Binding	Protein-C	(MyBP-C):	slow-skeletal,	fast-skeletal,	and	cardiac	(ssMyBP-C,	fsMyBP-C,	and	cMyBP-C,	respectively),	with	a	focus	on	the	least	characterized	isoform,	fsMyBP-C.	Using	a	variety	of	ex	vivo,	in	vitro,	and	
in	silico	methods,	my	research	demonstrated	that	the	N-terminal	region	of	all	MyBP-C	isoforms	bind	to	actin	and	shift	tropomyosin,	thus	activating	the	thin	filament	during	contraction.	Furthermore,	each	isoform	differentially	activated	the	thin	filament	over	isoform-specific	ranges	of	Ca2+:	slow-skeletal	activates	at	low	Ca2+,	fast-skeletal	activates	at	higher	Ca2+,	and	cardiac	activates	over	the	full	spectrum	of	Ca2+.	I	propose	that	different	expression	of	MyBP-C	isoforms	allow	striated	muscles	to	fine	tune	its	function.	For	example,	the	cardiac	muscle	sees	the	full	range	of	Ca2+	on	a	beat-to-beat	basis,	and	therefore	cMyBP-C	needs	to	operate	over	the	full	spectrum	of	Ca2+	with	much	higher	frequency.	Conversely,	various	skeletal	muscles	have	vastly	different	roles:	the	demands	of	postural	muscles	are	different	than	that	of	phasic	muscles;	thus,	varied	expression	of	slow-skeletal	and	fast-skeletal	MyBP-C	can	ideally	regulate	the	function	of	different	muscles.		
	
		 1	
CHAPTER	ONE	INTRODUCTION	The	clinical	significance	of	understanding	the	role	of	Myosin	Binding	Protein-C	(MyBP-C)	is	clear:	mutations	in	all	three	major	isoforms	of	MyBP-C	can	cause	cardiac	and	skeletal	muscle	diseases.	Notably,	mutations	in	the	cardiac	isoform	is	one	of	the	most	common	causes	of	hypertrophic	cardiomyopathy	(HCM)	(Bonne,	Carrier,	Richard,	Hainque,	&	Schwartz,	1998;	Schlossarek,	Mearini,	&	Carrier,	2011;	van	Dijk	et	al.,	2009;	Watkins	et	al.,	1995),	with	an	estimated	60	million	people	affected	worldwide(Dhandapany	et	al.,	2009).	cMyBP-C	mutations	also	cause	dilated	cardiomyopathy	(DCM)(Ehlermann	et	al.,	2008;	Hershberger	et	al.,	2010).	In	addition,	mutations	in	the	slow-skeletal	and	fast-skeletal	isoforms	have	been	implicated	in	distal	arthrogryposis,	type	1	(DA1)(Bayram	et	al.,	2016;	Gurnett	et	al.,	2010),	distal	arthrogryposis,	type	2	(DA2)	(X.	Li	et	al.,	2015),	and		lethal	congenital	contracture	syndrome,	type	4	(LCCS4)(Markus	et	al.,	2012)	(Figure	1).				 The	timeline	of	research	into	each	of	these	isoforms	is	marked	by	the	discovery	of	links	between	the	MyBP-C	isoform	and	human	disease.	These	links	demonstrate	a	clear	and	clinically	relevant	rationale	to	investigate	its	function,	but	these	links	have	been	unearthed	over	a	period	of	over	two	decades.	Mutations	in	cMyBP-C	and	myosin	have	long	been	implicated	as	the	two	major	factors	in	the	development	of	HCM	in	patients
		
2	(Geisterfer-Lowrance	et	al.,	1990;	Watkins	et	al.,	1995),	and	has	since	spurred	increasing	interest	in	the	role	of	the	cardiac	isoform	(Harris,	Lyons,	&	Bezold,	2011;	Sadayappan	&	de	Tombe,	2012).	Within	the	past	6	years,	studies	have	implicated	the	ssMyBP-C	in	skeletal	muscle	disease,	followed	by	a	subsequent	rise	in	interest	in	the	slow-skeletal	isoform	(Ackermann	&	Kontrogianni-Konstantopoulos,	2013;	Gurnett	et	al.,	2010;	Ha	et	al.,	2013).	Most	recently,	fsMyBP-C	has	been	implicated	in	human	disease(Bayram	et	al.,	2016).	Just	like	the	renewed	interest	in	the	slow-skeletal	isoform	and	the	cardiac	isoform	before	that,	the	discovery	of	a	genetic	link	between	fsMyBP-C	and	muscle	dysfunction	in	human	patients	is	likely	to	stimulate	attention	in	the	last	of	the	three	major	MyBP-C	isoforms.		
Therefore,	I	focused	my	present	dissertation	on	the	biophysical	mechanics	of	fsMyBP-C.	While	the	emphasis	is	on	this	overlooked	isoform,	the	scope	of	my	dissertation	research	includes	the	slow-skeletal	and	cardiac	isoforms.	In	doing	so,	comparisons	can	be	made	to	existing	knowledge	of	MyBP-C,	but	more	importantly,	this	expanded	scope	allows	a	more	comprehensive	analysis	of	the	MyBP-C	as	a	whole.	Indeed,	the	research	I	have	done	has	provided	greater	insight	than	the	sum	of	its	parts	on	individual	isoforms,	and	has	led	to	both	exciting	and	novel	concepts	regarding	the	role	of	MyBP-C	in	muscle	contraction.		
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Figure	1.		MyBP-C	mutations	cause	muscle	disease.	The	clinical	significance	of	studying	 Myosin	 Binding	 Protein-C	 (MyBP-C):	 mutations	 in	 MyBP-C	 cause	hypertrophic	 cardiomyopathy	 (HCM),	 dilated	 cardiomyopathy	 (DCM),	 distal	arthrogryposis	type	1	(DA1),	distal	arthrogryposis	type	2	(DA2),	lethal	congenital	contracture	 syndrome	 type	 4	 (LCCS4).	 Furthermore,	MyBP-C	 is	 dysregulated	 in	diseases	such	as	Duchenne	muscular	dystrophy	(DMD)	and	limb-girdle	muscular	dystrophy	(LGMD).	However,	the	function	of	MyBP-C	has	yet	to	be	fully	elucidated.		
		 4	
CHAPTER	TWO	MYBP-C	AND	THE	SARCOMERE	
Introduction			 Striated	muscles	consist	of	cardiac	and	skeletal	muscles	with	vastly	different	roles	in	the	body,	but	its	molecular	mechanisms	share	some	incredible	similarities.	Striated	muscle	proteins	(myofilaments)	do	not	exist	in	isolation	and	have	evolved	into	a	highly	sophisticated	ensemble	with	many	contributing	pieces.	To	affect	contraction	at	the	whole	muscle	level,	myofilament	proteins	work	together	in	concert	with	one	another	at	the	molecular	level.	At	this	level,	the	smallest	functional	unit	is	known	as	a	sarcomere.	The	sarcomere	consists	of	thick	and	thin	filaments	that	slide	across	one	another.	This	sliding	action	pulls	the	edges	of	the	sarcomere	together	and	is	the	basis	for	contraction.	Each	thick	and	thin	filament	consists	of	its	own	subset	of	myofilaments	that	operate	via	intricate	intrafilament	and	interfilament	interactions	during	the	contraction	process.	Thus,	the	goal	of	this	chapter	is	to	introduce	the	myofilaments	as	they	come	into	play	during	striated	muscle	contraction.
5	
	
A	Brief	History			 Major	advancements	have	been	made	in	our	understanding	of	muscle	contraction	at	the	molecular	level	since	the	initial	discovery	and	isolation	of	the	first	muscle	protein,	in	1864	by	the	German	physiologist	Wilhelm	Kühne,	which	he	called	myosin	(Kühne,	1864).	Subsequent	work	by	Vladimir	Engelhardt	and	Militza	Lyubimova	in	the	late	1930s	and	1940s	demonstrated	that	myosin	had	enzymatic	activity	capable	of	hydrolyzing	ATP	(Engelhardt,	1939).	This	ATPase	activity	drove	the	interaction	of	myosin	with	the	second	major	muscle	protein,	actin	(Straub,	1943.	;	Szent-Györgyi,	1943),	discovered	by	Brunó	Straub	and	Albert	Szent-Györgyi.	Then,	in	the	1950s,	the	work	led	by	Andrew	Huxley	and	Rolf		Niedergerke,	and	Hugh	Huxley	and	Jean	Hanson	demonstrated	the	sliding	filament	theory	(A.	F.	Huxley	&	Niedergerke,	1954a;	H.	Huxley	&	Hanson,	1954;	H.	E.	Huxley,	1953),	in	which	contraction	resulted	from	the	interaction	of	myosin	and	actin	filaments.	Other	elements	of	these	myofilaments	were	discovered	around	the	same	time	or	shortly	after:	Kenneth	Bailey	and	tropomyosin	(Bailey,	1946,	1948),	Setsuro	Ebashi	and	troponin	(Ebashi	&	Endo,	1968;	Ebashi	&	Kodama,	1965),	and	Gerald	Offer	and	Roger	Starr	(Offer,	Moos,	&	Starr,	1973).	The	work	by	these	and	other	pioneers	have	laid	the	foundation	for	our	understanding	of	striated	muscle	function.		
Striated	Muscles			 Striated	muscles	consist	both	cardiac	and	skeletal	muscle,	which	composes	30%	and	38%	of	total	body	mass	in	women	and	men,	respectively	(Janssen,	Heymsfield,	Wang,	&	Ross,	2000).	Cardiac	muscles	in	the	heart	are	responsible	for	
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circulating	blood	throughout	the	body(Friedland,	2009;	Harvey,	1628),	and	are	controlled	by	the	autonomic	nervous	system(Robinson,	Epstein,	Beiser,	&	Braunwald,	1966).	The	heart	consists	of	cardiac	muscle	cells,	or	cardiomyocytes,	that	are	linked	via	intercalated	discs	in	order	to	contract	as	a	syncytium(Severs,	2000).	These	cardiomyocytes	are	usually	bi-nucleated,	and	excitation-contraction	coupling	(ECC)(Bers,	2002)	is	induced	by	a	calcium-induced	calcium	release	(CICR)(Fabiato,	1983).	Briefly,	an	electrical	system	travels	via	the	T-tubules	resulting	in	an	initial	burst	of	Ca2+	from	L-type	voltage-dependent	Ca2+-channels	known	as	dihydropyridine	receptors	(DHPR),	which	is	detected	by	ryanodine	receptors	(RyR)	that	release	Ca2+	stores	from	sarcoplasmic	reticulum	(SR)(Fill	&	Copello,	2002).	Calcium	is	then	able	to	initiate	contraction,	which	will	be	explained	later	in	greater	detail	and	can	be	summarized	in	Online	Video	1	(https://vimeo.com/148663469).	In	contrast,	skeletal	muscle	is	responsible	for	both	support	and	voluntary	movement	of	the	body,	controlled	primarily	by	the	somatic	nervous	system.	Skeletal	muscle	fibers	are	generally	much	larger	than	cardiomyocytes,	consist	of	different	fiber	types,	and	a	single	fiber	can	stretch	from	tendon	to	tendon,	from	which	force	transmission	is	conducted(Schiaffino	&	Reggiani,	2011).	Skeletal	muscle	cells	are	multi-nucleated,	having	hundreds	of	nuclei	that	dot	the	fiber	from	one	end	to	another(Holtzer,	Marshall,	&	Finck,	1957;	Okazaki	&	Holtzer,	1966).	Contraction	of	individual	skeletal	muscle	fibers	depend	on	the	innervation	of	each	fiber	(Hughes,	Kusner,	&	Kaminski,	2006).	Activation	of	different	subsets	of	muscle	fibers	may	not	affect	activation	of	adjacent	muscle	fibers.	Unlike	in	
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cardiomyocytes,	the	electrical	signal	is	transduced	via	neuromuscular	junctions	and	RyR	are	physically	coupled	to	DHPR.	In	addition,	skeletal	muscle	cells	have	known	regenerative	capability,	stemming	from	a	reserve	of	satellite	cells(Morgan	&	Partridge,	2003;	Yin,	Price,	&	Rudnicki,	2013).	While	the	role	of	cardiac	and	skeletal	muscles	are	distinct	from	one	another,	there	are	striking	similarities	in	the	molecular	mechanisms	of	contraction	that	regulate	striated	muscles.	Specifically,	striated	muscles	have	the	same	functional	unit	of	contraction,	known	as	the	sarcomere.		
The	Sarcomere	is	the	Functional	Unit	of	Muscle	Contraction			 The	functional	unit	of	muscle	contraction	at	the	molecular	level	is	the	sarcomere,	which	comes	from	Greek	sarx	(flesh)	and	meros	(part).	(A.	F.	Huxley	&	Niedergerke,	1954b;	H.	Huxley	&	Hanson,	1954).	The	sarcomere	gives	striated	muscles	the	striations	that	give	them	its	name.	These	striations	are	visible	by	light	microscopy,	and	its	highly	organized	and	specific	architecture	is	due	to	the	alignment	of	Z-disc	proteins	that	delineate	individual	sarcomeres	(Figure	2).	Z-discs	are	named	from	the	German	word	“Zwischenscheibe,”	meaning	“between	discs.”	In	the	middle	of	the	sarcomere	is	the	M-line,	from	the	German	word	“Mittelscheibe,”	meaning	“center	disc.”	Using	electron	microscopy,	two	distinct	bands	are	clearly	visible:	a	light	band	(I-band)	and	a	dark	band	(A-band),	because	these	regions	of	the	sarcomere	are	isotropic	and	anisotropic	to	polarized	light,	respectively.	Within	the	darker	A-band	is	a	region	called	the	H-zone,	after	the	German	word	“heller.”	These	various	regions	are	populated	by	thin	and	thick	filaments	that	overlap	one	another	
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to	create	the	varying	densities	that	make	up	each	region.	The	thin	and	thick	filament	proteins	run	parallel	to	one	another	and	perpendicular	to	the	Z-discs.	The	thin	and	thick	filaments	overlap	and	slide	one	another	to	affect	contraction	at	the	molecular	level.	This	event	is	triggered	by	Ca2+	activation	of	the	thin	filament,	a	process	in	which	Ca2+-binding	to	the	troponin	(Tn)	complex	shifts	tropomyosin’s	(Tm)	position	along	the	thin	filament	from	a	“blocked”	to	a	“closed”	position,	which	exposes	myosin-binding	sites	on	actin	(Kobayashi	&	Solaro,	2005).	Once	the	myosin	head	binds	to	actin,	myosin	and	actin	undergo	a	transition	from	weak	to	strong	binding,	further	shifting	tropomyosin	to	the	“open”	position,	thus	fully	activating	the	thin	filament.	During	this	process,	myosin	hydrolyzes	ATP	(ATPase),	converting	chemical	energy	to	mechanical	energy,	thus	providing	the	power	to	slide	thin	filaments	over	the	thick	filaments	(H.	Huxley	&	Hanson,	1954;	Spudich,	2001).	Due	to	its	central	location	between	thick	and	thin	filaments,	MyBP-C	is	thought	to	modulate	contraction	through	its	effects	on	both	thin	filament	activation	and	cross-bridge	power	generation.
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Figure	 2.	 	MyBP-C	 and	 the	 sarcomere.	Top-down	 schematic	 of	 the	 location	 of	Myosin	 Binding	 Protein-C	 (MyBP-C)	 in	 muscle	 at	 the	 molecular	 level.	 Muscles	consists	 of	 bundles	 of	 muscle	 fibers,	 known	 as	 fascicles	 (top).	 Muscle	 fibers,	 or	myofibrils,	are	composed	of	sarcomeres,	 individual	 functional	units	of	contraction	(middle).	MyBP-C	is	localized	specifically	within	the	C-zone	of	the	sarcomere	in	7-9	transverse	stripes	 flanking	the	M-line.	Each	sarcomere	 is	delineated	by	the	Z-disc,	with	thick	and	thin	filaments	that	overlap	in	the	center.	The	thick	filament	primarily	consists	 of	 myosin,	 and	 thin	 filaments	 are	 composed	 of	 actin,	 troponin,	 and	tropomyosin	(bottom).	MyBP-C	interacts	with	both	the	thick	and	thin	filaments,	with	its	 C-terminus	 anchoring	 on	 the	 myosin	 LMM	 region	 and	 titin,	 and	 N-terminus	interacting	with	myosin	S2	region	and	actin.	
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The	Thin	and	Thick	Filaments	of	the	Sarcomere			 Thin	filaments	consist	primarily	of	actin	that	form	a	helical	rope	attached	at	the	Z-discs.	The	actin	filament	is	capped	at	the	Z-discs	by	CapZ	proteins	and	tropomodulin	towards	the	M-line.	Spanning	the	length	of	the	thin	filament	is	the	giant	protein,	nebulin.	Along	the	length	of	actin	are	tropomyosin,	which	also	forms	a	helical	structure,	and	periodically	dotted	by	troponin	complex	proteins.	Thick	filaments	consist	primarily	of	myosin,	which	consists	of	multiple	subfragments.	Myosin	is	the	motor	that	physically	interacts	with	actin	to	slide	the	filaments	across	one	another.	Myosin	itself	consists	of	several	distinct	regions,	including	the	head	domain,	neck	domain,	and	tail	domain.	Spanning	the	length	of	the	thick	filament	is	the	giant	protein,	titin.	Within	the	A-band	is	an	even	darker	region,	known	as	the	C-zone.	The	C-zone	consists	of	Myosin	Binding	Protein-C	(MyBP-C).	This	chapter	will	highlight	aspects	of	these	myofilament	proteins	in	the	order	they	come	into	play	during	contraction.		
Troponins:	TnC,	TnI,	TnT	
		 In	both	cardiac	and	skeletal	muscles,	molecular	contraction	at	the	sarcomeric	level	is	initiated	by	Ca2+.	The	influx	of	Ca2+,	and	the	signal	it	carries,	is	detected	and	transduced	by	the	troponin	complex,	which	consists	of	three	subunits	Troponin	C,	Troponin	I,	and	Troponin	T	(TnC,	TnI,	TnT,	respectively)	(Figure	2).	As	previously	mentioned,	initial	discovery	is	largely	attributed	to	the	work	by	Setsuro	Ebashi	(Ebashi	&	Endo,	1968),	and	much	has	since	been	learned	regarding	their	function..		
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TnC	binds	Calcium		
		 After	Ca2+	is	released	into	the	sarcomere,	the	first	troponin	to	come	into	play	is	TnC,	the	18	kDa	troponin	subunit	that	binds	Ca2+,	specifically	within	the	N-terminal	regulatory	domains.	TnC	structure	consists	of	two	globular	domains	at	the	N-	and	C-terminal	ends	(Herzberg	&	James,	1988;	Satyshur	et	al.,	1988)connected	via	α-helical	bridge	(Vassylyev,	Takeda,	Wakatsuki,	Maeda,	&	Maeda,	1998).	The	N-terminal	globular	domain	is	thought	to	be	the	primary	regulation	region,	capable	of	binding	Ca2+	via	one	of	four	EF	hand	motifs	(van	Eerd	&	Takahashi,	1975),	while	the	C-terminal	domain	is	thought	to	serve	a	structural	role.	EF	hand	motifs	are	numbered	Sites	I	–	IV,	with	N-terminal	sites	(I	and	II)	having	relatively	low	affinity	to	Ca2+	compared	to	C-terminal	sites	(III	and	IV).	However,	sites	III	and	IV	are	occupied	by	Mg2+	under	physiological	conditions	(Zot	&	Potter,	1987).	Interestingly,	the	C-terminus	also	has	the	EF	hand	motif,	and	evidence	suggests	some	contribution	to	regulatory	function	(Biesiadecki,	Kobayashi,	Walker,	Solaro,	&	de	Tombe,	2007).	The	N-terminal	domain	of	TnC	interacts	with	the	C-terminal	region	of	TnI	dubbed	the	“regulatory	head”	(Kleerekoper,	Howarth,	Guo,	Solaro,	&	Rosevear,	1995;	Takeda,	Yamashita,	Maeda,	&	Maeda,	2003),	and	the	binding	of	Ca2+	to	the	N-terminal	globular	domain	alters	its	interaction	with	TnI.	The	conformational	change	in	the	regulatory	head	transduces	the	Ca2+	signal.	
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TnI	is	the	inhibitory	subunit	
		 TnI	undergoes	a	conformational	change,	induced	by	Ca2+-binding	to	TnC,	and	this	structural	change	is	a	vital	step	in	thin	filament	activation.	TnI	is	a	21	kDa	troponin	subunit	known	to	be	an	important	inhibitor	of	sarcomeric	activation	due	to	its	interactions	with	the	other	troponin	subunits,	as	well	as	tropomyosin	and	actin	(Ohtsuki,	Maruyama,	&	Ebashi,	1986;	Zot	&	Potter,	1987).	TnI	inhibits	actomyosin	Mg-ATPase,	and	this	inhibition	is	enhanced	by	tropomyosin	(Greaser	&	Gergely,	1971;	Potter	&	Gergely,	1974).	TnI	has	been	demonstrated	to	be	a	potent	regulator	of	Ca2+-sensitivity	that	is	also	highly	regulated	by	phosphorylation	(Layland,	Solaro,	&	Shah,	2005;	Solaro	&	Van	Eyk,	1996;	Westfall	&	Metzger,	2001;	Westfall,	Turner,	Albayya,	&	Metzger,	2001),	with	the	central	region	of	TnI	primarily	for	both	actin	binding	and	inhibitory	capacity(Syska,	Wilkinson,	Grand,	&	Perry,	1976;	Talbot	&	Hodges,	1981),	with	some	contributions	to	inhibitory	activity	from	the	N-terminal	region(Sheng,	Pan,	Miller,	&	Potter,	1992),	as	well	as	the	C-terminal	region	(Farah	et	al.,	1994).	In	its	inactivated	state,	N-terminal	region	of	TnI	loosely	binds	TnC	and	TnT,	while	its	C-terminal	region	tightly	binds	actin.	Its	binding	affinities	change	upon	activation	by	Ca2+:	TnC	binding	to	Ca2+	causes	TnI	to	tightly	bind	TnC	and	TnT,	while	loosening	its	binding	to	actin(Potter	&	Gergely,	1974;	Syska	et	al.,	1976).	This	change	is	thought	to	transduce	the	signal	down	to	the	last	troponin	subunit,	TnT.	
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Troponin	T	binds	tropomyosin	
		 TnT	is	the	largest	of	the	troponin	subunits	at	36	kDa,	and	TnT	anchors	the	other	troponin	subunits	to	the	actin	filament,	as	well	as	binding	to	tropomyosin	(Tm)	(Hitchcock,	1975a,	1975b;	Hitchcock	&	Lutter,	1975).	The	structure	of	TnT	consists	of	two	helical	structures	(T1	and	T2),	as	well	as	an	unstructured	flexible	region	known	as	the	hypervariable	domain	(Takeda	et	al.,	2003).	The	C-terminal	T2	structure	interacts	with	TnI,	TnC,	and	actin(Heeley,	Golosinska,	&	Smillie,	1987;	Schaertl,	Lehrer,	&	Geeves,	1995),	as	well	as	the	central	region	of	Tm(Morris	&	Lehrer,	1984;	Pearlstone	&	Smillie,	1982).		The	central	T1	region	interacts	with	C-terminus	of	Tm;	however,	the	function	of	the	N-terminal	hypervariable	domains	(H1	and	H2)	remains	unclear,	though	these	regions	may	allow	TnT	to	adapt	to	specific	isoforms,	muscles,	or	species	(Biesiadecki,	Chong,	Nosek,	&	Jin,	2007;	Jin,	Chen,	Ogut,	&	Huang,	2000).	The	primary	role	for	TnT	is	thought	to	be	structural,	but	recent	studies	suggest	TnT	has	several	phosphorylation	sites	that	regulate	Ca2+-sensitivity	and	force	generation	(Jideama,	Crawford,	Hussain,	&	Raynor,	2006;	Noland	&	Kuo,	1992;	Sumandea,	Pyle,	Kobayashi,	de	Tombe,	&	Solaro,	2003).	The	interaction	between	Tm	and	TnT	is	likely	the	primary	mechanism	behind	its	regulation	of	thin	filament	activation.	(Pato,	Mak,	&	Smillie,	1981;	White,	Cohen,	&	Phillips,	1987)TnT	loosens	its	interaction	with	Tm,	which	allows	Tm	to	move	its	position	relative	to	actin	in	such	a	way	that	exposes	the	myosin-binding	site	on	actin	(Potter,	Sheng,	Pan,	&	Zhao,	1995).	
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Tropomyosin	
		 Tropomyosin	(Tm)	is	a	37	kDa,	42nm-long	protein	that,	much	like	actin,	consists	of	double	α-helices	that	form	a	coiled-coil	that	intertwines	with	the	actin	filament	(Woods,	1966,	1967).	There	are	multiple	isoforms	of	Tm,	such	as	α-Tm,	ß-Tm,	and	slow	α-Tm,	encoded	by	TPM1,	TPM2,	and	TPM3,	respectively	(Perry,	2001).	These	isoforms	are	structurally	similar,	but	variations	in	structural	homology	suggest	variations	in	their	capacity	to	regulate	contraction	at	the	molecular	level(Muthuchamy	et	al.,	1995).	Tm	polymers	can	form	both	homodimers	and	heterodimers,	though	in	striated	muscles	Tm	is	arranged	in	heterodimers	(Jancso	&	Graceffa,	1991;	Lehrer,	Qian,	&	Hvidt,	1989)	that	overlap	by	8-9	amino	acids	from	the	N-terminus	of	one	Tm	polymer	with	the	C-terminus	of	another	(McLachlan	&	Stewart,	1975).	Similar	to	one	of	its	binding	partners,	TnT,	Tm	is	thought	to	stabilize	thin	filaments:	its	interactions	in	conjunction	with	tropomodulin	reduce	depolymerization	of	the	thin	filament.	Functionally,	Tm	works	in	tandem	with	Tn	to	regulate	thin	filament	activation,	and	thus,	myosin-actin	interaction.	Tm	isoforms	dimerizes	and	polymerizes	end-to-end,	fitting	into	the	major	groove	within	the	actin	double	α-helix(Perry,	2001).	In	this	groove,	Tm	physically	blocks	the	myosin-binding	site	on	actin,	thus	preventing	contraction	by	interfering	with	myosin	and	actin	interactions	(Fraser	&	Marston,	1995).	The	conformational	shift	induced	by	Ca2+-bound	troponin	causes	Tm	to	shift	from	the	blocked	to	closed	position,	which	exposes	the	myosin-binding	sites	on	actin(McKillop	&	Geeves,	1993).	The	binding	of	myosin	to	actin	further	shifts	the	position	of	Tm	on	actin	from	the	closed	to	open	
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position(Rosol	et	al.,	2000).		
Actin	
		 The	thin	filament	is	primarily	composed	of	actin	filaments	which,	like	tropomyosin,	consists	of	double	α-helices	that	form	a	coiled-coil	within	the	sarcomere	(Holmes,	Popp,	Gebhard,	&	Kabsch,	1990;	Lorenz,	Poole,	Popp,	Rosenbaum,	&	Holmes,	1995).	Globular	actin	(G-actin)	polymerizes	into	filamentous	actin	(F-actin)	in	a	spontaneous	manner,	which	then	forms	the	major	element	of	the	thin	filament.	G-actin	consists	of	4	subdomains	(SD1-SD4)	(Kabsch,	Mannherz,	Suck,	Pai,	&	Holmes,	1990;	McLaughlin,	Gooch,	Mannherz,	&	Weeds,	1993;	Schutt,	Lindberg,	Myslik,	&	Strauss,	1989),	which	forms	a	binding	pocket	for	a	nucleotide	(ADP	and	ATP)	(Egelman	&	Orlova,	1995;	Kinosian,	Selden,	Estes,	&	Gershman,	1993a,	1993b)	and	for	a	divalent	ion	(Mg2+	or	Ca2+)	(Orlova	&	Egelman,	1995;	Orlova,	Prochniewicz,	&	Egelman,	1995).	There	are	7	actin	monomers	per	half-helical	turn	of	the	actin	filament,	which	interact	with	its	opposing	strand	via	subdomains	(SD)	3	and	4,	while	subdomains	1	and	2	can	interact	with	other	myofilament	proteins,	such	as	myosin	and	MyBP-C	(Figure	3).	Subdomains	on	the	actin	monomer	also	interacts	with	other	contractile	proteins(von	der	Ecken	et	al.,	2015).	Vertebrate	actin	is	composed	of	three	main	isoforms	that	are	highly	homologous	(α,	β,	and	γ),	and	skeletal,	cardiac,	and	smooth	variations	of	the	α	isoform	(Vandekerckhove	&	Weber,	1979).	The	skeletal	and	cardiac	isoforms	are	differentially	expressed,	and	expression	varies	on	muscle	type	and	species.	However,	actin	isoforms	are	highly	conserved,	with	only	minimal	variation	at	the	N-
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terminal	region(Vandekerckhove	&	Weber,	1979),	though		differences	of	just	15	amino	acids	can	result	in	structural	and	functional	variations(Brault,	Reedy,	et	al.,	1999;	Brault,	Sauder,	Reedy,	Aebi,	&	Schoenenberger,	1999).	The	importance	of	actin	function	is	clear:	actin	is	the	primary	component	of	the	thin	filament	that	serves	to	anchor	troponins	and	tropomyosin.	In	addition,	actin	functions	to	transduce	force	generation	via	interactions	with	thick	filament	proteins,	most	notably,	myosin.	Specifically,	actin	subdomain	1	(SD1)	binds	to	the	myosin	head	(also	known	as	the	myosin	subfragment	1	or	myosin	S1)	primarily	via	two	known	ionic	interactions:	1)	the	negative	charge	of	SD1	interacts	with	the	positively-charged	lysine	myosin	50k/20k	loop	2)	an	adjacent	SD1	interacts	with	myosin	amino	acid	residues	567-578(Milligan,	1996;	Milligan,	Whittaker,	&	Safer,	1990;	Rayment,	Holden,	et	al.,	1993).	A	third	interaction	occurs	between	myosin	S1	(amino	acids	404-415)	with	the	proline	residues	in	between	actin	SD1	and	SD3.	
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Figure	3.		Actin	has	four	subdomains.	Actin	monomer	is	the	base	unit	of	the	actin	filament	(F-actin),	which	is	a	helical	coiled-coil.	There	are	4	primary	subdomains	(SD)	 on	 the	 actin	 monomer	 that	 interact	 with	 other	 thick	 and	 thin	 filament	proteins.	SD1	is	the	primary	binding	site	for	myosin	S1	region	(represented	by	the	green	circle),	which	also	 is	known	to	 interact	with	the	pocket	between	SD1	and	SD3.	SD3	and	SD4	are	primarily	responsible	for	actin-actin	interactions.	
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Myosin	
		 Myosin	is	a	superfamily	of	proteins	with	many	classes	and	functional	roles(Foth,	Goedecke,	&	Soldati,	2006;	Krendel	&	Mooseker,	2005;	Woolner	&	Bement,	2009).	This	section	will	focus	on	the	class	2	myosin	in	striated	muscles	that	form	the	cross-bridge,	which	is	responsible	for	muscle	contraction.	Myosin	M2	was	originally	discovered	in	1864	by	Wilhelm	Kühne	(Kühne,	1864).	The	thick	filament	primarily	consists	of	myosin,	a	large	220	kDa	protein	responsible	for	binding	to	actin	and	pulling	the	thin	and	thick	filaments	across	one	another	to	affect	contraction.	Myosin	itself	consists	of	several	distinct	regions:	the	head,	neck,	and	tail	regions.	The	N-terminal	region	has	two	heads,	each	known	as	the	S1	subfragment(Dominguez,	Freyzon,	Trybus,	&	Cohen,	1998;	Rayment,	Holden,	et	al.,	1993;	Rayment,	Rypniewski,	et	al.,	1993).	The	S1	subfragment	projects	outward	from	the	thick	filament	at	14.3	nm	intervals	and	physically	interacts	with	actin	to	form	cross-bridges.	The	catalytic	head	is	the	motor	of	sarcomeric	muscle	contraction	(Toyoshima	et	al.,	1987)	and	is	primarily	responsible	for	the	sliding	of	the	thick	and	thin	filaments	across	one	another,	and	has	nucleotide	binding	pocket	capable	of	converting	chemical	energy	(ATP)	into	mechanical	energy	(Holmes,	Angert,	Kull,	Jahn,	&	Schroder,	2003).	In	the	rigor	state,	myosin	is	attached	to	actin,	with	ADP	and	inorganic	phosphate	attached.	The	release	of	ADP	and	inorganic	phosphate	results	in	the	myosin	head	to	shift	in	such	a	way	that	it	pulls	on	the	actin	thin	filament,	in	what	is	known	as	the	powerstroke.	As	ATP	binds	to	the	myosin	head,	myosin	detaches	from	actin.	Myosin	MgATPase	activity	hydrolyzes	the	ATP	
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into	ADP	and	inorganic	phosphate,	repositioning	the	myosin	head	in	its	original	position,	and	the	cycle	begins	anew	(Holmes	et	al.,	2003)(Figure	2).	Just	below	the	S1	subfragment	is	the	myosin	neck,	S2	subfragment,	and	the	S2	region	links	the	myosin	head	to	the	rest	of	the	thick	filament.	In	addition,	the	S2	region	interacts	with	two	myosin	light	chains	(MLC)	thought	to	fine-tune	myosin	function:	the	essential	light	chain	(ELC)	and	regulatory	light	chain	(RLC).	Further	towards	the	C-terminus	is	the	light	meromyosin	(LMM),	and	the	LMM	forms	the	coiled	coil	that	anchor	myosin	to	the	thick	filament,	where	it	interacts	with	titin	and	Myosin	Binding	Protein-C.	
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Myosin	Binding	Protein-C	
		 Interaction	between	myosin	and	actin	is	regulated	by	Myosin	Binding	Protein-C	(MyBP-C),	which	was	first	discovered	as	a	myosin	impurity	in	the	1970s	(Craig	&	Offer,	1976;	Offer	et	al.,	1973).	The	three	distinct	MyBP-C	isoforms:	slow-skeletal,	fast-skeletal,	and	cardiac,	are	each	encoded	by	a	distinct	gene	(MYBPC1,	
MYBPC2,	MYBPC3,	respectively)(Carrier	et	al.,	1993;	Weber,	Vaughan,	Reinach,	&	Fischman,	1993)	(Figure	4).	MyBP-C	isoforms	are	localized	within	the	C-zones(Offer	et	al.,	1973),	a	region	within	the	sarcomere	flanking	the	M-line(Gilbert,	
Figure	4.	There	are	three	isoforms	of	MyBP-C:	slow-skeletal,	fast-skeletal,	and	cardiac,	encoded	by	its	own	gene:	MYBPC1,	MYBPC2,	and	MYBPC3,	respectively.	All	isoforms	 share	 a	 conserved	 structure	 of	 immunoglobulin	 (blue	 circle)	 and	fibronectin	 (orange	 hexagon)	 –like	 domains,	 numbered	 C1	 through	 C10.	 All	isoforms	also	have	a	M-motif	(red	circle),	as	well	as	a	proline-alanine	(P/A)	rich	region	 (purple	 rectangle).	 However,	 there	 are	 significant	 differences	 between	isoforms,	particularly	 in	 the	N-terminal	region	of	MyBP-C.	First,	cardiac	MyBP-C	consists	of	an	additional	N-terminal	domain,	known	as	the	C0	domain.	Second,	the	location	of	phosphorylation	sites	are	different:	cardiac	MyBP-C	has	4	sites	in	the	M-motif	and	1	in	the	P/A	region,	while	slow-skeletal	has	3	sites	in	the	P/A	region	and	 1	 in	 the	 M-motif.	 Fast-skeletal	 MyBP-C	 currently	 has	 no	 identified	phosphorylation	sites.	The	function	of	all	three	N-terminal	regions	have	never	been	fully	elucidated	
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Cohen,	Pardo,	Basu,	&	Fischman,	1999),	arranged	in	7-9	transverse	stripes	at	43	nm	intervals(Bennett,	Craig,	Starr,	&	Offer,	1986;	Dennis,	Shimizu,	Reinach,	&	Fischman,	1984;	Flashman,	Redwood,	Moolman-Smook,	&	Watkins,	2004;	Rome,	Offer,	&	Pepe,	1973)	(Figure	2).	As	the	names	suggest,	slow-skeletal	and	fast-skeletal	isoforms	(ssMyBP-C	and	fsMyBP-C,	respectively)	are	expressed	in	skeletal	muscles,	whereas	the	cardiac	isoform	(cMyBP-C)	predominates	in	the	heart(Gautel,	Furst,	Cocco,	&	Schiaffino,	1998),	though	complexities	of	expression	are	further	discussed	in	Chapter	Three.	The	43	nm	interval	of	MyBP-C	and	14.3	nm	interval	of	myosin	heads	correlates	to	1:3	ratio	between	MyBP-C	and	myosin	within	the	C-zone(Craig	&	Offer,	1976;	Luther	&	Craig,	2011).	MyBP-C	structure	consists	of	seven	immunoglobulin	and	three	fibronectin	III	domains,	numbered	C1	through	C10,	from	the	N-terminus	to	the	C-terminus(Luther	et	al.,	2011).	In	addition,	there	is	a	proline/alanine-rich	(PA)	region	that	precedes	the	C1	domain,	as	well	as	a	M	motif	between	the	C1	and	C2	domains(Barefield	&	Sadayappan,	2010;	Gautel,	Zuffardi,	Freiburg,	&	Labeit,	1995;	Kuster	et	al.,	2012).	Despite	these	similarities,	MyBP-C	isoforms	are	structurally	distinct	and	there	are	many	key	differences	within	the	N-terminal	region.	Cardiac	MyBP-C	has	an	additional	immunoglobulin-like	domain,	the	C0	domain(Ratti,	Rostkova,	Gautel,	&	Pfuhl,	2011),	as	well	as	five	known	phosphorylation	sites:	four	within	the	M	motif(Copeland	et	al.,	2010;	Mohamed,	Dignam,	&	Schlender,	1998)	and	one	in	the	PA	region(Kuster	et	al.,	2013).	Conversely,	slow-skeletal	MyBP-C	has	one	known	phosphorylation	site	in	the	M	
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motif	and	three	phosphorylation	sites	in	the	PA	region(Ackermann	&	Kontrogianni-Konstantopoulos,	2011a).	Currently,	no	phosphorylation	sites	have	been	identified	in	fast-skeletal	MyBP-C,	but	evidence	suggest	the	presence	of	phosphorylation	sites	due	to	changes	in	the	phosphorylation	state	of	both	ssMyBP-C	and	fsMyBP-C	during	disease(Ackermann,	Kerr,	King,	C,	&	Kontrogianni-Konstantopoulos,	2015;	Ackermann	et	al.,	2013;	Ackermann,	Ward,	Gurnett,	&	Kontrogianni-Konstantopoulos,	2015).				 MyBP-C	primarily	operates	via	protein-protein	interactions	due	to	the	lack	of	evidence	of	enzymatic	activity,	nor	interactions	with	nucleic	acids	and	sugars(Pfuhl	&	Gautel,	2012),	though	a	low-affinity	zinc	binding	site	has	been	reported	in	the	C1	domain	of	MyBP-C(Ababou	et	al.,	2008),	the	vast	majority	of	studies	conducted	in	MyBP-C	focuses	on	its	interactions	with	other	myofilament	proteins.				 The	C-terminal	region	of	MyBP-C	has	been	demonstrated	to	interact	with	both	the	light	meromyosin	(LMM)	region	of	myosin(Miyamoto,	Fischman,	&	Reinach,	1999;	Moos,	Offer,	Starr,	&	Bennett,	1975;	Okagaki	et	al.,	1993)	and	titin(Freiburg	&	Gautel,	1996;	Furst,	Vinkemeier,	&	Weber,	1992)	of	the	thick	filament,	with	the	C8	through	C10	domains	being	vital	for	localization	to	the	A-band	of	the	sarcomere(Gilbert	et	al.,	1999).	MyBP-C	interaction	with	titin	in	particular	is	thought	to	be	important	for	determining	localization	and	periodicity	of	MyBP-C	within	the	sarcomere(Furst	et	al.,	1992;	Koretz,	Irving,	&	Wang,	1993):	titin	PEVK	super	repeats	(a	series	of	immunoglobulin	and	fibronectin	III	domains)	act	as	a	
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scaffold	for	MyBP-C	within	the	sarcomere(Labeit,	Gautel,	Lakey,	&	Trinick,	1992;	Trinick,	1992,	1994).	The	C-terminal	domains	may	also	participate	in	the	organization	and	stability	of	thick	filaments	during	development	(Nyland	et	al.,	2009).	However,	cMyBP-C	knock-out	mouse	models	of	cardiomyopathies	have	demonstrated	sarcomere	structures	are	still	conserved	(Harris	et	al.,	2002;	McConnell	et	al.,	1999).	Normal	sarcomere	structure	is	observed	in	human	patients	with	MyBP-C	mutations	that	result	in	hypertrophic	cardiomyopathy	and	distal	arthrogryposis	type	1(Vydyanath,	Gurnett,	Marston,	&	Luther,	2012),	suggesting	that	MyBP-C	role	in	sarcomeric	assembly	is	not	absolutely	necessary.	Though	the	MyBP-C	C-terminal	domains	anchors	MyBP-C	to	the	thick	filament,	the	MyBP-C	N-terminal	binding	partners	are	more	varied	and	functional	implications	more	complex.	
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Function	of	MyBP-C	
		 MyBP-C	has	been	known	as	the	braking	mechanism	in	cardiac	muscle	contraction	(Previs,	Beck	Previs,	Gulick,	Robbins,	&	Warshaw,	2012;	Razumova	et	al.,	2006),	due	to	its	ability	to	reduce	thin	filament	sliding	velocities.	Furthermore,	the	N-terminal	region	of	MyBP-C	have	been	demonstrated	to	bind	to	actin	and	shift	tropomyosin	from	the	blocked	to	closed	position,	in	a	similar	manner	to	Ca2+-bound	Tn	complex(Mun	et	al.,	2014).	Studies	using	recombinant	proteins	representing	the	cMyBP-C	N-terminus	have	demonstrated	that	cMyBP-C	has	a	significant	effect	in	promoting	Ca2+-sensitivity	and	rate	of	tension	redevelopment(Razumova,	Bezold,	Tu,	Regnier,	&	Harris,	2008;	Witayavanitkul	et	al.,	2014).	The	functional	mechanism	of	MyBP-C	is	likely	due	to	interactions	with	actin(Shaffer	&	Harris,	2009;	Squire,	Luther,	&	Knupp,	2003;	Whitten,	Jeffries,	Harris,	&	Trewhella,	2008),	myosin	subfragment-2	(S2)(Gruen	&	Gautel,	1999;	Gruen,	Prinz,	&	Gautel,	1999;	Moos	et	al.,	1975;	Offer	et	al.,	1973;	Starr	&	Offer,	1978),	and	regulatory	light	chain	of	myosin(Ratti	et	al.,	2011).	The	primary	interaction	MyBP-C	with	the	thin	filament	is	via	actin:	the	C1	domain	and	M-motif	are	required	for	interaction	with	actin(Bhuiyan,	Gulick,	Osinska,	Gupta,	&	Robbins,	2012;	Squire	et	al.,	2003;	Whitten	et	al.,	2008),	although	the	cardiac-specific	C0	domain	of	cMyBP-C	has	been	demonstrated	to	be	sufficient	to	interact	with	actin	and	elicit	some	functional	effects(Herron	et	al.,	2006).	This	indicates	MyBP-C	interaction	with	actin	likely	involves	several	N-terminal	domains.	In	contrast,	MyBP-C	interaction	with	myosin	
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subfragment-2	appears	to	be	limited	to	the	M-motif,	specifically	the	N-terminal	126	residues	of	S2(Gruen	&	Gautel,	1999),	and	may	be	mutually	exclusive	to	MyBP-C	interaction	with	actin(Bhuiyan	et	al.,	2012;	Gruen	&	Gautel,	1999).	However,	there	is	some	discrepancy	within	the	literature	on	what	this	entails	at	the	functional	level.	Kunst	et	al.	2000	demonstrated	that	the	C0	domain	alone	does	not	interact	with	myosin(Kunst	et	al.,	2000),	while	others	demonstrated	C0	does	interact	with	the	regulatory	light	chain	(RLC)	of	myosin	(Ratti	et	al.,	2011).	Interestingly,	Herron	et	al.	2006	demonstrated	C0	domain	alone	is	able	to	elicit	some	functional	effects	(Herron	et	al.,	2006),	suggesting	the	C0	domain	regulates	function	via	interactions	with	actin.				 Studies	demonstrating	MyBP-C	N-terminus	binding	to	actin	and	myosin	suggest	a	unique	orientation	between	the	thin	and	thick	filaments,	as	well	as	promiscuity	with	multiple	binding	partners	that	is	regulated	in	a	phosphorylation-dependent	manner(Barefield	&	Sadayappan,	2010;	Sadayappan	&	de	Tombe,	2012)	(Figure	4).	Kulikovskaya	et	al.	(2003)	demonstrated	that	phosphorylation	of	cMyBP-C	ablates	its	interaction	with	myosin	subfragment-S2,	thus	resulting	in	greater	force	production	by	allowing	myosin	to	bind	to	actin(Kulikovskaya,	McClellan,	Flavigny,	Carrier,	&	Winegrad,	2003).	Specifically,	phosphorylation	of	MyBP-C	regulatory	sites	(S276,	S285,	S304	in	humans)	results	in	the	N-terminal	region	to	favor	binding	with	actin	versus	myosin.	By	this	mechanism,	cMyBP-C	is	thought	to	provide	regulation	at	multiple	levels	during	contraction.	First,	MyBP-C	interaction	with	myosin	is	hypothesized	to	act	as	a	mechanical	load	on	myosin,	and	thus	reduce	its	ability	to	form	cross-bridges.	Phosphorylation	of	MyBP-C	releases	
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this	load	on	myosin,	thereby	promoting	cross-bridge	cycling	kinetics.	Recent	studies	demonstrated	phosphorylation	of	the	M-motif	of	cMyBP-C	confers	a	specific	structural	stiffness	to	the	region	and	results	in	a	conformation	change	in	the	N-terminal	region(Colson,	Thompson,	Espinoza-Fonseca,	&	Thomas,	2016;	Previs	et	al.,	2016).	In	these	studies,	phosphorylation	causes	the	N-terminal	region	of	cMyBP-C	to	fold	on	itself,	perhaps	shielding	interacting	residues	within	the	M-motif	that	are	responsible	for	myosin	binding.	This	would	subsequently	free	the	MyBP-C	N-terminus	for	interaction	with	actin,	to	facilitate	contraction.	However,	this	conformational	effect	is	ablated	at	high	Ca2+	(Previs	et	al.,	2016),	suggesting	that	MyBP-C	N-terminus	would	once	again	favor	myosin	binding.	This	model	allows	for	binding	of	MyBP-C	to	both	myosin	and	actin,	at	different	stages	of	contraction	(low	and	high	Ca2+),	but	whether	the	binding	interactions	are	mutually	exclusive	has	yet	to	be	resolved.		 	
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CHAPTER	THREE	EXPRESSION	PROFILE	OF	THE	THREE	MYBP-C	
2.1	Structures	of	MyBP-C	isoforms	are	both	similar	and	distinct	MyBP-C	is	a	family	of	thick	filament	contractile	proteins	with	three	predominant	isoforms:	slow-skeletal,	fast-skeletal,	and	cardiac	(ssMyBP-C,	fsMyBP-C,	and	cMyBP-C,	respectively),	which	are	expressed	by	individual	genes	(MYBPC1,	
MYBPC2,	MYBPC3,	respectively).	It	is	worth	mentioning	the	existence	of	an	additional	isoform,	MyBP-H	(encoded	by	MYBPH	gene),	whose	structure	resembles	that	of	the	C-terminal	half	of	MyBP-C(Gilbert	et	al.,	1999;	Vaughan,	Weber,	Einheber,	&	Fischman,	1993).	As	mentioned	in	the	Chapter	Two,	MyBP-C	isoforms	share	several	conserved	structural	elements,	including	seven	immunoglobulin	and	three	fibronectin	III	domains,	numbered	C1	through	C10,	from	the	N-terminus	(Luther	&	Vydyanath,	2011),	a	proline/alanine-rich	(PA)	sequence	preceding	the	C1	domain,	and	a	conserved	M	domain	between	the	C1	and	C2	domains	(Figure	4).	Where	the	notable	differences	exist	between	MyBP-C	isoforms	is	within	their	N-terminal	regions.	For	example,	cMyBP-C	has	an	additional	immunoglobulin-like	“C0”	domain	of	approximately	100	amino	acids,	which	binds	myosin	light	regulatory	chain	and	actin	in	vitro	(Gautel	et	al.,	1995;	Ratti	et	al.,	2011).	In	addition,	cMyBP-C	has	4	phosphorylation	sites	in	the	M	domain	(Barefield	&	Sadayappan,	2010)	and	one	in	the	PA	region	(Kuster	et	al.,	2013),	whereas	ssMyBP-C	has	one	phosphorylation	site	
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														in	the	M	domain	and	three	in	the	PA	region	(Ackermann	&	Kontrogianni-Konstantopoulos,	2011a)	and	no	phosphorylation	sites	have	yet	to	be	identified	in	fsMyBP-C.	Sequence	identity	between	isoforms	is	also	reduced	in	this	N-terminal	region	(Table	1).	Further	differences	are	notable	in	the	C5	domain	of	cardiac,	in	which	cMyBP-C	has	an	additional	flexible	insert	of	unknown	function	(Cecconi,	Guardiani,	&	Livi,	2008;	Guardiani,	Cecconi,	&	Livi,	2008a,	2008b;	Idowu,	Gautel,	Perkins,	&	Pfuhl,	2003),	though	more	recent	studies	have	suggested	that	this	confers	the	ability	to	bend	at	particular	hinge	points	centering	around	the	C5	domain(Previs	et	al.,	2016)
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2.2	Skeletal	isoforms	of	MyBP-C	are	present	in	the	heart	
		 As	the	names	suggest,	cardiac	MyBP-C	predominates	in	the	heart,	while	slow-	and	fast-skeletal	MyBP-C	predominates	in	skeletal	muscles.	Contrary	to	common	belief,	the	expression	profile	of	MyBP-C	isoforms	is	much	more	complicated	in	development	versus	adult	stages	and	healthy	versus	disease	states.	For	example,	avian	species	temporarily	expresses	cMyBP-C	in	skeletal	muscles	during	embryonic	development(Bahler,	Moser,	Eppenberger,	&	Wallimann,	1985;	Kawashima,	Kitani,	Tanaka,	&	Obinata,	1986;	Obinata	et	al.,	1984),	though	cMyBP-C	expression	is	not	observed	during	mammalian	embryonic	development	at	the	transcript	nor	protein	level	(Gautel	et	al.,	1998;	Kurasawa	et	al.,	1999).	However,	an	embryonic	isoform	is	
MyBP-C  
N-termini 
ssC1C2  
(a.a. 1-341) 
fsC1C2  
(a.a. 1-337) 
C0C2  
(a.a. 1-448) 
NCBI 
Accession 
Number 
NP_780627.2 NP_666301.2 AAI54409.1 
 
 
Identity Positives Gaps Identity Positives Gaps 
ssC1C2 53% 70% 5% 52% 67% 6% 
fsC1C2    48% 59% 8% 
MyBP-C Full 
Length ssMyBP-C fsMyBP-C cMyBP-C 
 
 
Identity Positives Gaps Identity Positives Gaps 
ssMyBP-C 51% 70% 2% 49% 67% 5% 
fsMyBP-C    53% 68% 4% 
Table	1.	N-terminal	homology	between	N-terminal	MyBP-C	proteins	(ssC1C2,	fsC1C2,	C0C2)	and	full-length	MyBP-C.			
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	expressed	in	mammalian	cardiac	and	skeletal	muscles(Gautel	et	al.,	1998),	after	which	the	cardiac	and	skeletal	MyBP-C	isoforms	begin	to	predominate	their	respective	muscles.	The	authors	argued	that	during	adulthood,	cardiac	and	skeletal	MyBP-C	were	specifically	expressed	in	cardiac	and	skeletal	muscles,	respectively,	though	later	studies	demonstrated	that	was	not	necessarily	the	case.		Adding	further	complication	to	our	understanding	of	MyBP-C	expression	patterns,	ssMyBP-C	was	detected	in	the	heart	(Dhoot	&	Perry,	2005),	albeit	in	small	quantities	in	the	right	atrium	and	interatrial	septum.	Perhaps	most	surprisingly,	the	cardiac	samples	used	in	this	study	were	from	healthy	tissues	and	not	diseased	hearts.		This	led	us	to	suspect	the	expression	of	MyBP-C	isoforms	may	be	altered	due	to	different	conditions	during	disease	states.	To	test	this,	we	used	a	murine	mouse	model	of	heart	failure,	the	cMyBP-C-/-	knock-out	mouse	known	as	the	(t/t)	mouse	(McConnell	et	al.,	1999).	The	t/t	mouse	expresses	a	truncated	cMyBP-C,	which	is	not	incorporated	properly	within	the	sarcomere	and	degraded,	creating	a	functional	knock-out.	Using	hearts	from	these	t/t	mouse,	we	demonstrated	the	presence	of	fsMyBP-C	in	the	heart	during	heart	failure	(B.	Lin	et	al.,	2013),	indicating	expression	patterns	of	MyBP-C	can	shift	due	to	physiological	or	pathophysiological	conditions	in	the	heart.	To	further	investigate	whether	expression	of	fsMyBP-C	was	specific	to	this	transgenic	mouse	model	in	which	cMyBP-C	was	completely	absent,	I	conducted	preliminary	investigations	in	other	transgenic	mouse	models	of	HF,	as	well	as	a	pressure-overload	mouse	model	of	HF.	In	addition	to	the	t/t	mouse	heart	samples,	our	lab	studies	other	mouse	models	of	heart	failure,	known	as	the	110	and	C10	mice,	
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	which	have	truncations	in	the	N-terminal	and	C-terminal	regions	of	cMyBP-C,	respectively.	In	addition,	I	analyzed	the	hearts	from	mice	that	have	undergone	TAC	(transaortic	constriction),	in	which	the	aortic	opening	is	sutured	to	induce	pressure-overload	hypertrophy	of	the	ventricle.	In	the	TAC	mouse	model,	we	have	previously	demonstrated	that	fsMyBP-C	expression	is	increased	at	the	transcript	level	(Figure	
5).	While	this	suggests	fsMyBP-C	may	be	upregulated,	it	is	not	a	foregone	conclusion	that	fsMyBP-C	protein	levels	increase.	The	hearts	from	mouse	models	were	compared	to	non-transgenic	controls,	while	hearts	from	TAC	mice	were	compared	with	sham	surgery	controls.	Our	preliminary	results	revealed	that	insult	to	the	heart,	in	general,	can	result	in	the	upregulation	of	fsMyBP-C	expression	in	the	heart	at	the	protein	level	(Figure	6).	Western	blot	analysis	determined	the	presence	of	fsMyBP-C	in	all	mouse	models	of	HF	that	we	tested.	In	addition	to	previously	published	evidence	demonstrating	the	presence	of	small	amounts	of	fsMyBP-C	in	the	t/t	mice,	110	mice	and	C10	mice	also	expressed	comparable	quantities	of	fsMyBP-C	(Figure	6).	Furthermore,	fsMyBP-C	was	also	detected	in	TAC	mouse	hearts,	suggesting	that	the	upregulation	of	fsMyBP-C	was	related	to	the	diseased	condition	of	the	heart	rather	than	a	specific	compensatory	upregulation	due	to	transgenic	modification	of	cMyBP-C.	I	theorize	that	upregulation	of	fsMyBP-C	in	the	heart	in	disease	may	be	reflective	of	a	reversion	to	fetal	programming,	commonly	observed	in	the	diseased	heart	in	which	genetic	programming	reverts	to	conditions	similar	to	embryonic	development gene	programming	(Olson,	2004;	Razeghi	et	al.,	2001).	Regulation	of	this	phenomena	is	highly	regulated,	(Dirkx,	da	Costa	Martins,	&	
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	De	Windt,	2013;	Dirkx,	Gladka,	et	al.,	2013),	though	much	has	yet	to	be	elucidated.	Some	studies	suggest	the	reversion	to	fetal	programming	is	initially	compensatory	(Olson,	2004;	Razeghi	et	al.,	2001),	but	continued	activation	of	fetal	gene	programming	is	detrimental	to	the	long-term	health	of	the	heart	(Olson,	2004).	It	should	be	noted	that	mouse	hearts	from	even	sham-surgery	also	exhibited	upregulation	of	fsMyBP-C,	suggesting	even	slight	insults	to	the	heart	may	result	in	fsMyBP-C	upregulation	and/or	strain	differences	in	the	mouse	models	used	(FVB/N	versus	C57BL	background).	
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Figure	5.	Increased	fsMyBP-C	transcript	levels	in	pressure-overload	mouse	model,	as	 induced	 by	 TAC	 surgery.	 RNA	 Seq	 (top	 row)	 and	 qPCR	 (bottom	 row)	demonstrate	 increased	 relative	 expression	 of	MYBPC2,	 the	 gene	 encoding	 fast-skeletal	MyBP-C,	but	not	MYBPC3,	the	gene	encoding	cardiac	MyBP-C.	MYH7,	the	gene	 encoding	 ß-myosin	 heavy	 chain	 was	 also	 elevated.	 Housekeeping	 genes	
GAPDH	and	CASQ2	were	also	analyzed	as	controls	and	were	unchanged.	TAC	mice	data	courtesy	of	Dr.	Dave	Barefield.	
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Figure	6.	Skeletal	MyBP-C	may	be	present	in	the	heart.	Hearts	from	multiple	mouse	models	of	heart	failure	were	examined	for	possible	expression	of	ssMyBP-C	 and	 fsMyBP-C.	 The	 t/t	mouse	model	 is	 a	 functional	 cMyBP-C	 knock-out,	 C10	mouse	 lacks	 the	C-terminal	region	of	 cMyBP-C,	 and	 the	110	mouse	 lacks	 the	N-terminal	region	of	cMyBP-C.	TAC	mice	are	pressure-overload	models	of	HF.	Heart	lysates	courtesy	of	Thomas	Lynch	and	Dave	Barefield.		
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2.3	Expression	profile	of	ssMyBP-C	and	fsMyBP-C	in	skeletal	muscles	
		 The	expression	profile	of	ssMyBP-C	and	fsMyBP-C	is	also	complicated	in	skeletal	muscles.	The	literature	provides	little	insight	into	ssMyBP-C(Ackermann	&	Kontrogianni-Konstantopoulos,	2013;	Gurnett	et	al.,	2010;	Ha	et	al.,	2013)	and	even	less	so	concerning	fsMyBP-C(Colson,	Rybakova,	Prochniewicz,	Moss,	&	Thomas,	2012;	M.	Li,	Andersson-Lendahl,	Sejersen,	&	Arner,	2016).	Based	on	the	name	“slow-skeletal”	and	“fast-skeletal,”	it	was	often	assumed	was	that	ssMyBP-C	was	expressed	in	“slow-type”	muscles	and	fsMyBP-C	was	expressed	in	“fast-type”	muscles.	Like	the	assumptions	made	regarding	MyBP-C	expression	profile	in	the	heart,	the	reality	is	much	more	complicated.	Employing	the	same	methods	to	determine	expression	profile	in	the	heart,	I	determined	the	expression	profile	of	ssMyBP-C	and	fsMyBP-C	in	skeletal	muscles.	Despite	its	expression	in	skeletal	muscles	of	avian	species	during	development(Bahler	et	al.,	1985;	Gautel	et	al.,	1995;	Obinata	et	al.,	1984),	I	did	not	determine	cMyBP-C	expression	in	skeletal	muscles,	because	it	has	been	convincingly	demonstrated	not	to	be	expressed	at	all	in	skeletal	muscles	of	mammalian	species(Gautel	et	al.,	1998;	B.	Lin	et	al.,	2013).	This	endeavor	was	complicated	by	several	factors.	First,	skeletal	muscles	encompass	a	variety	of	different	muscles	that	all	have	very	distinct	roles	in	providing	postural	and	locomotor	support	for	the	body.	Second,	within	a	specific	type	of	skeletal	muscle,	slow-	and	fast-type	muscle	fibers	can	co-exist	adjacent	to	one	another,	or	even	slow	and	fast	isoforms	of	the	same	protein	within	the	same	fiber.	Third,	there	are	
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	different	methods	of	classifications	of	skeletal	muscle	fiber	types,	such	as	myosin	ATPase	activity,	myosin	fiber	types,	and	biochemical	analysis.			Therefore,	to	determine	the	expression	profile	of	ssMyBP-C	and	fsMyBP-C,	several	different	skeletal	muscles	were	selected	for	analysis,	particularly	those	used	previously	in	the	skeletal	literature	to	represent	slow,	fast,	and	mixed	fiber	types.	These	muscles	included	the	SOL	(soleus),	a	slow-oxidative	muscle	and	commonly	used	to	represent	slow-type	muscles(Lutz,	Ermini,	&	Jenny,	1978;	Rubinstein	&	Kelly,	1981);	EDL	(extensor	digitorum	longus),	often	used	to	represent	fast	glycolytic	muscles,	but	is	actually	a	mixed	muscle	type;	TA	(tibialis	anterior),	a	larger	muscle	consisting	of	mixed	muscle	fiber	types;	and	finally	FDB	(flexor	digitorum	brevis),	a	fast-glycolytic	muscle	located	in	the	sole	of	the	foot	in	mammals	(Figure	7).	Dual-color	western	blot	analysis	confirmed	that	ssMyBP-C	was	expressed	in	all	skeletal	muscles	tested,	as	well	as	additional,	large	mixed	muscles,	such	as	the	quadriceps	and	the	gastrocnemius	(data	not	shown).	Interestingly,	fsMyBP-C	was	only	expressed	in	the	EDL	and	TA	skeletal	muscles,	but	not	the	FDB	nor	SOL.	This	was	confirmed	using	traditional	Western	blot	(Figure	8),	using	alternative	antibodies	for	fast-	and	slow-skeletal	MyBP-C.	Perhaps	most	surprisingly,	fsMyBP-C	was	not	expressed	in	the	FDB,	which	is	considered	a	fast-type	skeletal	muscle,	warranting	some	caution	when	considering	the	nomenclature	of	the	skeletal	isoforms.	Indeed,	earlier	researchers	also	found	the	naming	conventions	to	be	unsatisfactory(Dhoot,	Hales,	Grail,	&	Perry,	1985)	There	were	no	muscles	tested	with	only	fsMyBP-C,	though	there	are	muscles	in	avian	species	that	do	exclusively	express	fsMyBP-C	
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	isoform	in	adulthood(Obinata	&	Shinbo,	1987).	Overall,	the	expression	profile	suggests	ssMyBP-C	is	the	baseline	MyBP-C	isoform	necessary	for	normal	function	throughout	skeletal	muscles,	while	fsMyBP-C	expression	may	augment	particular	muscle	function.	Notably,	data	on	function	of	both	isoforms	are	lacking.			
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Figure	 7.	 Expression	 profile	 of	 skeletal	 MyBP-C	 in	 FVB/N	 WT	 mice.	 Four	skeletal	muscles	were	 chosen	 to	 represent	 different	 types	 of	muscles.	Extensor	
digitorum	 longus	 (EDL)	 and	 flexor	 digitorum	 brevis	 (FDB)	 are	 fast-type	 skeletal	muscles,	soleus	(SOL)	is	slow-type,	and	tibialis	anterior	(TA)	is	composed	of	both	slow-	and	 fast-type	 skeletal	muscles.	 fsMyBP-C	 is	 expressed	 in	 the	EDL	and	TA,	while	ssMyBP-C	is	expressed	in	all	skeletal	muscle	tested.		
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Figure	 8.	 Skeletal	 MyBP-C	 expression	 quantified.	 Densitometry	 scan	 of	traditional	Western	blots	validate	expression	profile	demonstrated	in	dual-color	immunoblots	(Figure	7).		
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2.4	Summary:	expression	of	MyBP-C	isoforms	is	complex		
		 Cardiac	and	skeletal	MyBP-C	isoforms	are	the	predominant	isoforms	expressed	in	cardiac	and	skeletal	muscles,	respectively.	However,	contrary	to	commonly	held	preconceptions,	MyBP-C	isoforms	often	co-express	with	one	another	in	health	and	disease,	cardiac	and	skeletal	muscle	(Figure	9).		Both	skeletal	isoforms	(ssMyBP-C	and	fsMyBP-C)	are	expressed	in	the	heart	at	the	protein	level:	ssMyBP-C	is	expressed	in	the	atrial	tissues	of	the	heart	and	fsMyBP-C	is	upregulated	in	the	heart	during	disease	conditions.	The	differential	expression	of	ssMyBP-C	and	fsMyBP-C	in	various	skeletal	muscles	adds	another	layer	of	complexity.	While	ssMyBP-C	is	expressed	in	every	skeletal	muscle	we	tested,	fsMyBP-C	is	expressed	only	within	mixed	skeletal	muscles	we	tested.	Further	complications	arise	when	one	considers	that	fsMyBP-C	is	not	expressed	in	skeletal	muscles	that	are	considered	‘fast’-type	(e.g.	FDB),	warranting	some	caution	when	considering	the	nomenclature.	It	is	worth	noting	that	the	naming	convention	of	slow-skeletal,	fast-skeletal,	and	cardiac	MyBP-C	provides	a	degree	of	insight	into	where	they	are	expressed.	Nevertheless,	the	expression	profile	of	MyBP-C	isoforms	in	cardiac	and	skeletal	muscles	depicts	a	complex	and	nuanced	contractile	protein	whose	function	warrants	detailed	investigation.	In	particular,	the	expression	of	skeletal	MyBP-C	practically	begs	the	question:	what	are	skeletal	MyBP-C	isoforms	doing	in	the	heart?			
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Figure	9.	Summary	of	skeletal	MyBP-C	Expression.	MyBP-C	are	differentially	expressed	in	health	and	disease,	cardiac	and	skeletal	muscles.	Therefore,	the	two	primary	goals	of	my	dissertation	are	to	determine	the	function	of	fsMyBP-C	in	the	context	of	cardiac	muscle	and	fsMyBP-C	function	in	skeletal	muscle.		
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CHAPTER	FOUR	AIMS	AND	HYPOTHESIS	In	the	previous	chapter,	the	combination	of	expression	profile	studies	(Figure	7)	and	previously	published	literature	(Figure	9)	(Dhoot	&	Perry,	2005;	B.	Lin	et	al.,	2013)	clearly	demonstrates	the	presence	of	skeletal	isoforms	of	MyBP-C	in	the	heart	in	health	and	disease,	contrary	to	what	the	names	would	suggest.	The	co-expression	of	various	MyBP-C	isoforms	prompted	the	question:	What	are	the	skeletal	MyBP-C	
isoforms	doing	in	the	heart?	This	question	really	then	prompted	another	question:	
What	are	the	skeletal	MyBP-C	isoforms	doing	in	skeletal	muscles?	The	literature	is	not	particularly	helpful	in	either	regard,	with	only	one	study	comparing	the	function	of	all	three	MyBP-C	(Colson	et	al.,	2012),	one	study	focusing	specifically	on	fsMyBP-C	(M.	Li	et	al.,	2016),	and	few	labs	focused	on	ssMyBP-C	(Ackermann	&	Kontrogianni-Konstantopoulos,	2013;	Gurnett	et	al.,	2010).	The	majority	of	the	research	on	MyBP-C	is	solely	dedicated	to	cMyBP-C,	from	which	my	dissertation	must	draw	certain	intuitive	insights.	However,	this	provides	a	fantastic	opportunity	to	meticulously	compare	and	contrast	fsMyBP-C,	the	least	characterized	isoform,	with	its	slightly	better	known	relative,	ssMyBP-C,	and	most	well-known	isoform,	cMyBP-C.	Therefore,	my	objective	is	to	comprehensively	characterize	the	function	of	
fsMyBP-C	in	the	context	of	cardiac	and	skeletal	muscles.	
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Aim	1.	Determine	the	steady-state	function	of	fsMyBP-C	in	the	cardiac	system	
		 Contrary	to	conventional	wisdom,	fsMyBP-C	is	demonstrated	to	be	expressed	in	the	heart	in	murine	models	of	heart	failure.	The	function	of	fsMyBP-C	in	the	cardiac	system	is	completely	unknown,	though	distinct	structural	differences	at	the	N-terminal	region	of	fsMyBP-C	suggest	functionally	distinct	regulation	of	muscle	contraction	compared	to	cMyBP-C.	In	the	case	of	the	cardiac	isoform,	the	N-terminal	region,	from	the	C0	domain	through	the	C2	domain,	has	been	demonstrated	to	be	necessary	and	sufficient	for	the	normal	function	of	cMyBP-C.	Therefore,	I	
hypothesized	that	fsMyBP-C	N-terminal	region	up	to	the	C2	domain	
differentially	regulates	steady-state	properties	of	cardiac	muscle	contraction.	To	test	this	hypothesis,	recombinant	proteins	were	generated	representing	the	N-terminal	region	of	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C	up	to	and	including	the	C2	domain,	and	were	thusly	named	ssC1C2,	fsC1C2,	and	C0C2,	respectively.	These	recombinant	MyBP-C	N-termini	were	utilized	for	a	battery	of	extensive	tests	based	primarily	using	cardiac	contractile	fibers	and	systems.	The	primary	functional	experiment	used	was	the	steady-state	fiber	force-ATPase	assay,	capable	of	simultaneously	measuring	force-pCa,	force-ATPase,	and	force-stiffness	relationships,	as	well	as	rate	of	tension	redevelopment	(ktr).	Actin	cosedimentation	with	ssC1C2,	fsC1C2,	and	C0C2	was	used	to	determine	differential	affinities	and	capacities	of	MyBP-C	isoforms	to	bind	actin.	These	results	will	determine	the	mechanism	that	may	underlie	differences	in	the	regulation	of	steady-state	function.		
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Aim	2.	Determine	the	dynamic	function	of	fsMyBP-C	in	the	cardiac	system			 Steady-state	measurements	capture	detailed	snapshots	of	a	dynamic	process.	Expression	of	fsMyBP-C	in	the	heart	may	directly	impact	the	dynamics	of	the	heart	at	the	cellular	level.	Previous	studies	have	suggested	diseased	hearts	may	revert	to	a	fetal	gene	programming	to	initially	compensate	for	dysfunction(Rajabi,	Kassiotis,	Razeghi,	&	Taegtmeyer,	2007),	giving	rise	to	re-expression	of	skeletal	isoforms	in	the	heart.	Given	that	cMyBP-C	mutations	are	the	leading	cause	of	HCM,	a	condition	in	which	abnormally	thickened	ventricular	walls	may	impair	relaxation(Bonne	et	al.,	1998;	Marston,	Copeland,	Gehmlich,	Schlossarek,	&	Carrier,	2012),	I	hypothesized	
that	fsMyBP-C	expression	in	cardiac	cells	would	facilitate	relaxation	kinetics.	To	test	the	effects	of	dynamic	contraction	on	function,	unloaded	shortening	was	examined	in	adult	rat	ventricular	myocytes	(ARVM)	overexpressing	full-length,	myc-tagged	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C.	In	addition,	to	elucidate	potential	mechanisms	that	underlie	dynamic	contractile	regulation,	I	applied	computer	modeling	previously	used	to	simulate	unloaded	shortening	of	cardiac	cells(Campbell,	Haynes,	Kelsey	Snapp,	Nava,	&	Campbell,	2013;	Kuo	et	al.,	2014).	Computer	modeling	of	unloaded	shortening	revealed	thin	filament	activation	as	a	unifying	mechanism	behind	both	steady-state	and	dynamic	contraction	experiments.		
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Aim	3.	Determine	the	steady-state	function	of	fsMyBP-C	in	skeletal	muscles		
		 Expression	of	fsMyBP-C	was	specific	to	skeletal	muscles	with	mixed	fiber	types	(Figure	7,8),	in	contrast	to	ssMyBP-C,	which	was	expressed	throughout	all	skeletal	muscles.	This	expression	profile	suggests	fsMyBP-C	exists	to	augment	skeletal	muscle	function	in	which	it	is	expressed.	The	only	study	to	compare	fsMyBP-C	function	with	other	MyBP-C	isoforms	suggests	fsMyBP-C	regulates	by	restricting	actin	torsional	dynamics	(Colson	et	al.,	2012).	In	the	cardiac	isoform,	actin	binding	has	been	demonstrated	to	directly	promote	thin	filament	activation(Mun	et	al.,	2014).	Therefore,	I	hypothesized	that	fsMyBP-C	regulates	
thin	filament	activation	in	skeletal	muscle	system.	To	test	this	hypothesis,	I	utilized	the	force-ATPase	assay	once	to	determine	the	skeletal	muscle	fiber	function	of	EDL	muscles	in	a	novel	mouse	model	dubbed	FSKO	(Fast-Skeletal	MyBP-C	Knock-Out)	mice.	EDL	tissues	were	selected	for	three	reasons:	1)	EDL	muscle	normally	expresses	fsMyBP-C.	The	absence	of	fsMyBP-C	in	FSKO	mice	would	thus	elicit	more	pronounced	skeletal	muscle	deficiencies	in	our	functional	assays	2)	the	fiber	size	of	EDL	is	ideal	for	use	in	force-ATPase	assay,	allowing	for	direct	comparison	with	force-ATPase	assay	3)	EDL	is	commonly	used	to	represent	‘fast-type’	skeletal	muscles	in	the	literature,	allowing	for	comparisons	with	previously	published	literature.	Within	the	scope	of	my	dissertation,	I	focused	on	the	steady-state	functional	aspects	of	the	EDL	of	FSKO	mice.	However,	it	is	worth	noting	additional	biochemical	and	functional	characterization	of	FSKO	mice	are	planned	to	fully	characterize	this	mouse	model.	
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CHAPTER	FIVE	FIBER	FORCE-ATPASE	ASSAY:	N-TERMINAL	REGION	OF	MYBP-C	DIFFERENTIALLY	REGULATES	MUSCLE	CONTRACTION	BY	ACTIVATING	THE	THIN	FILAMENT		
5.1	Abstract	Skeletal	and	cardiac	isoforms	of	MyBP-C	are	co-expressed	in	the	heart	during	health	and	disease,	but	how	ssMyBP-C,	fsMyBP-C	and	cMyBP-C	differ	in	their	regulation	of	function	is	unknown.	Previous	studies	demonstrated	the	necessity	of	the	N-terminal	region	of	cMyBP-C,	but	each	MyBP-C	isoform	is	structurally	distinct	within	this	region.	Therefore,	I	hypothesized	that	the	fsMyBP-C	N-terminal	region	up	to	the	
C2	domain	differentially	regulates	steady-state	properties	of	cardiac	muscle	
contraction.	To	test	this	hypothesis,	I	utilized	the	force-ATPase	assay	to	determine	the	function	of	recombinant	proteins	representing	the	critical	N-terminal	region	of	MyBP-C	(ssC1C2,	fsC1C2,	C0C2)	in	adult	rat	papillary	muscle	fibers	(Figure	10),	which	are	sufficiently	large	for	experiments	and	share	homology	with	mice.	The	results	demonstrated	that	fsC1C2	and	C0C2	increased	Ca2+-sensitivity	of	force	development,	as	well	as	rate	of	tension	redevelopment	at	submaximal	Ca2+	levels,	suggesting	that	these	N-terminal	regions	affect	thin	filament	activation.	While	ssC1C2	was	not	significantly	different	from	controls,	it	was	also	not	significantly	different	from	fsC1C2,	suggesting	this	isoform	may	operate	at	an	intermediary	modality	and/or	at	even	lower	ranges	of	Ca2+.		
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Figure	10.	MyBP-C	N-termini.	Recombinant	proteins	representing	the	N-terminal	functional	region	of	MyBP-C	isoforms	were	generated	up	to,	and	including,	the	C2	domain.	 SDS-PAGE	 gels	 demonstrate	 the	 relative	 size	 and	 purity	 of	 each	 of	 the	MyBP-C	 recombinant	 proteins,	 encompassing	 the	 N-terminal	 region,	 up	 to	 and	including	the	C2	domain.	The	N-terminal	fragments	for	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C	are	named	ssC1C2,	fsC1C2,	and	C0C2,	respectively.	Previous	studies	have	demonstrated	 that	 this	 region	 is	 necessary	 and	 sufficient	 to	 recapitulate	 the	function	of	cMyBP-C.	
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Figure	11.	Papillary	muscle	fiber	preparation.	Papillary	muscles	were	excised	from	rats	and	permeabilized	overnight.	Muscles	were	trimmed	down	to	size	and	t-clipped.	 The	 fibers	 need	 to	 be	 this	 size	 to	 ensure	 penetration	 by	 recombinant	MyBP-C	N-termini,	as	well	as	Ca2+.			
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5.2	Results	
5.2.1	Absolute	Force:	fsC1C2	and	C0C2	promotes	submaximal	force	
generation,	and	ssC1C2	trend	suggests	graded	regulation	Similar	studies	have	demonstrated	cMyBP-C	N-terminal	fragments	do	not	alter	maximal	force	production	in	the	heart(Herron	et	al.,	2006;	Razumova	et	al.,	2008).	At	maximal	activation	states,	permeabilized	fibers	are	exposed	to	pCa	4.5,	in	which	Ca2+	levels	are	in	excess	of	what	is	physiologically	experienced	by	the	sarcomere.	At	pCa	4.5,	maximal	force	generation	was	unchanged	between	fibers	incubated	with	ssC1C2,	fsC1C2,	and	C0C2,	reflecting	the	previous	functional	assays	using	N-terminal	fragments	of	cMyBP-C.	However,	our	studies	demonstrated	that	fsC1C2	and	C0C2	conferred	significant	force	generation	at	submaximal	Ca2+	levels	to	different	degrees	(Figure	12).	Interestingly,	at	most	submaximal	Ca2+	levels,	ssC1C2	was	not	significantly	different	from	controls	nor	other	MyBP-C	fragments,	suggesting	ssC1C2	may	operate	at	an	intermediary	step	or	at	even	lower	Ca2+	levels	that	are	outside	precision	of	the	force-ATPase	assay.	Changes	in	submaximal	force	generation	suggested	MyBP-C	isoforms	confer	Ca2+-sensitization	of	force	development	and/or	regulate	contraction	via	isoform-specific	mechanisms.			
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Figure	 12.	 Force-pCa	 relationship.	 fsC1C2	 and	 C0C2	 promoted	 greater	submaximal,	 but	 not	maximal,	 force	 generation.	 Graphs	 represented	 as	mean	 ±	SEM,	*p<0.05	vs.	controls,	**p<0.01	vs.	controls,	#p<0.05	vs.	ssC1C2/fsC1C2,	n=8-9	animals		
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5.2.2	Force-pCa:	fsC1C2	and	C0C2	confers	Ca2+-sensitization	of	force	
development			 To	determine	Ca2+-sensitivity	of	force	development,	submaximal	force	was	normalized	to	Fmax	for	each	fiber.	That	is,	maximal	force	was	set	to	1,	and	subsequent	submaximal	activations	of	the	fiber	was	normalized	as	a	percentage,	providing	a	force-pCa	curve	(Figure	13).	The	force-pCa	relationship	reveals	a	leftward	shift	in	fsC1C2	and	C0C2,	indicating	less	Ca2+	is	required	to	generate	the	same	amount	of	force.	Conversely,	a	relative	rightward	shift	would	signify	a	desensitizing	effect.	By	convention,	quantification	of	Ca2+-sensitivity	was	calculated	by	determining	the	pCa50,	which	is	the	pCa	value	at	which	half-maximal	force	is	generated.	This	revealed	greater	pCa50	values,	and	thus	Ca2+-sensitizing	effects,	by	both	fsC1C2	and	C0C2	compared	to	controls	(Figure	13).	Once	again,	the	pCa50	value	for	ssC1C2	was	between	controls	and	fsC1C2/C0C2,	further	demonstrating	MyBP-C	isoforms	are	not	functionally	equivalent	and	perhaps	operated	via	unique	mechanisms.			
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Figure	 13.	 Ca2+-sensitivity	 of	 force	 development.	 Relative	 force-pCa	 curves	demonstrate	 fsC1C2	and	C0C2	causes	a	 leftward	 shift	of	 the	 curve	 compared	 to	ssC1C2	and	control.	Quantification	of	pCa50	values	demonstrate	fsC1C2	and	C0C2	increase	Ca2+-sensitivity.	Graphs	represented	as	mean	±	SEM,	*p<0.05	vs.	controls,	**p<0.01	vs.	controls,	#p<0.05	vs.	ssC1C2/fsC1C2,	n=8-9	animals.	
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5.3.3	Stiffness-Force	Muscle	fiber	stiffness	is	simultaneously	recorded	during	force	recordings	and	are	a	measure	of	bound	cross-bridges.	Therefore,	stiffness	would	be	indicative	of	whether	MyBP-C	isoforms	differentially	regulated	myosin	binding	to	actin.	At	maximal	levels,	stiffness	is	not	significantly	different	between	ssC1C2,	fsC1C2,	and	C0C2,	suggesting	the	maximal	number	of	XB	that	can	be	bound	is	not	affected	by	MyBP-C	N-termini	(Figure	14).	When	stiffness-force	relationship	is	analyzed,	one	obtains	a	linear	relationship	that	is	one	measure	of	the	duty	ratio	(Figure	14).	The	slope	of	which	is	the	amount	of	XB	required	to	generate	a	certain	amount	of	force.	Quantification	of	the	slopes	(stiffness/force)	for	the	stiffness-force	relationship	reveals	no	significant	difference	between	groups.	The	closest	to	significance	was	fsC1C2’s	trend	towards	decreased	stiffness/force	values.	Interestingly,	two	inferences	can	be	made	from	these	observations.	First,	lack	of	regulation	in	stiffness	suggests	MyBP-C	N-termini	may	not	be	the	primary	regulators	of	myosin	during	contraction.	This	does	not	preclude	MyBP-C	regulation	of	myosin	during	relaxation,	MyBP-C	regulation	of	myosin	in	other	conditions	(e.g.	post-translational	modification,	disease,	etc.),	nor	the	possibility	that	the	assay	used	lacked	the	necessary	sensitivity.	Thus,	MyBP-C	isoforms	may	regulate	contraction	via	interactions	with	actin.	Second,	the	trend	in	fsC1C2	observed	suggested	potential	that	fsC1C2	may	regulate	another	aspect	of	contractile	function.			
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Figure	 14.	 Stiffness-force	 relationship.	 fsC1C2	 and	 C0C2	 trend	 towards	decreased	 stiffness,	 suggesting	 they	 may	 reduce	 the	 number	 of	 cross-bridges	required	per	unit	of	muscle	contraction.	However,	changes	were	not	significantly	different.	Graphs	represented	as	mean	±	SEM,	 *p<0.05	vs.	controls,	**p<0.01	vs.	controls,	#p<0.05	vs.	ssC1C2/fsC1C2,	n=8-9	animals.	
55	
	
	
5.2.4	ATPase-Force	ATPase	activity	of	muscle	fibers	during	steady-state	contraction	was	measured	using	spectrophotometric	recording	of	NADH	conversion	to	NAD+,	which	is	enzymatically	linked	to	ATPase	activity	of	the	myosin	head.	A	previous	trend	in	fsC1C2	stiffness/force	values	suggested	fewer	bound	XB	are	required	to	generate	force,	prompting	the	hypothesis	that	fsC1C2	improves	the	efficiency	of	contraction.	If	so,	tension	cost,	or	the	amount	of	ATP	required	to	generate	force,	would	also	be	reduced.	To	determine	tension	cost,	the	ATPase-force	relationship	was	plotted	for	individual	fibers,	generating	a	linear	relationship	whose	slope	would	represent	tension	cost	(Figure	15).	The	steeper	the	slope,	the	higher	the	tension	cost,	and	vice	versa.	Analysis	of	ATPase-force	relationship	demonstrated	fsC1C2	alone	significantly	reduced	tension	cost	compared	to	controls	(Figure	15),	suggesting	fsC1C2	regulation	of	contraction	reduced	the	demand	for	ATP	required	to	generate	force.	None	of	the	MyBP-C	N’	fragments	altered	maximal	ATPase	activity.	The	results	presented	thus	far	demonstrate	MyBP-C	differentially	facilitates	contraction,	but	not	necessarily	a	mechanism	by	which	contraction	is	regulated.	The	literature	points	to	two	powerful	interaction	partners,	myosin	and	actin,	but	stiffness	data	(or	lack	thereof)	suggests	MyBP-C	N-termini	may	function	via	actin	interactions.	Differential	binding	to	thin	filament	proteins	may	also	explain	why	fsC1C2	alone	decreased	tension	cost	in	the	fiber	studies,	which	is	explored	in	the	next	chapter.			
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Figure	 15.	 fsC1C2	 decreases	 tension	 cost.	 (left)	 ATPase-force	 relationship	(binned	data)	demonstrate	energy	expenditure	per	unit	force.	(right)	Slope	from	the	 ATPase-force	 relationship	 was	 then	 calculated	 to	 determine	 tension	 cost.	Graphs	 represented	as	mean	±	SEM,	 *p<0.05	vs.	 controls,	 **p<0.01	vs.	 controls,	#p<0.05	vs.	ssC1C2/fsC1C2,	n=8-9	animals.	
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5.2.5	Rate	of	tension	redevelopment	I	hypothesized	the	mechanism	for	MyBP-C	regulation	of	contraction	is	due	to	interactions	between	MyBP-C	N-termini	and	actin,	the	rate	of	tension	redevelopment	(ktr)	of	the	muscle	fibers	was	analyzed.	The	ktr	is	a	measure	of	XB	kinetics	and	thin	filament	activation.	To	determine	ktr	values,	a	rapid	release	and	restretch	maneuver	is	applied	to	the	muscle	fibers	at	the	end	of	contraction.	This	maneuver	breaks	XB	by	physically	disrupting	actomyosin	interactions	by	rapidly	shortening	the	muscle	fiber	sarcomere	length.	Subsequently,	the	restretch	back	to	the	original	sarcomere	length	will	allow	for	myosin	to	once	again	bind	to	actin,	in	which	the	rate	of	force	redevelopment,	ktr,	can	be	measured	(Figure	16).	Since	XB	interactions	have	been	broken,	the	primary	affecter	of	ktr	is	the	activation	state	of	the	thin	filament.	Results	demonstrate	that	at	maximal	activation	levels,	ktr	is	unchanged	between	groups	(Figure	17).	However,	at	submaximal	activation	levels	(pCa	6),	fsC1C2	confers	higher	ktr	relative	to	controls,	and	C0C2	confers	greater	ktr	relative	to	both	controls	and	ssC1C2,	indicating	MyBP-C	N-termini	have	graded	capacity	to	activate	the	thin	filament	(C0C2	>	fsC1C2	>	ssC1C2).	Interestingly,	these	results	correlate	with	the	force	generation	data	at	their	respective	activation	levels	(Figure	17).	Specifically,	Fmax	and	ktr	(pCa	4.5)	demonstrate	no	change	between	all	groups,	but	both	fsC1C2	and	C0C2	demonstrate	increased	submaximal	force	and	ktr	(pCa	6),	suggesting	thin	filament	activation	is	how	MyBP-C	differentially	regulates	contraction	at	these	ranges	of	Ca2+.	
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Figure	16.	Rapid	release	and	restretch	maneuver.	By	 rapidly	 shortening	 the	sarcomere	 to	 80%,	 attached	 cross-bridges	 are	 broken.	 The	 following	 restretch	back	to	resting	sarcomere	length	allows	the	detached	cross-bridges	to	re-attach,	thus	regenerating	 force.	The	rate	of	 tension	redevelopment	(ktr)	 is	a	measure	of	thin	 filament	 activation,	 because	 the	 state	 of	 thin	 filament	 is	 the	 primary	determinant	after	cross-bridges	are	removed.		
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Figure	 17.	 fsC1C2	 and	 C0C2	 increase	 cross-bridge	 cycling	 kinetics	 at	
submaximal	Ca2+	 levels.	The	rate	of	 force	redevelopment	(ktr)	was	determined	following	a	rapid	release	and	restretch	maneuver	(Figure	16).	Graphs	represented	as	 mean	 ±	 SEM,	 *p<0.05	 vs.	 controls,	 **p<0.01	 vs.	 controls,	 #p<0.05	 vs.	ssC1C2/fsC1C2,	n=5-9	animals.	
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 Control +ssC1C2 +fsC1C2 +C0C2 
pCa50 5.2 ± 0.46 5.47 ± 0.06 5.71 ± 0.06* 5.6 ± .16* 
Tension 
Cost 4.94 ± 0.45 3.95 ± 0.30* 2.7 ± .40** 4. 1 ± 0.36* 
ktr (pCa 6) 1.97 ± 0.98 3.70 ± 1.81 4.23 ± 0.50* 6.22 ± 0.53***# 
Force  
(pCa 6) 0.62 ± 0.32 3.27 ± 1.70 9.48 ± 2.40** 9.50 ± 2.09** 
Table	2.	Effects	of	MyBP-C	N-termini	as	determined	by	Force-ATPase	assay.	Units	for	tension	cost	(pmol/s/fiber	volume),	ktr	(s-1),	force	(mN/mm2).	Values	are	mean	±	SEM.	***p<0.0001,	**p<0.01,	*p<0.05	vs.	control;	#p<0.05	vs.	ssC1C2	(n=5-9	animals)		
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5.2.6	Changes	in	steady-state	function	were	not	due	to	changes	in	ionic	
strength	nor	presence	of	random	exogenous	protein			 Ionic	strength	has	been	previously	demonstrated	to	alter	steady-state	myofilament	properties	(April,	Brandt,	Reuben,	&	Grundfest,	1968;	Iwamoto,	2000;	Julian	&	Moss,	1981;	Martyn	&	Gordon,	1988;	Thames,	Teichholz,	&	Podolsky,	1974).	In	the	present	study,	recombinant	proteins	were	dialyzed	in	PBS	and	subsequently	lyophilized.	Briefly,	this	means	the	recombinant	proteins	in	solution	were	freeze-dried	(see	Chapter	12).	The	lyophilized	recombinant	proteins	(at	10	µM)	were	reconstituted	with	relaxing	or	preactivation	solution	prior	to	the	beginning	of	the	fiber	assays.	It	was	possible	that	the	residual	salts	that	remained	after	the	lyophilization,	however	minimal,	may	influence	functional	results	by	increasing	ionic	strength.	A	second	possible	source	of	aberrant	results	may	arise	from	the	presence	of	any	random	large	protein.	That	is	to	say,	the	results	were	from	random	large	proteins	interacting	with	the	myofilament	and	not	due	to	specific	interactions	of	MyBP-C	fragments.	Therefore,	to	determine	whether	the	additional	salts	from	the	lyophilization	process	was	sufficient	to	induce	changes	in	force	production,	stiffness,	and	ATPase	activity,	I	generated	recombinant	proteins	(ssC1C2,	fsC1C2,	and	C0C2)	dialyzed	in	PBS	and	diH2O,	followed	by	lyophilization	and	reconstitution	in	relaxing	and	preactivation	solutions	to	a	concentration	of	10	µM	(the	concentration	used	in	the	previously	presented	fiber	studies)	and	30	µM	(Figure	18).	Because	proteins	dialyzed	in	diH2O	would	not	have	residual	salts,	these	recombinant	proteins	would	
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	not	contribute	to	ionic	strength.	An	additional	control,	chicken	egg	albumin,	was	processed	in	parallel	with	MyBP-C	proteins	to	control	for	the	presence	of	a	random	large	protein	in	the	system.	Chicken	egg	albumin	was	chosen	as	a	control,	because	its	size	is	approximately	the	average	of	the	MyBP-C	fragments	(~45	kDa).	
Baseline	 activation	 data	 for	 fibers	 were	 first	 gathered	 in	 the	 absence	 of	recombinant	 proteins,	 followed	 by	 incubation	 with	 recombinant	 proteins	 and	 a	subsequent	maximal	activation.	The	differences	between	the	second	activation	and	initial	activation	were	calculated	as	ΔForce,	ΔStiffness,	and	ΔATPase	activity	(Figure	
19).	 Results	 demonstrate	 no	 significant	 changes	 in	 these	 functional	 parameters,	regardless	of	whether	10	µM	recombinant	proteins	were	dialyzed	in	PBS	and	diH2O.	This	suggests	that	the	functional	studies	conducted	with	recombinant	proteins	at	10	µM	were	not	influenced	significantly	by	increases	in	ionic	strength.	Furthermore,	the	observed	changes	in	function	in	previous	results	(e.g.	increase	in	force)	are	opposite	of	 what	 one	would	 predict	 if	 ionic	 strength	were	 increased,	 as	 increases	 in	 ionic	strength	have	been	previously	demonstrated	to	depress	force.		
To	determine	whether	even	higher	 concentrations	of	 recombinant	proteins	dialyzed	 in	 PBS	 can	 be	 used,	 fibers	 were	 also	 tested	 in	 the	 presence	 of	 30	 µM	recombinant	 proteins.	 Results	 demonstrate	 that	 even	when	 recombinant	 proteins	were	lyophilized	and	reconstituted	to	a	final	concentration	of	30	µM,	the	contribution	of	 the	 residual	 salts	 to	 ionic	 strength	were	 not	 sufficient	 to	 significantly	 alter	 the	steady-state	functional	parameters,	with	the	exception	of	fsC1C2	dialyzed	in	PBS,	
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	which	drastically	reduced	force	production	(Figure	19).	Because	recombinant	fsC1C2	 dialyzed	 in	 PBS	 was	 at	 such	 a	 low	 concentration	 initially,	 this	 required	significantly	 larger	volume	 to	be	 lyophilized	 to	 reach	a	 final	 concentration	30	µM.	Thus,	the	lyophilization	process	drastically	increased	the	quantities	of	residual	salts	in	 the	 lyophilized	 form.	 In	 support	 of	 this,	 fibers	 incubated	 with	 comparable	quantities	 of	 lyophilized	 salts	 also	 reflected	 the	 decrease	 in	 force	 production	observed	in	fsC1C2	in	PBS	(30	µM),	but	fibers	incubated	with	fsC1C2	in	diH2O	at	30	µM	 did	 not	 alter	 functional	 parameters.	 Thus,	 a	 high	 concentration	 is	 not	recommended	 when	 using	 low-yield	 recombinant	 proteins	 dialyzed	 in	 PBS.	 Even	slight	variations	in	initial	concentrations	of	recombinant	proteins	can	greatly	amplify	the	effects	of	ionic	strength	or	possibly	protein	stability.	Given	these	results,	careful	consideration	must	be	given	 to	 the	process	of	generating	 recombinant	proteins	 to	ensure	the	validity	of	assays	where	they	are	used	in	the	future.		
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Figure	18.	Protocol	to	determine	whether	changes	in	ionic	strength	affected	
force	 development.	 Papillary	 muscles	 were	 excised	 and	 initially	 activated	 to	obtain	baseline	force,	stiffness,	and	ATPase	measurements,	followed	by	incubation	with	MyBP-C	N-termini	dialyzed	in	PBS	or	diH2O	(10	and	30	µM).	This	was	followed	by	a	second	activation	and	changes	in	parameters	were	determined.		
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Figure	19.	 Ionic	 strength	 changes	do	not	 alter	 force	production	 at	 10	µM.	Chicken	egg	albumin	(Alb),	ssC1C2	(slow),	fsC1C2	(fast),	C0C2	(cardiac)	dialyzed	in	PBS	or	diH2O	were	incubated	with	muscle	papillary	fibers	using	the	protocol	in	Figure	18.	 (left)	No	changes	were	detected	when	10	µM	of	proteins	were	used,	demonstrating	ionic	strength	did	not	affect	force-ATPase	data.	(right)	There	were	also	no	difference	using	30	µM	of	proteins,	with	the	exception	of	fsC1C2	dialyzed	in	 PBS	 (fast	 PBS	 30),	 suggesting	 that	 the	 ionic	 concentration	 was	 sufficiently	increased	 to	 cause	 a	 significant	 depression	 in	 force.	 This	 was	 due	 to	 higher	concentration	of	salts,	as	demonstrated	by	an	included	group	of	just	the	salts	(PBS	30).	Graphs	represented	as	mean	±	SEM,	*p<0.01,	n=3-9	
66	
	
	
	
5.3	Discussion	
MyBP-C	N-termini	have	graded	ability	to	regulate	muscle	fiber	contraction			 The	primary	aim	of	the	experiments	in	this	chapter	is	to	determine	the	steady-state	regulation	of	contraction	by	the	N-terminal	region	of	fsMyBP-C	(fsC1C2)	in	the	context	of	the	heart,	because	skeletal	MyBP-C	isoforms	may	be	present	in	cardiac	muscles	(Figure	6).	In	addition,	I	compared	the	function	of	fsC1C2	to	the	N-terminal	region	of	ssMyBP-C	and	cMyBP-C,	the	latter	of	which	had	been	previously	demonstrated	to	increase	Ca2+-sensitivity	and	submaximal	force	generation	(Herron	et	al.,	2006;	Razumova	et	al.,	2008;	Razumova	et	al.,	2006;	Walcott,	Docken,	&	Harris,	2015).	Due	to	the	distinct	structural	differences	between	MyBP-C	isoforms	within	the	N-terminal	region,	I	had	hypothesized	each	isoform	has	distinct	regulatory	profiles.	The	N’	fragments	(ssC1C2,	fsC1C2,	and	C0C2)	were	applied	to	cardiac	papillary	muscle	fibers	in	the	force-ATPase	assay.		The	fiber	force-ATPase	assay	is	an	incredibly	powerful,	albeit	time-consuming,	experimental	assay,	capable	of	measuring	several	parameters	simultaneously	from	a	single	mounted	fiber.	In	reality,	the	assay	is	an	amalgamation	of	several	experiments	that	analyze	multiple	relationships	including	force-ATPase,	force-pCa,	stiffness-force,	and	ktr-pCa.	Furthermore,	modifications	can	be	easily	made	to	experiment	protocols	to	test	for	additional	effects	that	were	not	tested	for	in	the	present	study.	Here,	permeabilized	rat	papillary	muscle	fibers	were	incubated	with	10	μM	ssC1C2,	fsC1C2,	and	C0C2,	and	analyzed	the	resultant	relationships	
67	
	
	between	Force,	Ca2+	(pCa),	ATPase	activity,	stiffness,	and	ktr	(Figure	12	-	17).	The	presence	of	exogenous	N-terminal	fragments	had	no	effect	on	maximum	force	development	and	fiber	stiffness	at	pCa	4.5	(Figure	12,	14);	both	serving	as	measures	of	the	number	of	attached	cross-bridges.	However,	as	reported	previously	(Razumova	et	al.,	2008),	exogenous	C0C2	increased	Ca2+	sensitivity	of	force	development	as	evidenced	by	a	leftward	shift	in	the	normalized	force-pCa	curve	and	thus	a	significant	increase	in	the	pCa50	(Figure	13).	This,	too,	was	the	case	for	fsC1C2,	but	not	ssC1C2,	strongly	suggesting	the	various	MyBP-C	N-termini	are	not	functionally	equivalent.	The	differences	between	fsC1C2	and	C0C2	versus	ssC1C2	are	further	emphasized	by	analyzing	kinetic	parameters	of	cross-bridge	cycling	(Figure	17).				 Previous	studies	have	demonstrated	cMyBP-C	can	activate	the	thin	filament	independently	of	Ca2+	(Mun	et	al.,	2014),	which	may	underlie	its	ability	to	promote	submaximal	force	(Herron	et	al.,	2006)	(Figure	12).	To	determine	whether	this	may	be	a	unifying	mechanism	by	which	fsC1C2	and	C0C2	regulate	contraction,	we	applied	a	rapid	release	and	immediate	restretch	of	the	fiber’s	length	to	detach	cross-bridges.	As	expected,	at	maximal	activation	(pCa	4.5),	ktr	was	not	different	than	control	for	all	N-terminal	fragments	(Figure	17	and	Table	2).	However,	at	submaximal	Ca2+	levels	(pCa	6.0),	both	fsC1C2	and	C0C2	increased	ktr	relative	to	controls,	suggesting	that,	in	addition	to	Ca2+-sensitization	of	the	thin	filament,	these	fragments	can	also	modulate	cross-bridge	kinetics	by	activating	the	thin	filament	in	a	Ca2+-dependent	manner	to	promote	submaximal	force	generation	(Figure	12).	
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	The	effect	of	MyBP-C	N-termini	is	summarized	in	Online	Video	2	(https://vimeo.com/148663470).	Interestingly,	ssC1C2	was	not	significantly	different	from	control	nor	fsC1C2,	suggesting	the	slow-skeletal	isoform	may	regulate	function	at	an	intermediate	modality	or	at	even	lower	Ca2+	levels.	My	working	theory	is	that	ssC1C2	regulates	contraction	at	low	Ca2+,	while	fsC1C2	regulates	function	at	high	Ca2+,	while	C0C2	regulates	contraction	over	the	full	spectrum	of	Ca2+.		
Comparison	to	the	literature	provides	unique	insight	into	molecular	
mechanisms	by	which	MyBP-C	regulates	contraction	
		 The	objective	of	this	experiment	was	to	parse	out	differences	between	ssC1C2,	fsC1C2,	and	C0C2,	with	the	latter	fragment	acting	as	an	additional	control	in	order	to	compare	it	with	the	literature.	It	is	important	to	note	that	this	study	utilized	a	concentration	(10	µM)	that	was	much	higher	than	some	previously	published	studies	using	cMyBP-C	fragments	(Hofmann,	Hartzell,	&	Moss,	1991;	Previs	et	al.,	2012;	A.	Weith	et	al.,	2012;	A.	E.	Weith	et	al.,	2012),	comparable	to	others	(Razumova	et	al.,	2008;	Razumova	et	al.,	2006;	Witayavanitkul	et	al.,	2014),	and	much	lower	than	others	(Herron	et	al.,	2006).	When	comparing	results	with	previously	published	research,	one	must	consider	the	variability	in	concentrations	used	(from	nM	concentrations	–	80	µM),	species	used	(mouse,	rat,	chicken,	human),	exogenous	tags	(biotin,	cMyc,	His,	TEV-cleaved),	and	experimental	assays	(laser-trap	orbital,	motility	assay,	force-ATPase).	Further	complicating	matters	is	the	fact	that	within	the	same	group,	different	species	of	recombinant	cMyBP-C	were	used	in	
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	different	systems	(e.g.	mouse	cMyBP-C	fragment	in	chicken	skeletal	muscle)(A.	Weith	et	al.,	2012;	A.	E.	Weith	et	al.,	2012).			That	being	said,	there	were	many	similarities	and	differences	between	the	present	results	and	previously	published	literature,	some	of	which	are	worth	highlighting	for	discussion.		
		 As	previously	mentioned,	MyBP-C	promotion	of	Ca2+-sensitivity	and	submaximal	force	generation	from	our	results	is	in	agreement	with	similar	studies	in	the	literature	(Herron	et	al.,	2006;	Razumova	et	al.,	2008;	Razumova	et	al.,	2006),	though	some	disagreement	exists	within	the	literature	(Kulikovskaya	et	al.,	2003).	The	latter	study	did	conduct	its	experiments	at	a	longer	SL,	which	has	been	demonstrated	to	eliminate	the	effect	of	cMyBP-C(Witayavanitkul	et	al.,	2014),	suggesting	cMyBP-C	contributes	to	length-dependent	activation	(Cazorla	&	Lacampagne,	2011;	de	Tombe	et	al.,	2010;	Kumar	et	al.,	2015;	Mamidi,	Gresham,	Verma,	&	Stelzer,	2016).	Whether	cMyBP-C	is	physically	altering	myofilament	properties	to	activate	LDA	or	transducing	a	signal	to	its	myofilament	neighbors	requires	further	analysis	in	future	studies.		
		 One	particular	study	was	of	particular	interest	for	comparison	(Witayavanitkul	et	al.,	2014),	because	it	was	the	closest	to	the	present	study	and	the	similarities	and	differences	yielded	novel	insights	into	my	own	data.	In	the	aforementioned	study,	the	fragment	used	is	known	as	hC0C1f,	which	is	a	human	cMyBP-C	fragment	that	is	cleaved	after	a	major	cardiac	insult	(Govindan	et	al.,	2013;	Govindan	et	al.,	2012).	This	cMyBP-C	fragment	demonstrated	reduction	in	Fmax,	as	well	as	other	pathogenic	qualities,	in	contrast	to	observations	in	the	present	study	
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	and	other	studies	that	demonstrate	no	change	in	Fmax,	but	increases	in	submaximal	force	(Herron	et	al.,	2006).	Importantly,	the	source	of	this	fragment,	hC0C1f,	is	from	a	pathogenic	source	and	cleaves	at	a	critical	region	within	the	M-motif,	which	has	been	demonstrated	to	be	vital	for	cMyBP-C	function(Razumova	et	al.,	2008),	though	not	necessarily	binding	(Shaffer,	Kensler,	&	Harris,	2009).	Specifically,	the	first	17	amino	acids	of	the	M-motif	are	absolutely	necessary	which	is	absent	in	the	hC0C1f	(Witayavanitkul	et	al.,	2014).	Therefore,	the	hC0C1f	fragment	would	have	been	able	to	bind	to	the	thin	filament,	but	due	to	the	lack	of	this	critical	region	in	the	M-motif,	hC0C1f	also	was	unable	to	promote	force	generation.	One	reason	why	the	present	study	used	N-terminal	fragment	that	included	up,	and	including,	the	C2	region	was	because	of	the	numerous	studies	that	demonstrated	that	this	entire	N-terminal	region	was	necessary	to	recapitulate	cMyBP-C	function	and	that	missing	pieces	were	only	able	to	partially	regulate	contraction.	Thus,	the	hC0C1f	acts	as	competitive	inhibitor	of	force	generation:	it	binds	to	the	thin	filament,	but	lacks	the	critical	region	of	the	M-motif	and	C2	domain	that	are	required	to	help	promote	force	generation.		
		 But	the	hC0C1f	also	promoted	ktr	and	Ca2+-sensitivity,	reflecting	our	results	and	much	of	the	literature.	How	does	it	do	so,	considering	it	is	missing	a	specific	region	that	I	just	mentioned	was	critical	to	cMyBP-C	function?	The	answer	lies	within	the	data	set	itself:	promotion	of	ktr	implicates	the	hC0C1f	as	an	agent	capable	of	influencing	thin	filament	activation,	which	is	closely	related	to	Ca2+-sensitivity.	This	suggests	that	the	fragment	hC0C1f,	while	lacking	the	region	critical	for	force	
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	generation,	still	has	the	critical	regions	responsible	for	actin	binding	and	thin	filament	activation.	When	considering	the	results	from	the	present	study	and	Witayavanitkul	et	al.	2014,	there	appears	to	be	a	division	of	labor	between	the	domains	within	the	N-terminal	region	of	MyBP-C:	particular	domains	are	responsible	for	certain	aspects	of	MyBP-C	function	and/or	binding	to	different	locations	on	the	thin	filament.	Overall,	these	results	suggested	that	MyBP-C	N-termini	interaction	with	the	thin	filament	underlies	its	differential	regulation,	and	the	next	chapter	expounds	on	my	working	theory	through	experiments	that	examine	actin	binding.		
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CHAPTER	SIX	ACTIN	BINDING	STUDIES	
6.1	Abstract	The	fiber	force-ATPase	assays	from	Chapter	Five	demonstrated	that	the	MyBP-C	N-terminal	fragments	are	not	functionally	equivalent.	C0C2	and	fsC1C2	had	significantly	greater	activation	of	the	thin	filament	and	submaximal	force	production,	while	ssC1C2	only	trended	towards	significant	regulation	of	contraction.	These	results	suggested	that	MyBP-C	binding	to	the	thin	filament	may	underlie	functional	regulation	of	steady-state	contraction.	To	investigate	MyBP-C	binding	effects,	three	experiments	with	these	recombinant	proteins	were	employed:	1)	actin	cosedimentation	2)	3D	reconstructions	3)	TPA	assays.	My	results	with	the	actin	cosedimentation	suggests	that	fsC1C2	and	C0C2	have	greater	binding	capacity	to	bind	actin.	In	support	of	this,	3D	reconstructions	of	actin	binding	demonstrate	fsC1C2	and	C0C2	bind	two	subdomains	of	actin	(SD1	and	SD2),	while	ssC1C2	bind	only	one	subdomain	(SD1).	Interestingly,	SD1	is	the	binding	site	for	myosin,	and	thus	may	be	why	ssC1C2	is	unable	to	regulate	contraction	at	higher	Ca2+.	However,	at	low	Ca2+,	3D	reconstructions	of	thin	filaments	demonstrated	C0C2	and	ssC1C2	had	greater	capacity	to	activate	the	thin	filament	than	fsC1C2.	Finally,	TPA	assays	demonstrated	each	MyBP-C	uniquely	regulated	actin	torsional	movement,	with	C0C2	and	ssC1C2	exhibiting	increased	resilience	relative	to	fsC1C2.	
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6.2	Results	
6.2.1	Actin	binding	–	cosedimentation	assays	To	assess	the	binding	affinities	and	capacities	of	MyBP-C	N-termini	to	actin,	I	applied	actin	cosedimentation	assays	(Figure	20)	in	which	increasing	concentrations	of	ssC1C2,	fsC1C3,	and	C0C2	(1-30	µM)	were	incubated	with	F-actin	(5	µM)	and	rapidly	spun	down.	Combined	data	from	high-speed	cosedimentation	of	MyBP-C	fragments	(Figure	21)	revealed	affinity	(Kd)	to	actin	(Table	3)	and	binding	capacity	(Bmax)	for	each	isoform.	Previous	reports	have	independently	determined	the	Kd	and	Bmax	values	for	C0C2	(Shaffer	et	al.,	2009),	and	comparisons	with	our	C0C2	cosedimentation	results	reveal	similar	binding	values	(Shaffer	et	al.	2009:	Kd	13.7	±	5.5	and	Bmax	=	0.92	±	0.11).	Interestingly,	comparisons	with	the	ssC1C2	and	fsC1C2	reveals	unique	actin	binding	profiles.		The	ssC1C2	binding	curve	yielded	the	lowest	Kd,	suggesting	significantly	higher	binding	affinity	relative	to	fsC1C2	and	C0C2.	However,	fsC1C2	and	C0C2	exhibited	approximately	twice	the	Bmax	value	relative	to	ssC1C2,	suggesting	greater	binding	capacity.	This	last	result	suggested	fsC1C2	and	C0C2	may	bind	have	two	binding	sites	on	actin,	while	ssC1C2	only	had	one.	However,	cosedimentation	assays	alone	could	not	determine	whether	binding	was	the	case.	Therefore,	we	next	collaborated	with	the	lab	of	Dr.	Roger	Craig	to	confirm	binding	capacity	and	more	specifically	determine	localization	of	binding.			
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Figure	 20.	 Cosedimentation	 binding	 data	 for	 C0C2.	 A	 representative	 high	speed	cosedimentation	assay.	(left)	C0C2	(1-30µM)	was	mixed	with	5	µM	F-actin	and	 spun	 for	 30	min.	 at	 390,000	 x	 g.	 (right)	Quantification	 of	 binding	 curves	required	comparison	with	standard	curve	that	was	run	on	each	gel,	consisting	of	varying	 known	 molar	 ratios	 of	 C0C2	 to	 actin.	 This	 was	 done	 for	 multiple	experiments	using	ssC1C2,	fsC1C2,	and	C0C2.																																																
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Figure	 21.	 fsC1C2	 and	 C0C2	 have	 higher	 F-actin	 binding	 capacity.	 (left)	Summary	data	of	actin	cosedimentation	data	demonstrates	fsC1C2	and	C0C2	has	approximately	 twice	the	Bmax	(binding	capacity)	of	ssC1C2	(see	Table	3).	 (right)	actin	 monomer	 diagram	 showing	 the	 four	 subdomains.	 The	 higher	 capacity	suggests	possible	binding	to	twice	the	number	of	actin	subdomains.	(n=6-12)	
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MyBP-C isoform n Kd (µM) Bmax (mol/mol actin) 
ssC1C2  7 2.08 ± 0.76* 0.45 ± 0.15*# 
fsC1C2 6 10.51 ± 4.75 1.14 ± 0.25 
C0C2 12 16.62 ± 2.88 1.11 ± 0.12 
Table	3.	Summary	of	dissociation	constants	(Kd)	and	molar	binding	ratios	(Bmax)	calculated	from	binding	of	recombinant	MyBP-C	N-terminal	proteins	to	F-actin.	Values	are	mean	±	SEM.	(p<0.05	significant	change	compared	*vs.	C0C2	#vs.	fsC1C2)	
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6.2.2	Actin	binding	–	3D	reconstructions	In	collaboration	with	Dr.	Ji	Young	Mun	and	Dr.	Roger	Craig,	we	investigated	the	effects	of	ssC1C2,	fsC1C2,	and	C0C2	on	actin	binding.	While	the	ideas	and	conclusions	made	in	this	section	are	my	own,	the	figures	in	this	section	represent	the	work	of	Dr.	Mun	and	are	reproduced	here	with	permission.				 In	the	previous	cosedimentation	assay,	the	Bmax	value	for	fsC1C2	and	C0C2	were	approximately	twice	that	of	ssC1C2,	suggesting	the	fsC1C2	and	C0C2	has	twice	the	binding	capacity	as	ssC1C2.	Thus,	fsC1C2	and	C0C2	may	bind	to	twice	as	many	locations	on	actin	as	ssC1C2.	Specifically,	fsC1C2	and	C0C2	may	bind	to	two	subdomains	on	actin,	while	ssC1C2	only	binds	to	one	subdomain.	To	visualize	binding	interactions	of	recombinant	MyBP-C	N-termini,	we	utilized	3D	reconstructions	of	computer-aligned	actin	filaments	decorated	with	ssC1C2,	fsC1C2,	and	C0C2.	Both	filamentous	actin	(F-actin)	and	reconstituted	thin	filaments	were	decorated	with	MyBP-C	N-terminal	fragments	and	imaged	by	negative	stain	electron	microscopy	(EM)	at	low	Ca2+	(Figure	22).	The	increase	in	filament	diameter	for	F-actin	in	the	presence	of	each	MyBP-C	N-termini	confirms	the	fragments’	ability	to	bind	actin	(data	not	shown).		Similarly,	all	fragments	bound	to	reconstituted	thin	filaments,	consisting	of	actin	(A),	tropomyosin	(Tm),	and	troponin	(Tn)	(Figure	23).	We	propose	reconstituted	thin	filaments	represents	the	state	of	the	thin	filament	at	low	Ca2+,	because	Tn	and	Tm	are	present	on	the	actin	filament,	blocking	the	myosin-
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binding	site.	Conversely,	F-actin	alone	represents	the	state	of	the	thin	filament	at	high	Ca2+,	because	the	myosin-binding	sites	on	actin	are	not	obscured.			
In	agreement	with	the	actin	cosedimentation	assay	results,	3D	reconstructions	indicate	fsC1C2	and	C0C2	decoration	on	the	actin	filament	creates	a	greater	space-filling	density	(Figure	22),	correlating	roughly	with	actin	subdomains	1	(SD1)	and	subdomain	2	(SD2).	In	contrast,	ssC1C2	decoration	creates	a	much	smaller	density	that	correlates	with	subdomain	1	of	actin.	Interestingly,	subdomain	1	of	actin	is	also	known	to	be	the	primary	binding	site	for	the	myosin	S1	region.	At	higher	Ca2+,	myosin	S1	region	would	compete	for	the	SD1	region	and	displace	ssC1C2,	which	would	explain	why	its	regulatory	function	is	limited	at	higher	Ca2+.	However,	because	fsC1C2	and	C0C2	bind	to	both	SD1	and	SD2	of	actin,	these	isoforms	are	capable	of	continued	regulation	of	contraction	at	high	Ca2+.				 Previous	studies	reported	that	binding	of	cMyBP-C	N-terminal	fragments	(C0C2,	C0C3)	to	thin	filaments,	in	the	absence	of	Ca2+,	shifts	Tm	from	the	“blocked”	position	to	“closed”	position,	which	then	favors	weak	cross-bridge	formation	(Mun	et	al.,	2014).		3D	reconstruction	of	the	thin	filament	was	used	to	determine	the	degree	of	Tm	shift	by	ssC1C2,	fsC1C2,	and	C0C2.	To	visualize	relative	difference	in	MyBP-C-mediated	Tm	shift,	the	position	of	Tm	in	the	blocked	and	closed	positions	are	indicated	by	the	red	and	green	helices,	respectively	(Figure	23).	Densities	representing	Tm	position	demonstrate	that	all	MyBP-C	N-terminal	fragments	can	shift	Tm	position	at	least	from	the	blocked	to	closed	position,	and	thus	activate	the	thin	filament	in	a	manner	similar	to	that	initiated	by	Ca2+.	However,	C0C2	and	
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ssC1C2	mediated	a	greater	Tm	shift	compared	to	the	closed	Tm	position	(green	helix),	while	fsC1C2	only	shifted	Tm	equal	to	the	closed	position.	Furthermore,	C0C2	had	a	greater	capacity	to	shift	Tm	relative	to	ssC1C2,	revealing	a	graded	thin	filament	activation	capacity	(C0C2	>	ssC1C2	>	fsC1C2)	at	low	Ca2+.	The	unique	capacity	of	each	isoform	to	shift	Tm	strongly	suggests	differential	thin	filament	activation	may	be	one	mechanism	by	which	MyBP-C	isoforms	regulate	contraction	at	low	Ca2+.		
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Figure	22.	3D	reconstruction	of	F-actin	and	MyBP-C	visualize	binding	sites.	F-actin	were	decorated	with	MyBP-C	N-termini	and	computer-assisted	alignment	of	EM	images	was	used	to	create	3D	reconstructions.	(left)	Actin	filament	alone	was	used	as	a	reference	for	modeling	with	MyBP-C	N-termini,	and	the	actin	monomer	diagram	was	overlaid	to	identify	approximate	locations	of	subdomain	(SD)	1	–	4.	Densities	representing	ssC1C2	(red	circle),	fsC1C2	(blue	circle),	and	C0C2	(black	circle)	are	highlighted.	Original	image	courtesy	of	Dr.	Ji	Young	Mun	and	Dr.	Roger	Craig.	
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Figure	 23.	 3D	 reconstructions	 of	 reconstituted	 thin	 filament	 and	 MyBP-C	
demonstrate	 thin	 filament	 activation.	 Reconstituted	 thin	 filament	 consist	 of	actin,	tropomyosin	(Tm),	and	troponin	(Tn).	The	red	helix	is	the	Tm	in	the	blocked	position,	when	it	is	blocking	the	actin	SD1	where	myosin	binds.	The	green	helix	is	Tm	 in	 the	 closed	position,	with	actin	SD1	exposed.	Decoration	with	 ssC1C2	and	C0C2	are	able	to	shift	Tm	beyond	the	closed	position,	while	fsC1C2	shifted	Tm	to	the	 closed	 position.	Original	 image	 courtesy	 of	Dr.	 Ji	 Young	Mun	 and	Dr.	 Roger	Craig.		
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6.2.3	Actin	binding	–	TPA	assays	
In	collaboration	with	Dr.	Brett	Colson	and	David	Thomas,	we	investigated	the	effects	of	ssC1C2,	fsC1C2,	and	C0C2	on	actin	dynamics.	While	the	ideas	and	conclusions	in	this	section	are	my	own,	the	figures	in	this	section	represent	the	work	of	Dr.	Brett	Colson	and	are	reproduced	with	permission.				 To	test	whether	MyBP-C	isoforms	alter	the	nature	of	interaction	with	actin	at	low	and	high	Ca2+,	we	utilized	time-resolved	phosphorescence	anisotropy	(TPA)	to	determine	how	MyBP-C	isoforms	influence	the	torsional	dynamics	of	actin	filaments	(Figure).	We	propose	that	the	F-actin	model	allows	representation	of	the	state	of	the	thin	filament	at	high	Ca2+,	when	the	myosin-binding	sites	on	actin	are	exposed.	More	importantly,	TPA	assay	provides	data	on	actin	dynamics,	which	becomes	important	when	considering	actin	filaments	are	not	stationary	players	during	contraction:	the	helical	coils	of	actin	filaments	are	rapidly	twisting,	with	variable	amplitude	and	rates	of	torsion.	Differential	actin	binding	by	the	N-terminal	region	of	MyBP-C	isoforms	would	uniquely	restrict	the	amplitude	and	rates	of	actin,	potentially	in	a	manner	to	assist	or	resist	myosin	binding.				 To	determine	intrafilament	torsional	motions	with	the	TPA	assay,	actin	filaments	were	uniformly	labelled	at	Cys374	with	a	phosphorescent	dye	(Figure	
24A).	MyBP-C	N-termini	decreased	amplitude	of	labelled	actin	TPA	decay	(Figure	
24B),	and	all	three	MyBP-C	N-termini	had	similar	effects	in	increasing	final	anisotropy	at	low	and	high	occupancy	(Figure	24C).	TPA	amplitude	was	greatly	reduced	by	all	three	MyBP-C	N-termini	(Figure	24D),	with	C0C2	having	the	greatest	
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amount	of	restriction	on	the	amplitude	of	actin	motion,	followed	by	fsC1C2	and	ssC1C2.	Interestingly,	while	C0C2	increased	the	rate	of	actin	torsional	dynamics,	fsC1C2	decreased	this	torsional	rate	(Figure	24E	and	Table	4).	Because	C0C2	restricted	the	range	of	motion	of	actin,	the	rates	of	torsion	were	increased	as	expected,	a	trend	also	observed	in	ssC1C2-bound	actin.	Both	increased	rate	and	decreased	amplitude	is	indicative	of	an	actin	filament	whose	movement	is	constrained,	but	is	moving	very	rapidly	within	its	limitations	by	ssC1C2	and	C0C2.	However,	fsC1C2	reduced	both	amplitude	and	rate	of	actin	filament	torsion,	suggesting	fsC1C2	binding	may	result	in	an	actin	filament	that	is	less	dynamic	and	have	a	reduced	effect	on	the	resilience	of	the	actin	filament.	Resilience	is	an	indicator	of	stored	elastic	energy,	and	is	determined	by	Rate/Amplitude	(A.	Y.	Lin	et	al.,	2012).	We	observed	ssC1C2	and	C0C2	confer	higher	resilience	relative	to	fsC1C2	(Figure	24F),	and	higher	resilience	has	been	previously	shown	to	increase	tension	cost	(Jones	et	al.,	1999).	Interestingly,	our	fiber	studies	also	demonstrate	ssC1C2	and	C0C2	exhibit	higher	tension	cost	relative	to	fsC1C2	(Figure	15),	suggesting	fsC1C2	reduces	tension	cost	through	isoform-specific	regulation	of	actin	resilience.	Furthermore,	fsC1C2	also	reduced	tension	cost	relative	to	control	fibers,	suggesting	fsC1C2	is	an	active,	rather	than	passive,	participant	in	the	regulation	of	actin	resilience.	The	unique	restrictions	on	actin	torsional	motion	by	each	MyBP-C	isoform	all	indicate	unique	binding	interactions	with	actin.
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Figure	 24.	MyBP-C	 differentially	 regulates	 actin	 torsional	 dynamics.	Actin	binding	was	determined	by	time-resolved	phosphorescence	anisotropy	(TPA)	and	actin	co-sedimentation	assays.	1	µM	of	MyBP-C	N-termini	binding	to	actin	alters	actin	 amplitude,	 rate	 of	 twisting,	 and	 resilience.	 (A)	 Schematic	 of	 intrafilament	torsional	dynamics.	(B)	MyBP-C	N-termini	results	in	the	decay	of	ErIA-actin	(black	trace)	compared	to	actin	alone	(grey	trace)	and	(C)	Dependence	of	final	anisotropy	of	C0C2,	 fsC1C2,	 and	ssC1C2	on	actin	binding.	 (D)	Final	anisotropy	of	actin	as	a	function	of	the	fraction	bound	to	MyBP-C	N-termini.	All	three	MyBP-C	N-termini	restricted	 the	 amplitude	 of	 actin	 torsional	 dynamics,	 but	 C0C2	 significantly	reduced	 the	amplitude	 relative	 to	 fsC1C2	and	ssC1C2.	 (E)	 fsC1C2	decreased	 the	rate	 of	 actin	 torsion,	 but	 C0C2	 increased	 the	 rate	 of	 actin	 torsion.	 (F)	Maximal	relative	resilience	was	measured	as	rate/amplitude	compared	to	actin	alone.	C0C2	and	ssC1C2	both	significantly	increased	resilience,	but	fsC1C2	did	not.	Source	data	shown	 in	 Table	 4.	 Original	 image	 courtesy	 of	 Dr.	 Brett	 Colson	 and	 Dr.	 David	Thomas.	
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MyBP-C 
Isoform φ1 φ2 r1 r2 r∞ 
None 182±10 26±2 0.042±0.002 0.036±0.002 0.035±0.005 
C0C2 221±18 19±3 0.014±0.002* 0.030±0.003 0.079±0.006* 
fsC1C2 326±19* 21±3 0.023±0.002* 0.021±0.002* 0.062±0.008* 
ssC1C2 201±16 27±3 0.020±0.004* 0.029±0.001* 0.059±0.005* 
Table	4.		Effect	of	Saturating	Concentration	of	MyBP-C	N-terminal	regions	on	the	Parameters	of	Actin	TPA	Decay.	Values	are	mean	±	SEM	(n	>	5).	(*p<0.05	significant	change	compared	to	control)	
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6.3	Discussion	
		 The	mechanism	by	which	MyBP-C	isoforms	regulate	at	low	and	high	Ca2+	is	explored	in	this	section.	These	results	collectively	demonstrate	distinct	actin	profiles	by	each	MyBP-C	N-termini,	suggesting	its	functional	role	is	rooted	in	changes	at	the	molecular	level.	The	higher	affinity	(Kd)	and	lower	capacity	(Bmax)	of	ssC1C2	to	actin	(Figure	21	and	Table	3)	may	explain	why	ssC1C2	only	activates	during	the	early	stages	of	contraction	at	low	Ca2+	(Figure	23),	while	modestly	regulating	contraction	at	higher	Ca2+,	as	observed	in	fiber	studies	(Figure	17).	Conversely,	fsC1C2	and	C0C2	had	approximately	twice	the	capacity	to	bind	to	actin,	suggesting	these	isoforms	may	bind	to	an	additional	site	on	actin	(Figure	22).	This	additional	interaction	may	confer	the	greater	ability	to	regulate	contraction	at	higher	Ca2+	levels	later	in	the	contraction	process.	Indeed,	3D	reconstructions	of	F-actin	demonstrates	fsC1C2	and	C0C2	interact	with	actin	SD1	and	SD2,	while	ssC1C2	only	binds	SD1.	Assuming	binding	to	the	same	actin	monomer,	this	makes	perfect	sense	why	ssC1C2	is	no	longer	able	to	regulate	contraction	at	later	stages	of	contraction,	because	actin	SD1	is	also	a	well-known	myosin-binding	site	for	the	myosin	S1.	As	the	contractile	process	progresses,	additional	myosin	S1	will	directly	compete	with	MyBP-C	for	actin	SD1.	Therefore,	the	lone	actin-binding	site	for	ssC1C2	will	be	occupied	while	fsC1C2	and	C0C2	can	still	regulate	contraction	during	these	later	stages	of	contraction	via	its	interaction	with	SD2.	
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Some	questions	arise	when	considering	the	other	actin	subdomains	and	myosin	interaction	with	actin.	First,	why	does	MyBP-C	not	bind	to	actin	subdomains	3	and	4?	Second,	how	might	myosin	binding	to	actin	SD1	disrupt	fsC1C2	and	C0C2?	The	literature	provides	clues	that	may	answer	both	in	the	future.	First,	MyBP-C	is	unlikely	to	bind	to	SD3	and	SD4:	these	subdomains	are	thought	to	be	responsible	for	intrafilament	interactions	(Chapter	Two)(Kabsch	et	al.,	1990).	The	helical	structure	of	F-actin	requires	tight	interactions	between	its	actin	monomers,	which	provides	a	major	groove	in	which	another	helical	thin	filament,	Tm,	and	SD3	and	SD4	mediate	that	function.				 Second,	myosin	would	certainly	compete	with	fsC1C2	and	C0C2	binding	to	actin	SD1,	though	evidence	of	myosin	binding	to	other	regions	of	actin	indicate	myosin	S1	interaction	may	actually	be	further	away	from	where	fsC1C2	and	C0C2	bind	to	actin.	Our	data	does	not	preclude	MyBP-C	or	myosin	binding	on	different	sites	on	multiple	actin,	nor	binding	to	inter-subdomain	pockets.	While	SD1	is	thought	to	be	the	primary	binding	site	for	myosin,	an	unresolved	loop	region	of	myosin	head	is	known	to	interact	with	the	SD1	and	SD3	junction	(Milligan,	1996;	Milligan	et	al.,	1990).	However,	this	junction	is	further	away	from	SD2	and	less	likely	to	interfere	with	fsC1C2	and	C0C2	binding	to	SD2	(Figure	21),	though	myosin	S1	and	MyBP-C	are	still	in	close	proximity	and	our	data	does	not	preclude	this	possibility.	Furthermore,	myosin	S1	and	MyBP-C	may	interact	on	different	actin	
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monomers	along	the	F-actin	filament	and	not	necessarily	be	in	direct	competition.	Interestingly,	the	actin-binding	affinities	of	MyBP-C	N-termini	versus	myosin	S1	have	not	been	compared.	As	an	aside,	it	may	very	well	be	that	MyBP-C	N-termini	have	a	higher	affinity	for	actin	SD1	compared	to	myosin	and	its	role	is	to	block	actomyosin	interaction.	This	is	unlikely,	as	fiber	studies	performed	with	fragments	in	the	present	study	and	elsewhere	would	have	shown	significant	suppression	of	force	production,	especially	in	light	of	the	high	concentrations	used.	Furthermore,	even	if	this	was	the	case	in	vivo,	this	effect	would	be	localized	to	every	third	myosin	within	the	C-zone	and	not	throughout	the	sarcomere.				 MyBP-C	isoforms	exhibit	different	capacity	to	shift	Tm	(C0C2	>	ssC1C2	>	fsC1C2)	(Figure	23).	Remarkably,	ssC1C2	and	C0C2	were	able	to	shift	Tm	position	beyond	the	‘closed’	position,	suggesting	the	greater	capacity	to	shift	Tm	by	C0C2	and	ssC1C2	at	low	Ca2+	is	important	for	initiating	the	contraction	process.	At	higher	Ca2+,	fsC1C2	and	C0C2	are	the	predominant	activators	of	the	thin	filament	(Figure	17),	suggesting	these	isoforms	are	responsible	for	regulation	in	the	later	stages	of	contraction.	Increased	thin	filament	activation	by	fsC1C2	and	C0C2	would	expose	the	myosin-binding	site	on	actin,	promoting	actomyosin	interaction	and	thus	cross-bridge	duration.	This	supports	the	previous	research	that	suggests	MyBP-C	contributes	to	the	maintenance	of	longer	cross-bridge	duration	(Palmer	et	al.,	2011),	and	may	thus	explain	why	we	observe	greater	submaximal	force	production	(Figure	
12).	Enhancement	of	cross-bridge	duration	almost	assuredly	rests	on	the	ability	of	MyBP-C	to	regulate	actomyosin	interaction	via	direct	interaction.	
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In	support	of	this,	MyBP-C/actin	binding	confers	structural	stability	to	actin	akin	to	myosin/actin	binding	during	cross-bridge	formation	(Figure	24),	suggesting	maintenance	of	actin	resilience	structural	stability	may	be	necessary	to	facilitate	optimal	force	production,	which	is	often	disrupted	in	disease	states	(A.	Y.	Lin	et	al.,	2012).	MyBP-C	stabilization	of	actin	may	therefore	be	an	important	aspect	of	its	role	at	high	[Ca2+],	and	provides	evidence	of	a	so-called	“C-bridge,”	in	which	MyBP-C	binding	to	actin	creates	a	second	thick-to-thin	filament	interaction	to	modulate	the	cross-bridge.	This	MyBP-C/actin	interaction	may	compete	with	myosin	for	binding	site	or	place	a	load	on	actin,	thus	limiting	contractility	(Walcott	et	al.,	2015;	A.	Weith	et	al.,	2012;	A.	E.	Weith	et	al.,	2012).	Alternatively,	MyBP-C	may	place	a	load	on	myosin,	limiting	cross-bridge	formation	via	a	tethering	mechanism	(Barefield	&	Sadayappan,	2010;	Kampourakis,	Yan,	Gautel,	Sun,	&	Irving,	2014).	Indeed,	recent	studies	show	MyBP-C	may	favor	myosin	binding	at	high	[Ca2+]	(Kampourakis	et	al.,	2014;	Previs	et	al.,	2016),	further	highlighting	the	Ca2+-dependent	effects	of	MyBP-C.	Whether	MyBP-C	acts	on	myosin	or	actin	at	high	[Ca2+],	these	constraints	suggest	an	important	physiological	role	for	MyBP-C	in	preventing	muscle	hypercontractility	(Spudich,	2014).	Although	our	studies	focused	on	MyBP-C	N-terminal	interactions	with	actin,	they	certainly	do	not	preclude	MyBP-C	interaction	with	myosin,	and	may	indeed	suggest	interactions	both	myosin	and	actin,	possibly	even	simultaneously.		
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CHAPTER	SEVEN	
UNLOADED	SHORTENING	IN	VITRO:	FROM	STEADY-STATE	TO	DYNAMIC	CONTRACTION	
7.1	Abstract	How	does	MyBP-C	regulation	of	steady-state	contractile	properties	translate	to	dynamic	contraction?	To	answer	this	question,	unloaded	shortening	kinetics	experiments	were	applied	to	determine	how	MyBP-C	isoforms	may	differentially	regulate	dynamic	contraction.	Using	cultured	adult	rat	ventricular	myocytes	(ARVM)	as	our	baseline	model,	we	overexpressed	full-length,	cMyc-tagged	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C	using	adenoviral	constructs	(Figure	25).	After	48H	in	culture,	biochemical	and	unloaded	shortening	analysis	were	used	to	determine	expression,	localization,	and	function.	Western	blot	demonstrated	partial	replacement	of	the	endogenous	cMyBP-C	in	cardiac	cells,	and	immunofluorescence	demonstrated	localization	of	exogenously-expressed	MyBP-C	isoforms	approximately	within	the	C-zone.	Surprisingly,	functional	data	demonstrates	no	change	in	contraction	kinetics,	but	ARVM	overexpressing	ssMyBP-C	and	fsMyBP-C	exhibited	faster	relaxation	kinetics	relative	to	cMyBP-C.	This	suggests	that	cMyBP-C	expression	may	prolong	relaxation	kinetics	and/or	ssMyBP-C	and	fsMyBP-C	facilitate	faster	relaxation	kinetics.	To	parse	out	the	potential	mechanisms	behind	this	unexpected	result,	computer	modeling	was	employed	next.	
	 	 91	
	
	
	
	
	
Figure	25.	Adenoviral-mediated	overexpression	of	MyBP-C	in	ARVM.	Adult	rat	ventricular	myocytes	(ARVM)	were	isolated,	infected	with	full-length,	cMyc-tagged	 MyBP-C	 isoforms,	 and	 cultured	 for	 48	 hours.	 Replacement	 levels,	localization,	and	unloaded	shortening	function	was	then	measured.		
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7.2	Results	
7.2.1	Replacement	Levels	ARVM	were	infected	with	adenoviral	constructs	(MOI:	1000)	overexpressing	full-length,	Myc-tagged	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C,	and	cultured	for	48	hours.	After	48	hours,	ARVM	were	prepared	for	Western	blot	analysis	to	determine	the	amount	of	replacement	of	endogenous	cMyBP-C	(Figure	26).	ARVM	groups,	including	an	uninfected	control	(UI),	were	probed	with	antibodies	for	ssMyBP-C,	fsMyBP-C,	cMyBP-C,	and	cMyc	antibodies	to	determine	the	amount	of	exogenously	expressed	MyBP-C	isoforms	present	in	ARVM.	Results	demonstrate	that	ARVM	infection	was	specific	to	the	adenoviral	construct,	as	well	as	cMyc.	Due	to	limitation	of	culture	time	(48	hours),	replacement	levels	were	low,	though	still	significantly	higher	compared	to	UI	controls	and	not	significantly	different	between	groups.			
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Figure	26.	Adenoviral	 constructs	 partially	 replaced	 endogenous	MyBP-C.	 .	ARVM	infected	with	adenoviral	constructs	overexpressing	full-length,	myc-tagged	MyBP-C	isoforms	were	cultured	for	48	hours	(MOI	1000).	Uninfected	ARVM	were	included	 as	 controls.	 (left)	 Western	 blots	 demonstrate	 specific	 expression	 of	ssMyBP-C	and	fsMyBP-C.	Due	to	the	presence	of	endogenous	cMyBP-C	in	ARVM,	adenoviral-mediated	MyBP-C	expression	was	determined	by	cMyc	tag	detection.	All	 analyses	 are	 shown	 normalized	 to	 ß-actin.	 (right)	 Adenoviral-mediated	overexpression	of	ssMyBP-C	(red	stripes),	fsMyBP-C	(blue	stripes)	and	cMyBP-C	(black	 stripes)	 partially	 replaced	 endogenous	 cMyBP-C	 (black	 solid),	 as	demonstrated	by	densitometry	analysis.	There	were	no	significant	differences	in	replacement	 levels	 between	 adenoviral-mediated	 ssMyBP-C,	 fsMyBP-C,	 and	cMyBP-C.	
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7.2.2	Localization	determined	by	IF	Infected	ARVM	were	also	imaged	using	immunofluorescence,	and	included	immunolabeling	with	α-actinin,	which	detected	the	Z-disc	locations	(Figure	27).	This	allowed	visualization	of	the	exogenously	expressed	MyBP-C	within	the	sarcomere.	IF	data	demonstrates	that	exogenously-expressed	MyBP-C	isoforms	were	localized	specifically	within	the	sarcomere	and	probably	within	the	C-zone,	as	determined	by	doublets	located	within	the	Z-discs.	Resolution	of	the	IF	images	were	not	precise	enough	to	determine	whether	adenovirally-mediated	expression	of	MyBP-C	caused	localization	into	the	adjacent	D-zone.			
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Figure	27.	Exogenous	MyBP-C	isoforms	localized	within	the	sarcomere.	ARVM	infected	 with	 adenoviral	 constructs	 overexpression	 of	 full-length,	 myc-tagged	ssMyBP-C,	 fsMyBP-C	 and	 cMyBP-C	 were	 cultured	 for	 48	 hours.	 Localization	 of	exogenous	 (A-F)	 ssMyBP-C,	 (G-L)	 fsMyBP-C,	 and	 (M-R)	 cMyBP-C	 was	 detected	using	 immunofluorescence.	 Staining	 for	 α-actinin	 delineates	 the	 location	 of	cardiomyocyte	Z-discs,	the	borders	of	the	sarcomere	(A,	D,	G,	J,	M,	P).	Localization	of	adenoviral-mediated	overexpression	of	MyBP-C	was	detected	using	antibodies	for	ssMyBP-C	(B,	E)	fsMyBP-C	(H,	K)	and	cMyc	(N,	Q).	Merged	images	demonstrated	MyBP-C	expression	was	limited	specifically	within	the	sarcomere	(C,	F,	I,	L,	O,	R).	
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7.2.3	Unloaded	Shortening	After	48	hours	in	culture,	ARVM	were	paced	(2.0	ms,	1	Hz,	20V),	and	contractile	kinetics	were	analyzed.	Baseline	parameters	were	not	significantly	different,	such	as	resting	sarcomere	length	nor	percent	shortening.	Combined	traces	of	each	group	demonstrated	no	significant	changes	in	contraction	kinetics,	but	suggested	MyBP-C	isoforms	altered	relaxation	kinetics	(Figure	28).	Time	to	%Baseline	is	a	measure	of	how	fast	a	cell	returns	to	resting	sarcomere	length	(Baseline).	Thus,	time	to	50%	baseline	is	how	long	the	cell	takes	from	peak	contraction	to	50%	of	its	resting	sarcomere	length.	Quantification	of	time	to	10%	baseline,	50%	baseline,	and	90%	baseline	reveals	cMyBP-C	prolongs	relaxation	kinetics.	Fitting	of	the	relaxation	constant,	tau,	also	demonstrates	cMyBP-C	extends	the	amount	of	time	the	cell	takes	to	relax.			
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Figure	28.	cMyBP-C	prolongs	relaxation	kinetics.	(far	left)	Unloaded	shortening	was	measured	by	changes	 in	sarcomere	 length	(SL)	during	dynamic	contraction	and	 relaxation	 (ARVM	 paced	 at	 1Hz,	 20V,	 2ms).	 Trace	 images	 of	 combined	unloaded	 shortening	 demonstrates	 changes	 to	 relaxation	 kinetics	 (error	 bars	removed	for	clarity).	Relaxation	kinetics	were	quantified	by	(top	 left)	 time	to	%	baseline,	how	fast	the	cell	returns	to	a	%	of	resting	SL,	and	(top	right)	relaxation	constant	tau,	a	logarithmic	fit	of	the	relaxation	curve.	Both	relaxation	parameters,	combined	with	 composite	 traces	of	unloaded	shortening,	demonstrate	 cMyBP-C	prolongs	 relaxation	 kinetics.	 (graphs	 represented	 as	 mean	 ±	 SEM,	 *p<0.05	 vs.	uninfected	controls,	#p<0.05	vs.	cMyBP-C).	(bottom	left)	Resting	sarcomere	length	of	 ARVM	 were	 unchanged	 suggesting	 similar	 starting	 points	 of	 contraction.	(bottom	 right)	 Percent	 shortening	 was	 also	 not	 different	 between	 groups	suggesting	similar	contractility.	(n=42-78	cells,	n=	4-6	animals)	
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7.3	Discussion	To	our	surprise,	MyBP-C	overexpression	in	ARVM	resulted	in	changes	to	relaxation	kinetics,	while	no	changes	were	detected	in	contraction	kinetics.	This	may	have	been	due	to	limitations	of	the	experimental	parameters	and/or	the	ARVM	model	system.	Several	scientific	and	practical	considerations	were	taken	when	designing	the	experiment	to	accommodate	the	ARVM	model.	For	example,	unlike	previous	steady-state	experiments	that	used	just	the	N-terminal	region,	full-length	MyBP-C	isoforms	were	used,	because	our	studies	have	previously	demonstrated	abnormal	localization	and	function	due	to	the	lack	of	the	C-terminal	region	in	the	ARVM	system	(Kuster	et	al.,	2015),	although	the	N-terminal	region	may	still	localize	within	the	A-band	(Herron	et	al.,	2006).	Immunofluorescence	imaging	revealed	adenoviral-mediated	MyBP-C	isoforms	expressed	and	localized	properly	to	the	sarcomere	A-band	where	myosin	thick	filaments	reside	(Figure	27),	and	doublets	reveal	the	exogenously-expressed	MyBP-C	may	even	have	localized	specifically	within	the	C-zone,	though	IF	images	were	not	at	sufficient	resolution	to	preclude	possible	expression	in	the	D-zone	as	well.	Similarities	between	the	MyBP-C	isoforms	in	the	C-terminal	region	suggest	potential	for	such	proper	C-zone	localization.	However,	the	PEVK	repeats	of	cardiac	and	skeletal	isoforms	of	titin	(to	which	MyBP-C	C-terminus	purportedly	anchors	to	the	thick	filament)	have	distinctive	binding	properties	(Linke	et	al.,	2002),	and	one	can	not	presume	skeletal	MyBP-C	isoforms	would	bind	to	cardiac	titin	PEVK	with	the	same	affinity,	and	therefore	affect	contractile	kinetics.	
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In	addition,	only	partial	replacement	of	the	endogenous	cMyBP-C	occurred	after	48	hours,	suggesting	the	changes	in	relaxation	kinetics	were	a	combination	of	the	contribution	of	endogenous	cMyBP-C	and	exogenous	MyBP-C	isoforms.	While	percentage	of	cells	that	contract	in	the	adult	rat	cardiomyocyte	system	is	considered	greater	than	mouse(Pavlovic,	McLatchie,	&	Shattock,	2010),	cellular	viability	is	still	limited	post-isolation(Westfall,	Rust,	&	Metzger,	1997)	due	to	its	lack	of	regenerative	and	proliferative	ability(van	Berlo	et	al.,	2014).	This	allows	adenoviral-mediated	expression	from	30%	to	90%	replacement	of	smaller	proteins,	but	in	those	instances,	structural	integrity	is	compromised,	as	shown	in	their	IF	images	(Fink	et	al.,	2001;	Westfall	et	al.,	1997).	Furthermore,	these	functional	experiments	were	in	permeabilized	cells	rather	than	intact	cells,	and	cell	sarcomere	lengths	were	mechanically	set.	In	my	preparations	for	intact	cardiomyocytes,	reliable	cell	viability	could	only	be	maintained	for	48	–	72	hours.	After	this	time	period,	detectable	sarcomere	lengths	were	considerably	shorter.	In	addition,	cardiomyocyte	structure	had	either	noticeably	deteriorated,	maintained	their	structure	but	were	no	longer	responsive	to	electrical	stimulation,	or	responded	to	stimulation	initially	followed	by	rapid	deterioration	in	cell	structure.		
Isolation	and	culture	techniques	appear	to	be	as	varied	as	the	labs	that	implement	primary	cardiomyocyte	systems	(Wolska	&	Solaro,	1996).	Therefore,	longer	culture	times	were	attempted	via	changing	several	parameters	that	have	
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been	suggested	to	work,	including,	but	not	limited	to,	changing	media	more	frequently	(every	12	hours)	and	adding	ascorbic	acid	to	remove	oxygen	radicals	and	cellular	waste,	cellular	pacing	(0.1	Hz,	2.0ms)	during	culture	to	maintain	contractility,	and	addition	of	2,3-butanedioxome	(BDM)	to	inhibit	contraction	during	culture.	The	most	successful	protocol	tested	was	an	adaptation	of	a	long-term	mouse	cardiomyocyte	isolation	protocol	(O'Connell,	Rodrigo,	&	Simpson,	2007)	that	utilized	a	custom	HMEM-based	media	that	contained	BDM,	which	was	then	carefully	and	slowly	washed	out	with	Tyrode’s	solution	just	prior	to	experimentation.	This	was	a	compromise	of	several	systems	we	tested,	and	is	not	without	its	own	advantages	and	disadvantages,	as	discussed	previously.	However,	this	method	yielded	the	most	consistently	usable	cells	and	was	therefore	implemented	for	the	in	vitro	unloaded	shortening.				 Regarding	the	fact	that	only	relaxation	kinetics	were	altered	and	not	contraction	kinetics,	the	limitations	in	experimental	parameters	(1	Hz,	2.0	ms)	could	have	limited	what	changes	could	be	detected.	Voltage	was	most	commonly	set	at	20V,	but	was	adjusted	such	that	the	minimal	amount	was	required	to	stimulate	the	ARVMs.	At	a	frequency	of	1	Hz,	the	contraction	rate	of	ARVMs	would	closer	reflect	that	of	a	human	heart.	However,	these	conditions	do	not	truly	reflect	that	of	a	human	heart	nor	rodent	heart,	because	the	cardiac	system	would	not	have	the	same	MHC	composition	as	humans	(Miyata,	Minobe,	Bristow,	&	Leinwand,	2000),	and	is	paced	much	slower	than	the	frequency	experienced	in	a	rat	heart	(Azar,	Sharp,	&	Lawson,	2011).	Furthermore,	the	MyBP-C	isoforms	used	in	all	steady-state	and	
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dynamic	experiments	were	that	of	mouse	isoforms,	though	mouse	and	rat	MyBP-C	isoforms	share	similar	homology.	While	there	is	much	to	be	said	regarding	the	caveats	of	choosing	particular	conditions,	the	mix-and-match	of	different	systems	in	the	literature	have	yielded	many	answers	as	well	as	more	questions.				 The	question	originally	proposed	was:	how	does	MyBP-C	regulation	of	steady-state	contractile	properties	translate	to	dynamic	contraction?	The	answer	from	unloaded	shortening	in	intact	myocytes	turned	out	to	be:	cMyBP-C	prolongs	relaxation	kinetics	relative	to	ssMyBP-C	and	fsMyBP-C.	The	question	now	becomes:	by	what	mechanism	does	cMyBP-C	facilitate	prolonged	relaxation	kinetics	relative	to	ssMyBP-C	and	fsMyBP-C?			
	
		 	
	102	
CHAPTER	EIGHT	UNLOADED	SHORTENING	IN	SILICO:	COMPUTER	MODELING	DEMONSTRATES	THIN	FILAMENT	ACTIVATION	BY	MYBP-C	ISOFORMS	CONTRIBUTES	TO	REGULATION	OF	RELAXATION	
8.1	Abstract	To	determine	whether	our	steady-state	observations	on	thin	filament	activation	can	explain	changes	in	relaxation	kinetics	during	dynamic	contraction,	we	utilized	an	online	muscle	simulator	(OMS)	that	had	been	previously	established	to	simulate	unloaded	shortening	of	a	single	cardiomyocyte	(Campbell	et	al.,	2013;	Kuo	et	al.,	2014).	I	applied	parameters	based	on	our	steady-state	experiments	to	the	OMS	that	accounted	for	differential	capacity	to	activate	the	thin	filament	(Figure	29	and	
Table	5).	The	steady-state	studies	suggest	that	ssMyBP-C	activates	the	thin	filament	at	low	[Ca2+],	fsMyBP-C	at	high	[Ca2+],	and	cMyBP-C	activates	at	both	low	and	high	Ca2+.	When	accommodating	for	the	greater	capacity	of	cMyBP-C	to	activate	the	thin	filament,	in	silico	unloaded	shortening	traces	demonstrate	increased	thin	filament	activation	capacity	results	in	prolonged	relaxation	kinetics	(Figure	29).	The	right-shift	of	cMyBP-C’s	relaxation	trace	in	silico	reflects	the	in	vitro	unloaded	shortening	data,	in	which	cMyBP-C	prolongs	relaxation	kinetics	relative	to	ssMyBP-C	and	fsMyBP-C	(Figure	28,	29).	Combined,	these	studies	indicate	that	thin	filament	activation	capacity	can	directly	contribute	to	relaxation	kinetics.		
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8.2	Results	
8.2.1	Thin	filament	activation	
		 In	collaboration	with	Dr.	Stuart	Campbell,	we	investigated	the	effects	of	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C	using	a	muscle	simulation	program.	While	alterations	to	the	simulations	were	conducted	by	myself	and	conclusions	made	in	this	section	are	my	own,	the	muscle	simulation	program	itself	was	written	and	made	available	for	use	by	Dr.	Campbell.	The	results	from	the	simulations	reproduced	are	here	with	permission.		
		 The	muscle	simulation	(OMS)	applied	in	the	present	study	was	previously	used	to	model	unloaded	shortening	of	intact	cardiomyocytes(Campbell	et	al.,	2013;	Kuo	et	al.,	2014;	Sheikh	et	al.,	2012),	and	adapted	for	the	purpose	of	modeling	how	different	MyBP-C	isoforms	may	alter	contractile	kinetics.	Previous	implementations	of	this	simulation	did	not	account	for	contribution	of	cMyBP-C,	and	thus	provided	an	opportunity	to	model	how	all	three	isoforms	regulate	contractile	function.	Based	on	the	results	from	steady-state	experiments,	I	concluded	that	MyBP-C	isoforms	differentially	regulated	thin	filament	activation:	ssMyBP-C	activates	the	thin	filament	at	low	[Ca2+],	fsMyBP-C	activates	at	high	[Ca2+],	and	cMyBP-C	activates	at	both	low	and	high	[Ca2+]	(Online	Video	3	https://vimeo.com/148663467).The	online	muscle	simulation	has	several	parameters	relating	to	various	contractile	properties,	and	the	closest	parameter	that	fit	changes	in	thin	filament	activation	is	kon,	or	the	rate	constant	for	Ca2+	association(Kreutziger,	Gillis,	Davis,	Tikunova,	&	Regnier,	2007)	(Table	5).	Due	to	the	complexities	of	the	simulation,	only	one	
		
104	parameter	was	altered	to	minimize	variability	in	the	output.	Simulation	results	demonstrate	that	increased	ability	for	thin	filament	activation,	the	relaxation	kinetics	of	the	unloaded	shortening	trace	is	clearly	prolonged	with	no	such	changes	in	contraction	kinetics.	This	data	suggests	that	the	expanded	capacity	of	thin	filament	activation	by	cMyBP-C	accounts	for	the	prolonged	relaxation	kinetics	demonstrated	by	in	vitro	unloaded	shortening	experiments	(Figure	29).	
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Figure	29.	Computer	modeling	of	unloaded	shortening	demonstrate	thin	
filament	 activation	 can	 affect	 relaxation	 kinetics.	To	 determine	whether	steady-state	 regulations	 (Figure	 12,17,23)	 can	 explain	 observed	 dynamic	contraction,	 computer	 simulations	 of	 unloaded	 shortening	 were	 run	accommodating	 the	 differential	 capacity	 of	MyBP-C	 isoforms	 to	 activate	 the	thin	 filament.	 See	 Table	 5	 for	 source	 values.	 (bottom)	 Traces	 of	 in	 silico	unloaded	shortening	suggest	the	increased	capacity	of	cMyBP-C	to	activate	thin	filament	contributes	mechanistically	to	relaxation	kinetics.	
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MyBP-C 
isoform kb ku kon koff fapp gapp hf hb gxb gammaB 
Temp. 
(K) 
ssMyBP-C 0.09 0.45 375 0.33 0.30 70e-3 2000e-3 400e-3 0.25 300 323 
fsMyBP-C 0.09 0.45 360 0.33 0.30 70e-3 2000e-3 400e-3 0.25 300 323 
cMyBP-C 0.09 0.45 500 0.33 0.30 70e-3 2000e-3 400e-3 0.25 300 323 
Table	 5.	 	 Computational	 modeling	 parameters	 account	 for	 differential	 thin	filament	activation	(kon)	capacities	of	MyBP-C.	(kb:	rate	of	Ca2+	binding	to	troponin	C;	ku:	rate	of	Ca2+	dissociation	from	troponin	C;	kon	rate	of	tropomyosin	transition	from	blocked	 to	 closed	 state;	koff:	 rate	of	 tropomyosin	 transition	 from	closed	 to	blocked;	 fapp:	 rate	 of	 XB	 attachment;	 gapp:	 rate	 of	 XB	 detachment	 from	 pre-powerstroke	 state;	 hf:	 rate	 of	 forward	 powerstroke;	 hb:	 rate	 of	 reverse	powerstroke;	 gxb:	 rate	 of	 XB	 detatchment	 from	 the	 post-powerstroke	 state;	gammaB:	 cooperative	 coefficient	 representing	 tropomyosin-tropomyosin	interactions;	Temp:	temperature	in	degrees	Kelvin).	
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8.3	Discussion	
		 Our	data	suggests	thin	filament	activation	can	directly	contribute	to	relaxation	kinetics.	I	theorize	this	effect	occurs	because	MyBP-C	activation	of	the	thin	filament	would	favor	cross-bridge	attachment.	Because	cMyBP-C	has	a	greater	capacity	to	activate	the	thin	filament,	the	actin-myosin	interaction	would	presumably	be	stronger	and	longer.	The	longer	duration	of	these	cross-bridges	would	prolong	relaxation,	which	is	observed	in	both	in	silico	and	in	vitro	unloaded	shortening.	This	effect	is	summarized	in	Online	Video	4,	and	has	been	suggested	previously(Davis	et	al.,	2016;	Moss,	2016).	However,	important	limitations	should	be	addressed	to	maintain	perspective	when	interpreting	these	results.	It	is	worth	noting	that	our	modeling	only	accounted	for	differential	MyBP-C	thin	filament	activation	to	focus	on	how	steady-state	experiments	from	the	present	study	translates	to	dynamic	contraction	and	by	what	mechanism.				 The	simulation	does	not	account	for	the	presence	of	endogenous	cMyBP-C	present	in	the	ARVM	system,	and	assumes	the	only	contribution	to	relaxation	kinetics	is	that	of	the	particular	MyBP-C	isoform.	This	is	distinctly	different	from	in	
vitro	experiments,	as	endogenous	cMyBP-C	is	present	in	ARVM.	One	alternative	was	to	utilize	cMyBP-C	knock-out	mice	models	that	lack	cMyBP-C	incorporation	in	the	sarcomere,	two	of	which	are	available	(Harris	et	al.,	2002;	McConnell	et	al.,	1999).	As	the	first	experiment	conducted	to	determine	differences	between	the	MyBP-C	isoforms,	this	was	not	the	route	chosen	due	to	complications	from	the	development	
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of	HCM	and	DCM	in	these	mice	that	may	mask	or	obscure	isoform-specific	changes.	In	addition,	mouse	cardiomyocytes	are	much	less	resilient	than	rat	cardiomyocytes;	thus,	the	adenoviral-mediated	strategy	of	gene	transfer	would	be	significantly	more	difficult	to	implement	or	an	alternative	in	vivo	delivery	approach	would	have	been	required.	Therefore,	as	previously	mentioned,	the	in	vitro	ARVM	express	endogenous	cMyBP-C	that	was	only	partially	replaced	by	exogenous	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C	after	48H	in	culture.	The	differences	in	MyBP-C	regulation	of	relaxation	kinetics	is	thus	likely	underestimated	by	experimental	data.				 The	steady-state	experiments	that	were	used	to	draw	conclusions	regarding	thin	filament	activation	are	also	worth	considering.	Steady-state	experiments	are	like	snapshots	of	a	dynamic	process,	and	the	variety	of	experiments	used	capture	the	process	from	different	vantage	points.	Both	of	which	lend	insight	into	MyBP-C	regulatory	function,	but	highlight	considerations	when	translating	the	results.	Besides	the	fact	that	the	changes	to	the	simulations	were	made	based	on	steady-state	and	not	dynamic	experimental	data	and	that	several	steady-state	experiments	were	utilized,	the	most	discernable	difference	is	the	use	of	N-terminal	versus	full-length	MyBP-C	isoforms	in	the	steady-state	and	full-length.	As	MyBP-C	localization	is	highly	regulated	within	the	C-zone,	the	effects	using	N-terminal	proteins	is	likely	representative	of	an	enhanced	effect	of	MyBP-C.	This	indicates	that	our	steady-state	experiments	exaggerate	MyBP-C	isoform	function	while	dynamic	experiments	underestimates	MyBP-C	function.	Thus,	the	relaxation	data,	however	congruent,	must	be	interpreted	cautiously.	
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	 In	both	the	in	silico	and	in	vitro	unloaded	shortening	studies,	the	stimulation	parameters	of	cardiomyocytes	were	not	altered,	which	allowed	for	comparison,	but	also	limited	the	scope	of	what	we	could	ascertain	between	MyBP-C	isoforms.	The	simulator	did	not	yet	have	function	to	alter	the	stimulation	parameters,	which	would	then	therefore	allow	for	greater	flexibility	in	potential	comparisons	with	in	
vitro	data.	Changes	in	frequency,	pulse	duration,	and	voltage	could	be	altered	to	more	clearly	parse	out	differences	between	MyBP-C	isoforms,	such	as	kinetics-frequency	relationships.	Permeabilized	ARVM	experiments	can	also	be	pursued	to	determine	force-frequency	and	force-pCa	relationships,	bridging	the	gap	in	understanding	from	the	steady-state	fiber	function	data	and	the	dynamic	intact	myocytes	data.	These	experiments	would	provide	greater	evidence	that	thin	filament	activation	can	contribute	to	changes	in	relaxation	kinetics,	and	also	determine	whether	this	mechanism	precludes	alternative	roles	for	MyBP-C	in	regulating	contraction.		
Do	relaxation	results	have	any	physiological	implications?	
		 Why	does	MyBP-C	regulate	relaxation?	The	answer	may	lie	in	what	we	know	regarding	the	expression	profile	of	skeletal	MyBP-C.	In	a	healthy,	adult	heart,	fsMyBP-C	is	not	expressed,	but	is	present	after	some	insult	to	the	heart,	such	as	HF	(B.	Lin	et	al.,	2013).	HF	is	defined	by	the	American	Heart	Association	as:	‘…	a	
complex	clinical	syndrome	that	results	from	any	structural	or	functional	impairment	
of	ventricular	filling	or	ejection	of	blood.’	(Yancy	et	al.,	2013)	
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Because	mutations	in	the	cMyBP-C	are	a	primary	cause	of	HCM,	the	ventricular	or	septal	wall	thickens,	and	the	ventricular	chamber	has	difficulty	filling	with	blood.	In	order	to	compensate	for	the	lack	of	ability	to	relax,	fetal	isoforms	of	MyBP-C	that	facilitate	relaxation	kinetics	are	expressed.	This	reversion	to	fetal	gene	programming	has	been	suggested	to	be	cardioprotective(Depre	et	al.,	1998;	Rajabi	et	al.,	2007).	Conversely,	disruption	of	the	normal	signaling	pathways	that	regulate	gene	expression	have	been	suggested	to	be	maladaptive	(Dirkx,	da	Costa	Martins,	et	al.,	2013;	Hannenhalli	et	al.,	2006).	The	expression	of	fsMyBP-C	in	the	heart	during	HF	is	therefore	an	artifact	of	these	changes.	The	truth	is	likely	somewhere	in	the	middle:	the	expression	of	fetal	gene	programming	may	express	contractile	proteins	that	are	initially	compensatory,	but	long-term	re-expression	of	these	non-native	isoforms	eventually	becomes	disadvantageous	and	harmful.				 The	skeletal	isoforms	are	expressed	in	the	heart	only	conditionally	and	in	relatively	low	quantities,	and	thus	the	physiological	impact	of	unloaded	shortening	results	may	be	limited	in	scope.	The	question	then	is:	do	changes	in	relaxation	kinetics	reflect	a	physiological	phenomenon	in	the	context	of	skeletal	muscles?	The	key	to	answering	this	question	may	rest	within	what	we	know	about	skeletal	disease-causing	mutations	in	ssMyBP-C	and	fsMyBP-C.	Currently,	mutations	in	the	skeletal	MyBP-C	isoforms	are	known	to	cause	three	distinct	skeletal	myopathies:	1)	distal	arthrogryposis,	Type	1	(DA1)	2)	distal	arthrogryposis,	Type	2	(DA2)	and	3)	lethal	congenital	contracture	syndrome,	type	4	(LCCS4).	In	these	diseases,	patients	experience	the	inability	or	extreme	contractures	of	the	hand	and	feet,	a	congenital	
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deformity	known	as	‘club	foot’	or	‘club	hand’.	Patients	with	DA2	also	exhibit	distinct	contractures	of	craniofacial	muscles.	These	abnormalities	suggest	skeletal	MyBP-C	is	responsible	for	relaxation	of	these	muscles	and	important	in	the	structural	development	of	these	skeletal	muscles.	However,	there	is	a	noticeable	lack	of	skeletal	muscle	deformities	in	other	muscles	in	these	human	patients,	such	as	large	locomotor	muscles	in	the	leg	and	vital	diaphragm	muscles	required	for	breathing.	This	may	indicate	that	MyBP-C	expression	is	more	critical	for	muscles	that	require	fine	motor	skills,	or	these	known	mutations	only	affect	the	molecular	function	of	MyBP-C	that	are	essential	in	the	hands	and	feet.	
8.5	Alternative	molecular	mechanisms			 As	previously	suggested,	MyBP-C	may	also	act	as	a	viscous	load	(Palmer	et	al.,	2011;	A.	Weith	et	al.,	2012;	A.	E.	Weith	et	al.,	2012)	to	put	a	brake	on	contraction	during	the	later	stages	of	contraction	(Previs	et	al.,	2012).	MyBP-C	N-termini	binding	to	actin	may	act	as	a	drag	on	actin	(Walcott	et	al.,	2015)	or	form	a	so-called	“C-bridge,”	in	which	MyBP-C	binding	to	actin	creates	a	second	thick-thin	filament	interaction,	though	the	latter	mechanism	may	be	more	pronounced	had	full-length	MyBP-C	been	used.	Whether	MyBP-C	enhances	cross-bridge	duration,	viscous	load,	or	actin	drag,	unloaded	shortening	data	suggests	relaxation	kinetics	can	be	influenced	as	a	result.	Further	complicating	matters,	other	assays	have	suggested	changes	in	functional	effects	by	MyBP-C	can	be	explained	by	a	tethering	mechanism	in	which	MyBP-C	acts	as	a	load	on	myosin,	limiting	cross-bridge	formation	(Barefield	&	Sadayappan,	2010).	In	support	of	this	mechanism,	high	Ca2+	causes	a	
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	conformational	change	in	cMyBP-C	N-terminal	region	that	may	favor	myosin	interaction	(Previs	et	al.,	2016).	Regardless	of	mechanism,	these	constraints	on	the	sarcomere	at	higher	Ca2+	suggest	a	role	for	MyBP-C	in	limiting	muscle	hypercontractility:	which	is	often	observed	in	HCM,	of	which	cMyBP-C	mutations	are	a	major	cause	(Spudich,	2014).	As	such,	our	experiments	do	not	preclude	MyBP-C	interaction	with	myosin,	or	other	regulatory	effects	on	the	thin	filament	(Walcott	et	al.,	2015).	Indeed,	though	our	mechanistic	studies	features	MyBP-C	interactions	with	actin,	our	data	also	suggests	further	studies	are	required	into	different	MyBP-C	isoforms’	interactions	with	myosin	to	fully	understand	the	function	of	each	MyBP-C	isoform.	More	specifically,	focus	needs	to	be	directed	towards	the	function	of	skeletal	isoforms	of	MyBP-C	where	they	are	predominantly	expressed:	in	skeletal	muscles.	
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CHAPTER	NINE	FSKO	MICE:	FAST-SKELETAL	MYBP-C	KNOCK-OUT	SKELETAL	MUSCLE	DEFICIENCES	OFFSET	ONE	ANOTHER	
9.1	Abstract	FSKO	(fast-skeletal	MyBP-C	knock-out)	mice	are	the	first	mouse	model	designed	to	investigate	the	function	of	fsMyBP-C.	EDL	(extensor	digitorum	longus)	muscle	fibers	from	non-transgenic	(NTG),	heterozygous	(FSKO-HET),	and	homozygous	(FSKO-HOM)	were	selected	for	analysis	by	force-ATPase	assay.	EDL	were	selected	due	to	robust	expression	of	fsMyBP-C	in	NTG	muscles	and	would	therefore	exhibit	the	greatest	alterations	to	molecular	function.	Our	results	demonstrate	that	FSKO	mice	do	not	alter	force	generation	nor	Ca2+-sensitivity	of	force	development.	Stiffness	is	decreased	in	FSKO-HOM	mice,	suggesting	that	the	absence	of	fsMyBP-C	releases	a	load	on	myosin	that	would	facilitate	myosin	binding	to	actin	and	is	therefore	predicted	to	promote	force	production.	In	support	of	this,	the	ATPase	activity	in	FSKO-HOM	mice	is	also	decreased,	suggesting	less	energy	expenditure	is	required	to	form	an	attached	cross-bridge.	However,	rate	of	tension	redevelopment	(ktr)	is	significantly	reduced	in	FSKO-HOM	mice,	which	is	predicted	to	decrease	force	production.	Together,	this	suggests	that	absence	of	fsMyBP-C	results	in	offsetting	deficiencies	in	the	FSKO	mice,	though	the	contribution	of	ssMyBP-C	needs	to	be	considered.	
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9.2	Results	
9.2.1	Expression	profile	in	FSKO	mice	Western	blot	analysis	was	used	to	determine	the	protein	expression	profile	of	NTG,	HET,	and	HOM	FSKO	mice	that	were	5	–	6	months	old.	FSKO	mice	were	generated	by	targeting	exons	2-4,	and	20-22	of	the	MYBPC2	gene.	The	expression	of	fsMyBP-C	and	ssMyBP-C	of	NTG	FSKO	mice	(Figure	31),	which	is	C57BL6	background,	matches	that	of	FVB/N	WT	mice	(Figure	7).	Four	commonly-studied	muscles	were	selected	to	represent	different	types	of	skeletal	muscles:	extensor	digitorum	longus	(EDL),	
flexor	digitorum	brevis	(FDB),	a	slow-type	muscle,	soleus	(SOL),	and	tibialis	anterior	(TA).	The	EDL	and	FDB	are	considered	fast-type	skeletal	muscles,	SOL	is	a	slow-type,	and	TA	is	a	mix	of	fast-	and	slow-type	muscle	fibers.	The	EDL	and	TA	are	on	analogous	to	muscles	on	your	shin,	the	FDB	is	located	on	the	soles	of	your	feet,	and	the	SOL	is	located	beneath	your	calf	muscles.	In	NTG	and	HET	mice,	ssMyBP-C	is	present	in	all	skeletal	muscles	tested	and	fsMyBP-C	is	expressed	only	in	EDL	and	TA.	However,	HOM	mice	demonstrated	a	complete	lack	of	fsMyBP-C	in	all	muscles,	and	ssMyBP-C	expression	levels	are	unchanged	in	response	to	the	lack	of	fsMyBP-C	in	these	studies	(Figure	32).		 	
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Figure	30.	Targeting	 strategy	 for	 FSKO	mice.	 (top)	wild-type	 fsMyBP-C	 gene	(bottom)	 targeted	 fsMyBP-C	 gene.	 Exons	 2-22	 were	 replaced	 with	 a	 neomycin	resistance	gene.		
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Figure	31.	FSKO	mice	lack	fsMyBP-C.	Dual-color	western	blot	was	employed	to	determine	 expression	 profile	 of	 FSKO	 (fast-skeletal	 MyBP-C	 knock-out)	 mice,	which	 are	 of	 C57BL6	 background.	 NTG	 and	 HET	 FSKO	mice	 expression	 profile	reflects	that	of	FVB/N	WT	mice	(Figure	7)	
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Figure	32.	FSKO	mice	do	not	 significantly	alter	 ssMyBP-C	expression.	 (left)	Knock-out	of	fsMyBP-C	does	not	alter	the	expression	of	ssMyBP-C,	as	determined	by	quantification	of	Western	blots.	(right)	fsMyBP-C	is	not	present	in	FSKO-HOM	mice,	though	there	may	be	partial	dysregulation	in	HET	mice.		
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9.2.2	Force	Generation	and	Ca2+-sensitivity	of	force-development	For	comparison	with	previous	steady-state	experiments,	the	force-ATPase	assay	used	was	essentially	the	same	with	some	distinct	changes	to	accommodate	the	skeletal	muscle.	EDL	muscle	fibers	were	prepared	as	previously	described	(Wood,	1978;	Wood,	Zollman,	Reuben,	&	Brandt,	1975).	Briefly,	muscles	were	excised	tendon-to-tendon	and	tied	to	wooden	sticks	with	silk	surgical	suture	such	that	the	muscle	was	taut	to	prevent	damage	during	the	permeabilization/cryopreservation	process.	The	muscle	were	skinned	over	a	period	of	at	least	2	weeks	in	1:1	glycerol/relax	solution	at	-20°C,	after	which	the	fibers	were	mechanically	separated,	t-clipped	and	attached	to	a	force	transducer	and	length	controller.	The	sarcomere	length	of	EDL	fibers	were	set	to	a	slack	length	of	2.5	µm	(Hofmann,	Greaser,	&	Moss,	1991)			 Force-pCa	relationships	demonstrate	no	significant	differences	between	NTG,	HET,	and	HOM	FSKO	mice	(Figure	33).	While	the	result	was	expected	between	NTG	and	HET	mice,	the	lack	of	change	in	FSKO-HOM	mice	was	surprising.	Once	the	force	was	normalized,	there	was	no	observable	shift	in	force-pCa	curves	between	all	groups,	and	quantification	of	the	pCa50	confirmed	there	were	no	changes	in	Ca2+-sensitivity	of	force	development	(data	not	shown).			
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Figure	33.	FSKO	mice	do	not	 exhibit	 changes	 in	 force	 nor	 Ca2+-sensitivity.	Knock-out	of	fsMyBP-C	did	not	significantly	alter	force-pCa	relationship	(left),	nor	relative	force-pCa	relationship	(right).	Graphs	represented	as	mean	±	SEM,	*p<0.05	vs.	NTG,	n=5-6	animals.	
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9.2.3	Stiffness-Force	Relationship	and	ATPase-Force	Myosin	S1	interaction	with	actin	is	a	key	event	in	the	contraction	process,	and	MyBP-C	regulation	of	this	process	is	likely	due	to	either	interaction	with	actin	and/or	myosin.	Therefore,	I	analyzed	parameters	that	would	elucidate	how	fsMyBP-C	regulates	myosin	and	actin	by	analyzing	stiffness	and	ktr,	respectively.	It	should	be	noted	that	these	measurements	are	influenced	by	several	factors.	Stiffness	is	a	measure	of	attached	cross-bridges	and	is	proportional	to	tension.	Stiffness	is	measured	by	applying	rapid,	oscillating	length	changes	and	recording	the	change	in	force	(Δforce/Δlength)	(Ford,	Huxley,	&	Simmons,	1977).	Results	demonstrate	no	changes	in	maximal	stiffness	levels	(Figure	34),	but	when	stiffness	was	normalized	to	force,	FSKO-HOM	mice	demonstrated	significant	decrease	stiffness-force	relationship.	This	suggests	fsMyBP-C	may	place	a	load	on	myosin,	and	this	load	is	released	due	to	the	absence	of	fsMyBP-C	in	FSKO-HOM	mice.			 The	lack	of	inhibitory	activity	of	fsMyBP-C	in	FSKO-HOM	mice	would	predict	increased	force	generation,	but	this	was	not	the	case	(Figure	33).	However,	the	ATPase-force	relationship	of	FSKO-HOM	mice	suggest	that	less	energy	expenditure	is	required	per	unit	of	force	(Figure	35).	Quantification	of	ATPase-force	slopes	determined	tension	cost,	but	only	demonstrates	a	trend	towards	decreased	energy	expenditure	and	is	not	significantly	different.			
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Figure	34.	FSKO	mice	exhibit	reduced	stiffness.	(left)	knock-out	of	fsMyBP-C	did	not	alter	maximal	stiffness	levels.	(right)	However,	reduced	stiffness	per	unit	force	demonstrates	 fewer	 cross-bridges	 are	 required	 to	 generate	 force.	 Graphs	represented	as	mean	±	SEM,	*p<0.05	vs.	NTG,	n=5-6	animals.	
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Figure	35.	FSKO	mice	trend	towards	reduced	ATPase	activity.	(left)	ATPase-force	 relationship	 demonstrates	 the	 energy	 expenditure	 required	 to	 generate	force.	 (right)	 Quantification	 of	 slopes	 of	 the	 ATPase-force	 relationship	 gives	tension	cost,	which	trends	towards	significance,	but	is	not	significantly	different.	Graphs	represented	as	mean	±	SEM,	*p<0.05	vs.	NTG,	n=5-6	animals.	
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9.2.4	Rate	of	Tension	Redevelopment	The	rate	of	tension	redevelopment	(ktr)	is	a	measure	of	thin	filament	activation,	as	previously	described	in	Chapter	Five.	After	the	previous	experiments	were	completed,	ktr	was	analyzed	following	a	rapid	release-restretch	maneuver.	Results	demonstrate	that,	at	high	Ca2+	(pCa	4.5),	FSKO-HOM	mice	have	significantly	decreased	ktr	relative	to	NTG,	but	not	FSKO-HET	(Figure	36).	However,	at	low	Ca2+	(pCa	6),	ktr	is	not	significantly	different	between	all	groups.	First,	this	suggests	fsMyBP-C	also	regulates	thin	filament	activation	in	skeletal	muscles.	Second,	regulation	of	fsMyBP-C	regulation	of	thin	filament	activation	seems	to	limited	to	higher	[Ca2+].	The	lack	of	fsMyBP-C	in	FSKO-HOM	mice	thus	would	partially	diminish	thin	filament	activation	in	the	sarcomere,	and	therefore,	one	would	predict	reduced	force	production	and	this	is	not	the	case	(Figure	33).	Recall	that	stiffness	data	suggest	FSKO	mice	exhibit	reduced	myosin	inhibition,	and	therefore	the	opposing	effects	may	cancel	one	another	out.					
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Figure	36.	FSKO	mice	are	deficient	 in	thin	filament	activation	at	high	Ca2+.	(left)	 FSKO	 mice	 exhibit	 reduced	 ability	 to	 activate	 the	 thin	 filament,	 as	demonstrated	by	reduced	ktr.	(right)	At	submaximal	Ca2+,	there	was	no	difference,	suggesting	fsMyBP-C	regulates	thin	filament	activation	specifically	at	higher	Ca2+	levels	in	striated	muscle.	Graphs	represented	as	mean	±	SEM,	*p<0.05	vs.	NTG,	n=4-6	animals.	
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9.3	Discussion	Collectively,	the	current	data	on	FSKO	mice	demonstrate	two	intriguing	effects	due	to	the	lack	of	fsMyBP-C.	First,	FSKO-HOM	mice	exhibit	decreased	stiffness-force	ratios,	suggesting	that	fsMyBP-C	normally	places	a	load	on	myosin.	One	would	predict	the	release	of	this	inhibitory	load	would	result	in	increased	force,	but	the	data	showed	no	change	in	force	production	(Figure	33).	Second,	FSKO-HOM	mice	have	decreased	ktr,	suggesting	fsMyBP-C	also	activates	the	thin	filament.	Therefore,	the	diminished	activation	capacity	would	thereby	also	result	in	reduced	force	production,	but	again	force	was	unchanged.	At	face	value,	these	data	sets	do	not	make	any	sense	on	their	own.	Together,	these	data	suggest	that	fsMyBP-C	has	dual	effects	on	myosin	and	actin	that	offset	one	another	and	is	therefore	why	no	change	in	force	nor	Ca2+-sensitivity	of	force	development	was	observed.	Moreover,	these	effects	may	be	Ca2+-dependent	and	occur	at	different	stages	of	contraction.	For	example,	inhibition	of	myosin	by	fsMyBP-C	may	occur	during	relaxation,	while	activation	of	actin	thin	filament	may	occur	during	contraction.	The	ktr	data	certainly	suggest	that	fsMyBP-C	activation	capacity	occurs	at	higher	[Ca2+]	and	is	congruent	with	previous	data	in	the	cardiac	muscle	system	that	suggested	fsMyBP-C	operates	at	higher,	but	not	lower	[Ca2+]	(Figures	17).	However,	this	range	is	shifted	towards	maximal	[Ca2+].			 One	noticeable	observation	from	the	ATPase-force	relationship	is	that	FSKO-HOM	mice	trends	towards	a	decrease	in	ATPase	activity,	but	the	quantification	of	
		
126	the	ATPase-force	slopes	to	determine	tension	cost	is	not	significantly	different.	This	brings	up	an	important	stipulation	regarding	the	muscle	fibers	used.	Closer	inspection	revealed	the	possibility	of	distinct	subpopulations	within	the	data	set.	In	other	words,	the	fibers	in	the	EDL	fiber	bundles	may	have	consisted	of	distinct	types	of	fibers	(Augusto,	2004).	When	manually	dissecting	the	fibers	under	the	scope,	one	can	not	accurately	distinguish	the	difference	between	fiber	types,	and	thus	the	EDL	fiber	bundles	used	were	of	unknown	composition.	In	combination	with	the	presence	of	ssMyBP-C,	the	unknown	percentage	of	fast-	vs.	slow-type	fibers	may	contribute	to	the	relatively	muted	effects	observed	in	the	functional	assays.	Therefore,	to	fully	elucidate	fsMyBP-C	function,	other	studies	must	be	disseminated	to	piece	together	a	comprehensive	functional	story.			 Intriguingly,	there	is	one	recent	study	that	also	focused	on	fsMyBP-C,	though	in	a	zebrafish	model	(M.	Li	et	al.,	2016).	In	this	study,	morpholino	antisense	nucleotides	were	used	to	knockdown	approximately	50%	of	fsMyBP-C,	variant	2B.	Despite	vastly	different	methodologies,	this	study	is	worth	discussing,	because	it	is	currently	the	only	study	that	focuses	on	fsMyBP-C.	Their	results	demonstrated	structural	abnormalities,	such	as	shorter	sarcomere	lengths,	a	well	as	functional	changes,	such	as	increased	maximal	shortening	velocity	and	decreased	active	force.	The	latter	functional	effect	reflects	our	own	data	suggesting	fsMyBP-C	places	a	load	on	myosin.	The	removal	of	this	load	would	thereby	also	promote	shortening	velocity	in	both	FSKO	mice	and	the	zebrafish	morphants.	However,	limitations	must	be	
		
127	considered	when	comparing	these	very	different	studies.	One	significant	difference	between	the	FSKO	mice	and	zebrafish	was	how	drastic	the	difference	in	deficiencies	observed.	In	the	zebrafish	study,	just	50%	knockdown	of	fsMyBP-C,	variant	2B	resulted	in	gross	morphological	shrinkage,	contractile	changes	in	shortening	velocity,	as	well	as	elevated	apoptosis	and	protein-degradation	factors.	In	the	FSKO	mice	I	studied,	there	is	absolutely	no	fsMyBP-C	present,	though	the	functional	changes	were	mild	by	comparison.	The	difference	in	species	may	explain	this	dichotomy.	First,	fsMyBP-C	variant	2B	is	the	dominant	isoform	in	zebrafish,	with	some	fsMyBP-C	variant	2A,	and	very	little	ssMyBP-C.	Conversely,	in	mice,	ssMyBP-C	is	by	far	the	predominant	MyBP-C	isoform,	being	expressed	in	all	skeletal	muscles	and	fsMyBP-C	is	only	expressed	in	mixed-type	muscles.	Therefore,	we	would	expect	a	stronger	phenotype	in	a	ssMyBP-C	knock-out	mouse	model	rather	than	the	current	fsMyBP-C	knock-out	mice.	Second,	there	are	several	known	splice	variants	of	ssMyBP-C	in	mammals	and	only	one	fsMyBP-C	isoform	(Ackermann,	Kerr,	et	al.,	2015;	Ackermann	&	Kontrogianni-Konstantopoulos,	2011b,	2013).	In	contrast,	the	opposite	is	true	in	zebrafish:	there	are	two	fsMyBP-C	variants	and	only	one	ssMyBP-C	variant.	Third,	cMyBP-C	is	present	in	zebrafish	skeletal	muscle	during	development(Chen	et	al.,	2013;	Cheng	et	al.,	2013),	but	cMyBP-C	is	not	present	at	all	in	mouse	skeletal	muscle	during	at	any	time	(Gautel	et	al.,	1998;	B.	Lin	et	al.,	2013).	The	last	limitation	that	I	will	discuss	is	that	while	their	structural	assays	demonstrate	that	sarcomere	length	is	diminished	after	fsMyBP-C	knockdown	(M.	Li	et	al.,	2016),	their	active	force	measurements	to	not	normalize	to	the	lower	
		
128	sarcomere	length.	Therefore,	the	higher	force	production	observed	in	controls	may	simply	be	due	to	changes	in	length	(de	Tombe	et	al.,	2010).			 These	limitations	are	not	meant	to	diminish	the	results	from	the	zebrafish	study.	On	the	contrary,	these	simply	illustrate	the	need	for	more	in	depth	investigation	into	the	function	of	fsMyBP-C.	Clearly,	deficiency	in	MyBP-C	can	directly	affect	structure	and	function.	This	becomes	particularly	vital	as	mutations	in	the	skeletal	MyBP-C	isoforms	are	discovered	as	the	cause	for	skeletal	myopathies.	(Bayram	et	al.,	2016;	Gurnett	et	al.,	2010;	X.	Li	et	al.,	2015).			 	
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CHAPTER	TEN	FUTURE	DIRECTIONS	
Abstract	There	are	many	avenues	of	research	to	pursue	in	the	relative	short-term	to	elucidate	more	about	the	MyBP-C	family	of	proteins.	Even	within	the	research	specific	to	cMyBP-C,	much	has	yet	to	be	determined.	It	is	very	exciting	to	think	about	the	numerous	and	intriguing	avenues	of	research	that	can	be	conducted	in	the	near	future.		
Recombinant	Proteins	with	phosphomimetic	sites	and	PKA	challenge	It	is	well	known	that	cMyBP-C	has	several	phosphorylation	sites	that	alter	its	regulation	of	actin	and	myosin	(Barefield	&	Sadayappan,	2010;	Sadayappan	&	de	Tombe,	2012),	and	studies	are	always	being	conducted	on	the	mechanism	of	cMyBP-C	phosphorylation	(Colson	et	al.,	2016;	Previs	et	al.,	2016).	However,	there	is	little	known	about	how	skeletal	MyBP-C	isoforms	are	phosphorylated.	ssMyBP-C	has	several	known	phosphorylation	sites	(Ackermann	&	Kontrogianni-Konstantopoulos,	2011a),	and	circumstantial	evidence	suggests	fsMyBP-C	also	has	phosphorylation	sites(Ackermann,	Ward,	et	al.,	2015),	which	will	have	to	be	clearly	identified	using	mass	spectrometry.	Isoproterenol	challenge	to	intact	cells	or	incubation	of	PKA	in	permeabilized	fiber	studies	would	be	able	initially	highlight	how	skeletal	MyBP-C	phosphorylation	modulates	their	regulation.	To	more	clearly	delineate	how	skeletal	
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MyBP-C	phosphorylation	sites	alter	regulation	of	function,	phosphomimetic	and	phosphoablated	recombinant	proteins	can	be	utilized	to	determine	how	they	affect	interactions	with	actin	and	myosin,	as	well	as	function	in	a	variety	of	single	myocyte	and	fiber	bundle	assays.	Future	studies	could	also	incorporate	partial	phosphomimetic/phosphoablated	sites	to	determine	hierarchy	of	regulation	of	these	sites.	Finally,	transgenic	models	expressing	phosphomimetic	or	phosphoablated	MyBP-C	may	be	necessary	to	demonstrate	a	physiological	consequence	of	skeletal	MyBP-C	PTM.			
Sufficiency	of	N-terminal	domains	(e.g.	C0-P/A-C1-C2)	Studies	have	painstakingly	demonstrated	which	domains	of	cMyBP-C	are	required	for	regulation	of	function	(Bezold,	Shaffer,	Khosa,	Hoye,	&	Harris,	2013;	Colson	et	al.,	2012;	Herron	et	al.,	2006;	Kensler,	Shaffer,	&	Harris,	2011;	Razumova	et	al.,	2008).	Presumably,	skeletal	MyBP-C	functional	domains	are	similar,	but	there	are	distinct	structural	differences	between	MyBP-C	isoforms.	Determination	of	analogous	or	distinct	binding	and	functional	regulation	may	yield	greater	insights	into	MyBP-C	function.	Just	within	the	context	of	the	FSKO	mice,	determining	whether	the	addition	of	recombinant	fsC1C2	is	sufficient	to	recover	changes	in	function	would	be	an	important	first	step	and	relatively	simple	experiment,	given	the	materials	and	baseline	data	are	already	there.	Incubation	with	various	lengths	of	MyBP-C	N-termini	in	skeletal	fibers	or	adenoviral-mediated	expression	in	skeletal	muscles	may	further	yield	interesting	functional	regulation,	though	the	latter	
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strategy	is	difficult	given	the	resistance	of	adult	skeletal	muscle	fibers	to	adenoviral	infection	due	to	downregulation	of	adenoviral	receptors.		
What	does	the	C0	domain	do?		One	of	the	most	stark	differences	between	cMyBP-C	and	its	skeletal	counterparts	is	the	presence	of	an	additional	C0	domain	on	cMyBP-C:	an	N-terminal	sequence	of	approximately	100	amino	acids	(Harris,	Belknap,	Van	Sciver,	White,	&	Galkin,	2016;	Ratti	et	al.,	2011).	The	function	of	this	distinct	structure	in	cMyBP-C	is	still	debated	in	the	literature(Herron	et	al.,	2006).	One	possible	experiment	is	to	create	a	recombinant	skeletal	MyBP-C	protein	with	the	C0	domain	artificially	added	to	the	N-terminus	to	investigate	whether	this	would	render	skeletal	MyBP-C	binding	and	function	more	similar	to	that	of	cMyBP-C.	In	the	same	vane,	the	C0	domain	can	be	specifically	removed	and	used	to	demonstrate	whether	this	would	render	cMyBP-C	more	similar	in	binding	and	function	to	that	of	skeletal	MyBP-C.	Removal	of	the	C0	domain	has	previously	been	investigated,	but	not	specifically	conducted	to	differentiate	functional	regulation	between	skeletal	and	cardiac	MyBP-C.		
MyBP-C,	the	Myosin	Mesa,	and	the	Super-Relaxed	State	Recently,	research	has	demonstrated	specific	interactions	of	myosin	head	and	MyBP-C(Spudich,	2015),	whose	formation	entails	unknown	consequences.	The	proposed	interaction	site	between	a	flat	region	of	the	myosin	S1	region	and	the	M-motif	of	cMyBP-C	suggests	charged	residues	are	responsible	for	regulating	their	interaction.	This	interaction	may	very	well	be	one	mechanism	that	stabilizes	the	myosin	head	in	the	relaxed	state	(Woodhead	et	al.,	2005),	as	well	as	the	super-
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relaxed	state(McNamara	et	al.,	2016).	The	physiological	implication	of	this	are	completely	unknown.		
MyBP-C,	Actin,	and	the	‘C-bridge’	Myosin	S1	interaction	with	actin	forms	a	cross-bridge	that	is	central	to	the	sliding	filament	theory	of	sarcomeric	contraction(Spudich,	2001).	However,	MyBP-C	activation	of	the	thin	filament	via	binding	to	actin	(Mun	et	al.,	2014)	(Figure	23)	would	indicate	the	presence	of	a	second	thick-to-thin	filament	interaction,	which	is	colloquially	known	as	the	‘C-bridge.’	The	C-bridge	would	presumably	not	contribute	to	active	force	production	directly,	but	its	formation	could	affect	passive	tension	and	stiffness.	Therefore,	to	elucidate	the	potential	presence	or	impact	of	such	a	C-bridge,	one	could	simply	study	function	in	the	presence	of	a	myosin	inhibitor,	such	as	BDM	or	blebbistatin.		
ssMyBP-C	splice	variants	One	factor	of	complication	regarding	ssMyBP-C	are	the	numerous	splice	variants	known,	which	result	ssMyBP-C	that	have	unique	N-terminal	regions	and	C-terminal	regions	(Ackermann,	Kerr,	et	al.,	2015;	Ackermann	&	Kontrogianni-Konstantopoulos,	2011b).	While	in	mouse,	only	two	variants	have	been	identified,	the	possibility	of	specific	roles	and	differential	expression	of	ssMyBP-C	variants	may	drastically	alter	known	function	of	ssMyBP-C.	Whether	ssMyBP-C	variations	result	in	subtle	changes	in	regulation	or	have	completely	different	regulation	is	unknown,	and	may	further	elucidate	why	we	express	multiple	isoforms	of	MyBP-C.	
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in	vivo	function	The	biophysical	assays	of	FSKO	mice	in	the	present	study	sheds	light	on	the	mechanics	at	the	fiber	level.	However,	experiments	are	necessary	to	determine	whether	fsMyBP-C	is	necessary	in	vivo,	such	as	treadmill	function,	grip	strength,	voluntary	wheel	run,	gait/locomotion	analysis.	More	specific	analysis	can	be	done	on	anesthetized	FSKO	mice	by	analyzing	torque	injury,	fatigability,	and	nerve-evoked	muscle	function.	There	are	two	possible	scenarios	that	I	predict,	both	of	which	are	opposite	one	another:	first,	given	the	mild	changes	in	fiber	studies,	the	in	
vivo	studies	may	demonstrate	only	subtle	changes	in	function.	This	would	require	challenging	the	animal	with	stressors,	such	as	forced	exercise.	Second,	the	opposite	may	occur,	where	in	vivo	function	is	severely	diminished.	The	expression	profile	of	fsMyBP-C	demonstrates	its	presence	in	mixed	skeletal	muscles,	such	as	the	EDL	and	TA	(Figure	7,30),	as	well	as	gastrocnemius	and	quadriceps	(data	not	shown).	These	latter	muscles	suggest	fsMyBP-C	regulates	function	of	very	large	muscle	groups	and	therefore,	FSKO	mice	would	exhibit	significant	in	vivo	functional	deficits.		
SSKO	mice	Concurrently	with	the	development	of	the	FSKO	mice,	SSKO	mice	(slow-skeletal	MyBP-C	knock-out)	are	now	available	for	study.	SSKO	mice	are	not	to	be	confused	with	liver-specific	squalene	synthase	knock-out	mice,	L-SSKO	(Nagashima	et	al.,	2015).	In	contrast,	the	SSKO	mice	exhibit	higher	rates	of	early	death	relative	to	the	FSKO	mice	(data	not	shown),	suggesting	a	greater	necessity	for	ssMyBP-C	which	
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is	expressed	in	all	muscle	types.	The	unique	advantage	of	using	SSKO	mice	is	that	the	targeting	strategy	removes	all	variants	of	ssMyBP-C,	both	known	and	unknown.	Therefore,	the	functional	data	from	this	mouse	model	would	define	the	collective	function	of	ssMyBP-C.		
DSKO	mice	as	the	baseline	Crossing	SSKO	mice	with	FSKO	mice	yields	the	DSKO	mice	(double-skeletal	MyBP-C	knock-out),	which	would	lack	both	skeletal	MyBP-C	isoforms.	This	is	the	baseline	that	should	be	used	to	compare	both	SSKO	and	FSKO	mice.	In	FSKO	mice,	ssMyBP-C	present	and	therefore,	FSKO	mice	actually	demonstrates	the	contribution	of	ssMyBP-C	to	function.	Conversely,	SSKO	mice	still	express	fsMyBP-C,	and	therefore	SSKO	mice	would	actually	demonstrate	the	contribution	of	fsMyBP-C	to	function.	Thus,	comparison	to	a	DSKO	mouse	model	will	provide	a	much	clearer	understanding	of	skeletal	MyBP-C.		
Length-Dependent	Activation		The	mechanism	behind	length-dependent	activation	(LDA)	is	still	erroneously	taught	in	medical	texts	as	due	to	optimal	overlap	of	thick-	and	thin-	filaments(Berne,	Koeppen,	&	Stanton,	2010).	However,	studies	have	demonstrated	the	precise	mechanism	may	lie	within	cellular	and	myofilament	properties	(Allen	&	Kentish,	1985;	Kentish,	ter	Keurs,	Ricciardi,	Bucx,	&	Noble,	1986;	Kobayashi,	Jin,	&	de	Tombe,	2008;	Konhilas,	Irving,	&	de	Tombe,	2002a;	Kumar	et	al.,	2015;	ter	Keurs,	Rijnsburger,	van	Heuningen,	&	Nagelsmit,	1980),	rather	than	purely	structural	explanations	(Farman,	Walker,	de	Tombe,	&	Irving,	2006).	More	recently,	cMyBP-C	
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has	been	demonstrated	to	specifically	regulate	length-dependency	(Kumar	et	al.,	2015;	Mamidi,	Gresham,	&	Stelzer,	2014;	Mamidi	et	al.,	2016;	Witayavanitkul	et	al.,	2014).	It	should	be	noted	that	LDA	effects	are	relatively	muted	in	skeletal	muscle	systems	(Konhilas,	Irving,	&	de	Tombe,	2002b;	Konhilas	et	al.,	2003).	In	these	studies,	the	partial	replacement	with	the	ssTnI	significantly	blunted	LDA,	suggesting	isoform-specific	and	muscle-specific	regulation	of	contraction.	However,	other	studies	have	demonstrated	that	fast-skeletal	muscles	and	cardiac	muscles	exhibit	more	length-dependent	effects	than	slow-skeletal(Konhilas	et	al.,	2002b).	This	correlates	with	the	present	data	that	demonstrates	fsC1C2	and	C0C2	have	similar	function	at	higher	[Ca2+].	Therefore,	I	hypothesize	fsMyBP-C	has	a	greater	contribution	to	LDA	relative	to	ssMyBP-C	in	cardiac	and	skeletal	muscles.	The	experiments	presented	in	this	study	can	be	replicated	at	both	low	(2.0	µm)	and	high	(2.3	µm)	sarcomere	lengths	to	determine	whether	the	MyBP-C	N-termini	could	regulate	LDA	and	whether	to	the	same	degree.	This	was	not	pursued	due	to	purely	experimental	reasons:	the	fragility	of	the	papillary	fibers	and	the	time-consuming	nature	of	the	experiment	precluded	additional	experiments	at	high	SL.	Switching	to	trabeculae	or	skeletal	muscle	fibers,	which	are	more	stable,	may	allow	us	to	conduct	serial	measurements	of	the	same	fiber	at	low	and	high	SL.	Furthermore,	narrowing	the	focus	to	just	ssMyBP-C	or	fsMyBP-C	would	also	free	up	time	in	a	day	in	which	to	do	experiments.		
Removing	the	effects	of	endogenous	MyBP-C			 Because	the	experiments	used	WT	rats	as	the	baseline	model	system,	the	
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presence	of	endogenous	cMyBP-C	in	our	studies	complicates	interpretation	of	the	results.	The	alternative	is	to	use	papillary	muscles	from	one	of	two	cMyBP-C	knock-out	mouse	models	that	originated	from	the	Moss	and	Seidman	group	(Harris	et	al.,	2002;	McConnell	et	al.,	1999),	and	continue	pursuing	experiments	involving	the	FSKO,	SSKO,	and	DSKO	mice.	Our	objective	was	to	determine	the	baseline	physiological	function	of	MyBP-C	N-termini,	and	thus	we	did	not	pursue	using	these	knock-out	models	as	the	baseline	model	several	reasons.	First,	both	the	Moss	and	Seidman	mouse	models	exhibit	cardiac	disease	phenotype,	specifically	HCM	and	DCM,	respectively.	The	contribution	of	fibrosis	alone	could	mask	several	parameters	that	we	measured.	Second,	the	mouse	model	presents	particular	challenges.	Mouse	papillary	muscles	are	smaller	and	would	not	have	yielded	as	many	usable	fibers	as	rat	papillary	muscles.	Given	the	context	of	our	study	with	four	experimental	groups,	there	would	have	been	very	slim	margin	of	error	for	the	trimming	of	papillary	muscles.	In	addition,	mouse	ventricular	myocytes	are	also	not	nearly	as	robust	as	rat	ventricular	myocytes.	As	such,	our	culture	experiments	would	have	required	additional	time	and	expertise,	with	comparatively	little	payoff.	Rat	and	mouse	cardiomyocyte	culture	experiments	were	pursued	side-by-side,	and	our	mouse	cardiomyocyte	experiments	were	much	less	fruitful.	Finally,	the	SSKO	and	FSKO	mice	are	simply	so	new	that	we	do	not	know	whether	the	absence	of	either	ssMyBP-C	nor	fsMyBP-C	cause	changes	in	morphology	or	exhibit	a	disease	phenotype	that	may	complicate	function.	All	of	these	together	indicated	a	simpler	system	using	WT	animals	for	our	initial	experiments.	That	is	not	to	say	that	these	experiments	are	not	
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worth	pursuing.	On	the	contrary,	they	would	be	very	informative	on	two	fronts.	They	would	validate	whether	the	functional	results	we	observed	in	WT	systems	were	accurate	and	not	obfuscated	by	endogenous	MyBP-C.	Moreover,	these	experiments	would	be	interesting	in	whether	N-termini	are	sufficient	to	rescue	function	in	disease	states.		 	
		 138	
CHAPTER	ELEVEN	FINAL	THOUGHTS	Based	on	my	data,	ssMyBP-C	and	fsMyBP-C	regulation	of	contraction	is	limited	to	low	and	high	ranges	of	Ca2+,	respectively,	while	cMyBP-C	regulation	extends	over	the	full	spectrum	of	Ca2+.	This	interpretation	is	supported	by	the	role	of	cardiac	versus	skeletal	muscles:	the	cardiac	sarcomere	is	exposed	to	a	wide	and	dynamic	range	of	Ca2+	on	a	beat-to-beat	basis.	Conversely,	skeletal	muscles	are	not	contracting	and	relaxing	every	second	and	therefore	not	exposed	to	the	same	range	of	Ca2+	with	the	same	frequency.	Various	skeletal	muscles	also	have	different	purposes:	postural	muscles	have	different	roles	than	locomotor	muscles.	Therefore,	skeletal	muscles	can	fine-tune	the	role	of	specific	muscles	by	expressing	different	amounts	of	slow-	and	fast-skeletal	MyBP-C	to	accommodate	the	role	of	specific	skeletal	muscles.	cMyBP-C	has	been	demonstrated	to	be	highly	tunable	via	post-translational	modification	(Colson	et	al.,	2012;	Colson	et	al.,	2016;	Jia,	Shaffer,	Harris,	&	Leary,	2010),	and	such	modifications	can	potentially	act	on	actin	and	myosin	at	different	contractile	stages	as	either	facilitator,	inhibitor,	or	both.	Such	modifications	to	each	MyBP-C	isoform	structure	and	function	deserve	further	studies,	particularly	in	light	of	the	vast	amount	of	information	that	can	be	elucidated	from	the	study	of	multiple	isoforms	together.	The	convergence	of	steady-state	and	dynamic	experiments	in	the	present	study,	as	well	in	vitro	and	in	silico	methods	all	suggest	MyBP-C	isoforms	are	distinctive	in	their	regulation	of	muscle	contraction.	
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CHAPTER	TWELVE	MATERIALS	AND	METHODS	
Expression	and	Purification	of	Recombinant	MyBP-C	proteins	
Recombinant	proteins	representing	the	N-terminal	domains	up	to	the	C2	domain	of	slow-skeletal,	fast-skeletal,	and	cardiac	(ssC1C2,	fsC1C2,	and	C0C2,	respectively)	were	generated,	purified,	and	analyzed	with	SDS-PAGE(Govindan	et	al.,	2012)	(Figure	10).	Each	MyBP-C	isoform	was	expressed	using	a	pET28	Expression	system	(Millipore	70777)	in	E.	coli,	and	included	an	N-terminal	His-tag	consisting	of	six	histidine	residues.	Protein	expression	in	BL21	was	induced	by	IPTG	and	purified	through	a	nickel-nitrilotriacetic	acid	affinity	column	in	which	eluted	fractions	were	combined	and	dialyzed	in	PBS.	Recombinant	proteins	were	used	in	all	following	steady-state	biophysical	studies	to	determine	the	functional	differences	between	the	slow-skeletal,	fast-skeletal,	and	cardiac	isoforms	of	MyBP-C.	Details	regarding	the	transcript	and	amino	acid	sequence	of	N-terminal	peptides	can	be	found	in	Table	1.	Recombinant	proteins	were	quantified	and	the	volume	required	for	the	final	desired	concentration	was	calculated.	Proteins	were	then	aliquoted,	lyophilized,	and	stored	at	-80°C	until	ready	for	use	in	fiber	experiments.	
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Papillary	Muscle	Fiber	Bundle	Preparation	
		 Male	Sprague-Dawley	rats	(250g)	(Harlan)	were	euthanized	using	Beuthanasia	in	accordance	to	Institutional	Animal	Care	and	Use	Committee	protocol	at	Loyola	University	Chicago.	The	whole	heart	of	the	rat	was	rapidly	excised	underwent	retrograde	perfusion	with	Krebs-Henseleit	Buffer	(KHB)	via	proximal	aorta.	The	heart	was	cut	to	carefully	expose	the	papillary	muscles	in	the	left	ventricle.	Papillary	muscles	were	carefully	excised	under	a	dissecting	scope	(Zeiss	Discover.V8	Stereo,	PlanAPO	S	0.63x	FWD	81mm)	and	permeabilized	overnight	in	1%	Triton	X-100	(Sigma)	in	mounting	relaxing	solution	(6.3	mM	ATP,	6.48	mM	Mg	Cl2,	10mM	EGTA,	10	mM	Na2CrP,	49.76	mM	Kprop,	100	mM	BES,	pH	7)	at	4°C,	removing	cell	membrane	and	membrane-bound	proteins.	After	overnight	permeabilization,	papillary	muscles	were	further	trimmed	into	fiber	bundles	approximately	1	mm	in	length	under	the	dissecting	microscope	(Figure	11).	Straight	and	parallel	fiber	bundles	were	selected	based	on	uniformity	and	attached	at	each	end	with	aluminum	t-clips.	Images	were	taken	under	the	dissecting	scope	using	an	attached	digital	camera	(Canon	EOS	Rebel	T3i).	Each	fiber	bundle	was	gently	cleansed	by	transferring	between	a	series	of	4	washes	containing	fresh	relaxing	solution	on	ice	and	used	within	12	hours.	The	t-clipped	fibers	were	attached	to	a	force	transducer	(BAM21-LC;	World	Precision	Instruments,	Sarasota,	FL)	and	high	speed	length	controller	(Aurora	Scientific,	Inc.).	Muscle	dimensions	(cross-sectional	area,	length,	and	volume)	were	determined	using	an	ocular	micrometer	mounted	in	the	dissection	microscope	(resolution,	~10	μm).	These	
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muscle	dimensions	were	used	to	normalize	contractile	force,	sarcomere	length	(SL)	and	ATPase	activity.	SL	was	measured	in	passive	relaxed	condition	by	laser	diffraction	as	previously	described(de	Tombe	&	ter	Keurs,	1990),	adjusted	to	and	maintained	at	2μm.	Briefly,	a	helium-neon	laser	beam	was	directed	through	the	isolated	muscle	fiber	bundle,	in	which	muscle	striation	pattern	diffract	the	laser	beam	into	a	diffraction	pattern.	The	striations	of	the	muscle	fiber	bundle	act	as	a	grating,	with	known	angles	of	diffraction,	and	the	projected	pattern	can	therefore	be	used	to	measure	average	SL.		
Skeletal	Muscle	Fiber	Preparation	
		 Skeletal	muscles	were	permeabilized	as	previously	described	(Wood	et	al.,	1975).	Extensor	digitorum	longus	(EDL)	and	soleus	(SOL)	muscles	were	excised	from	the	legs	of	FSKO	mice.	Care	was	taken	to	limit	the	damage	to	the	muscle	fibers	by	cutting	at	the	tendons,	followed	by	submergence	in	4°C	relax	solution	(67.93	mM	KOH,	6.24mM	ATP,	10mM	EGTA,	10mM	Na2CrP,	47.58	Kprop,	100	mM	BES,	6.54	mM	MgCl2,	pH	7).	Fiber	muscles	were	attached	to	short	sticks	by	tying	surgical	sutures	around	the	muscle	tendons,	under	a	dissecting	scope	(Zeiss	Discover.V8	Stereo,	PlanAPO	S	0.63x	FWD	81mm).	These	‘muscles-on-a-stick’	were	then	submerged	in	1:1	glycerol/relax	solution	in	a	5	mL	conical	tube	and	stored	at	-20°C	for	at	least	two	weeks	prior	to	use	in	functional	assays.	The	purpose	was	two-fold:	1)	to	ensure	optimal	permeabilization	and	2)	to	cryoprotect	the	muscle	fibers	for	long-term	storage.	After	at	least	two	weeks,	fibers	were	taken	out	and	split	into	smaller	fiber	bundles	of	approximately	1	mm	in	length	and	t-clipped.	Images	were	taken	under	
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the	dissecting	scope	using	an	attached	digital	camera	(Canon	EOS	Rebel	T3i).	Each	fiber	bundle	was	gently	cleansed	by	transferring	between	a	series	of	4	washes	containing	fresh	relaxing	solution	on	ice	and	used	within	12	hours.	The	t-clipped	fibers	were	attached	to	a	force	transducer	(BAM21-LC;	World	Precision	Instruments,	Sarasota,	FL)	and	high	speed	length	controller	(Aurora	Scientific,	Inc.).	Muscle	dimensions	(cross-sectional	area,	length,	and	volume)	were	determined	using	an	ocular	micrometer	mounted	in	the	dissection	microscope	(resolution,	~10	μm).	These	muscle	dimensions	were	used	to	normalize	contractile	force,	sarcomere	length	(SL)	and	ATPase	activity.	SL	was	measured	in	passive	relaxed	condition	by	laser	diffraction	as	previously	described(de	Tombe	&	ter	Keurs,	1990),	adjusted	to	and	maintained	at	2.5μm.	Briefly,	a	helium-neon	laser	beam	was	directed	through	the	isolated	muscle	fiber	bundle,	in	which	muscle	striation	pattern	diffract	the	laser	beam	into	a	diffraction	pattern.	The	striations	of	the	muscle	fiber	bundle	act	as	a	grating,	with	known	angles	of	diffraction,	and	the	projected	pattern	can	therefore	be	used	to	measure	average	SL.	
Incubating	with	MyBP-C	N-termini	
		 The	permeabilized	fibers	were	incubated	with	10	μM	of	the	ssC1C2,	fsC1C2,	and	C0C2	recombinant	proteins	or	unincubated	for	3	minutes	in	relaxing	solution,	followed	by	3	min	in	preactivating	solution,	before	measuring	force	in	activating	solution	(Witayavanitkul	et	al.,	2014).	Activating	solution	contained	20	mM	Ca2+-EGTA,	1.55	mM	potassium	propionate,	6.59	mM	MgCl2,	100	mM	N,N-bis	(2-hydroxyethyl)	taurine;	N,N-Bis-(2-hydroxyethyl)-2-aminoethanesulfonic	acid,	5	mM	
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sodium	azide,	1	mM	DTT,	10	mM	phosphoenolpyruvate,	0.01	mM	oligomycin,	0.1	mM	PMSF,	and	0.02	mM	A2P5,	and	a	commercial	protease	inhibitor	cocktail	(Sigma).	Relaxing	solution	was	the	same	as	activating	solution,	but	contained	n20	mM	EGTA,	21.2	mM	potassium	propionate,	7.11	mM	MgCl2,	and	no	calcium.	Preactivating	solution	was	the	same	as	the	activating	solution,	but	contained	0.5	mM	EGTA,	19.5	mM	1,6-diaminohexane-N,N,N,N’-tetraacetic	acid,	21.8	mM	potassium	propionate,	and	no	calcium.	All	solutions	contained	0.5	mg/ml	pyruvate	kinase	and	0.05	mg/ml	lactate	dehydrogenase	(Sigma)	and	had	an	ionic	strength	of	180	mM,	5	mM	free	ATP,	and	1	mM	free	magnesium.	Recombinant	proteins	were	present	in	relaxing	and	preactivation	solutions	for	subsequent	measurements.	Activation	solution	did	not	have	recombinant	proteins	present	to	avoid	potential	complications	with	changes	in	Ca2+	levels.		Isometric	tension	and	ATPase	activity	were	measured	at	various	levels	of	Ca2+	activation	as	previously	described(de	Tombe	&	Stienen,	1995;	Rundell,	Manaves,	Martin,	&	de	Tombe,	2005).	Briefly,	the	isolated	muscle	was	exposed	to	a	range	of	calcium	solutions	obtained	by	proportional	mixing	of	activating	and	relaxing	solutions.	The	force	generated	and	ATP	consumed	were	measured	simultaneously	during	the	contraction.		
Force-pCa,	Force-ATPase,	and	rate	of	tension	redevelopment	
		 Force-pCa	relationship	was	determined	by	titrating	the	activation	and	relaxing	solutions(Witayavanitkul	et	al.,	2014).	Maximal	isometric	tension	was	measured	at	100%	activation	solution,	followed	by	sequential	washes	in	relaxing	and	preactivating	solutions	for	5	minutes	each.	However,	subsequent	measurements	
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of	isometric	tension	occurred	in	solutions	titrated	with	decreasing	ratio	of	activation-to-relaxation	solutions:	95%,	90%,	85%,	80%,	70%,	and	0%	activation	solution,	which	corresponded	to	pCa	values	of	approximately	4.50,	5.11,	5.42,	5.61,	5.77,	6.00,	and	10.00,	respectively,	as	determined	by	the	Fabiato	program	(van	der	Velden,	Moorman,	&	Stienen,	1998).	The	integrity	of	the	fibers	was	tested	afterwards	by	measuring	maximal	tension	after	the	experiment.	Any	fibers	that	did	not	maintain	80%	or	greater	maximal	tension	were	excluded	from	analysis.	Force-ATPase	relationship	was	determined	using	an	optical	absorbance	enzyme	assay(Guth	&	Wojciechowski,	1986).	Briefly,	ATP	consumption	was	determined	by	measuring	the	absorbance	of	UV	light	at	wavelength	340	nm.	ATP	hydrolyses	into	ADP	and	inorganic	phosphate	inside	the	fiber,	which	is	stoichiometrically	coupled	to	the	oxidation	of	NADH	to	NAD+.	This	oxidization	reaction	is	catalyzed	by	pyruvate	kinase	and	lactate	dehydrogenase	in	our	activating	solutions.	NADH,	but	not	NAD+,	absorbs	light	specifically	at	340	nm.	A	series	of	50	nl	of	10	mM	ADP	were	injected	into	the	measuring	chamber.	Each	injection	of	ADP	induced	a	rapid	reduction	in	fluorescence	and	allowed	the	calculation	of	the	rate	of	ATP	consumption,	determined	by	measuring	the	fluorescent	decay	rate	at	340	nm.	After	completion	of	the	Force-ATPase	assay,	papillary	muscles	underwent	a	rapid	release-restretch	maneuver	in	order	to	break	previously	formed	cross-bridges	and	allow	cross-bridges	to	reform.	The	rate	constant	of	tension	redevelopment	(ktr)	was	then	measured	at	maximal	activation,	as	previously	described(Rundell	et	al.,	2005;	Swartz	&	Moss,	1992).	Force-pCa	and	Force-ATPase	relationships	were	fitted	with	a	
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modified	Hill	equation(Chandra	et	al.,	2001;	Rundell	et	al.,	2005;	Sumandea	et	al.,	2003).	Stiffness	and	tension	costs	were	fitted	linearly	to	the	Force-stiffness	and	Force-ATPase	data,	respectively.	(Figure	14,15,33,34)	Stiffness	is	a	measure	of	attached	cross-bridges	and	is	proportional	to	tension.	Stiffness	is	measured	by	applying	rapid,	oscillating	length	changes	and	recording	the	change	in	force	(Δforce/Δlength)	(Ford	et	al.,	1977).	
Actin	cosedimentation	
		 Assay	cosedimentation	was	conducted	on	recombinant	MyBP-C	proteins,	as	previously	described(Kuster	et	al.,	2015;	Shaffer	et	al.,	2009).	Increasing	concentrations	of	ssC1C2,	fsC1C2,	and	C0C2	(1	–	30	µM)	was	added	to	5µM	F-actin	(Cytoskeleton	AFK99A)	in	cosedimentation	buffer	that	contained	1mM	ATP	and	DTT.	Reactions	were	allowed	to	equilibrate	for	30	minutes	at	room	temperature.	Samples	were	spun	in	an	ultracentrifuge	(Beckman)	for	30	minutes,	100,000	RPM,	using	a	TLA	100	rotor	at	4oC.	Supernatants	were	removed	and	pellets	gently	washed	with	cosedimentation	buffer,	followed	by	an	additional	spin.	Samples	were	then	dissolved	in	a	1:1	cosedimentation/urea	buffer	for	5	minutes	at	room	temperature.	4x	Laemmli	buffer	was	added	to	the	samples	and	run	on	a	10%	SDS-PAGE	gel.	Along	with	the	sample	preparations,	standard	curves	were	run	along	side,	consisting	of	increasing	amounts	of	MyBP-C	N-termini	(4-40	pmol)	and	F-actin	(40	pmol)	for	a	molar	ratio	of	0.10,	0.20,	0.35,	0.50,	0.65,	0.80,	1.00	(Figure	20).	Gels	were	stained	with	coomassie	blue	R-250	solution	(0.05%	in	25%	isopropanol,	10%	acetic	acid)	and	imaged	using	ChemiDoc	imager	(Bio-Rad).	Densitometry	analysis	of	sample	
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bands	was	conducted	with	ImageJ	(NIH)	and	the	intensity	ratio	of	MyBP-C	to	F-actin	was	converted	to	a	molar	ratio	using	the	standard	curve.	Cosedimentation	sample	curves	were	fit	to	a	one-site,	specific	binding	nonlinear	regression.	Combined	ssC1C2,	fsC1C2,	and	C0C2	cosedimentation	curves	were	generated	(Figure	21).	Bmax	and	Kd	values	were	obtained	from	this	fit	and	given	in	Table	4.		
Computational	modeling	
		 We	used	an	adapted	version	of	computational	model	that	had	been	previously	demonstrated	to	predict	changes	in	unloaded	shortening	of	individual	cardiomyocytes(Campbell	et	al.,	2013).	The	Online	Muscle	Simulation	(OMS)	was	made	available	online:	http://onlinemusclesim.org/	and	the	myofilament	model	accounts	for	length-dependent	activation	and	strain-dependent	XB	kinetics(Razumova,	Bukatina,	&	Campbell,	1999;	Rice,	Wang,	Bers,	&	de	Tombe,	2008),	but	not	the	contribution	of	MyBP-C.	Since	our	goal	is	to	model	unloaded	shortening,	in	which	individual	cardiomyocytes	are	isolated,	components	accounting	for	force(Rice	et	al.,	2008;	Sheikh	et	al.,	2012)	were	set	to	zero.	Computer	modelling	accounts	for	results	suggesting	differential	MyBP-C	capacities	on	thin	filament	activation,	as	defined	as	kon,	or	the	rate	of	tropomyosin	shift	from	blocked	to	closed	position	(see	Table	6).	All	other	parameters	were	unchanged	to	limit	variability	in	our	data	and	specifically	determine	whether	thin	filament	activation	accounted	for	changes	in	relaxation	kinetics.		
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Isolation	of	adult	rat	cardiomyocytes	
		 Cardiomyocytes	from	adult	Sprague-Dawley	rats	(250g)	were	isolated	as	previously	described	(33).	After	isolation,	cardiomyocytes	were	gradually	switched	into	plating	media,	which	contained	HMEM	supplemented	with	100U/mL	penicillin/streptomycin	(pen/strep),	10%	fetal	bovine	serum,	and	10mM	BDM.	For	functional	measurements,	cardiomyocytes	were	plated	on	laminin-coated	25mm	coverslips.	For	protein	analysis,	cells	were	directly	plated	onto	laminin-coated	35mm	circular	dishes.	After	1-hour	incubation,	plating	media	was	removed,	and	culture	media	was	added.	Culture	media	consisted	of	HMEM,	supplemented	with	0.1%	BSA,	100UmL	pen/strep,	2mM	glucose,	10mM	BDM,	and	5ug/mL	insulin/transferrin/selenium	(ITS)	supplement.	Cells	were	kept	in	a	2%	CO2	incubator	to	maintain	a	pH	of	7.0	and	maintained	for	48	hours.	
Adenovirus	Infection	and	Cell	Culture	
		 Commercially	purchased	slow	and	fast	skeletal	MyBP-C	clones	from	Origene	(NM_175418.3	and	NM_004533,	Rockville,	MD)	were	used	to	construct	the	adenoviruses	used	to	overexpress	skeletal	isoforms	of	MyBP-C.	Cardiac	MyBP-C	adenoviral	vectors	were	generated	by	the	core	facilities	at	Loyola	University	Chicago.	Adenoviral	constructs	were	created	by	cotransfection	of	MyBP-C	cDNA	into	DH5α	E.	coli.	Adenoviruses	containing	slow,	fast,	or	cardiac	MyBP-C	included	a	CMV	promoter	and	c-Myc	tag	to	distinguish	between	endogenous	and	adenovirus-mediated	MyBP-C	protein	expression.	Uninfected	cells	and	c-Myc-tagged	cMyBP-C	overexpressing	cells	were	used	as	experimental	controls	Adenoviral	constructs	
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overexpressing	slow,	fast,	and	cardiac	MyBP-C	(Multiplicity	of	Infection	MOI:	1000)	were	added	to	the	culture	media	1	hour	after	incubation	and	allowed	to	infect	cardiomyocytes	for	24	hours.	Culture	media	was	changed	after	24	hours,	removing	the	adenovirus	and	waste,	and	replenishing	nutrients	in	the	media.	
Immunofluorescence	Imaging	
		 Cultured	adult	rat	cardiomyocytes	were	plated	in	chamber	slides	(Lab-Tek	II,	Thermo	Scientific)	for	immunofluorescence	imaging.	After	48	hours	in	culture,	cells	were	rinsed	twice	with	PBS	and	fixed	with	cold	(4°C)	4%	paraformaldehyde	for	3	minutes,	followed	by	1	minute	in	ice	cold	(-20°C)	methanol.	Cells	were	then	permeabilized	in	0.5%	Triton	X-100	in	PBS	(20	minutes),	0.1%	Triton	X-100	twice	(10	minutes),	and	antigen-retrieval	solution	(0.1M	glycine,	pH	7.4)	(30	minutes),	and	rinsed	three	times	with	PBS.	Cells	were	blocked	with	0.1%	BSA,	0.1%	gelatin,	0.1%	tween-20,	0.0001%NaN3,	and	incubated	with	primary	antibodies	for	ssMyBP-C	(ProSci	6679),	fsMyBP-C	(ProSci	5651),	and	rabbit	c-Myc	(1:500	Roche)	and	mouse	α-actinin	(1:500	Sigma)	overnight.	After	rinsing	with	PBS,	corresponding	secondary	antibodies	(AlexaFluor	rabbit	488	at	1:50	dilution	and	mouse	568	at	1:50	dilution)	were	added	for	1	hour	at	room	temperature,	rinsed,	coverslipped	with	VectaShield	mounting	medium	(Vector	Labs	H-1500	10mUL	1.5ug/mL)	for	imaging	with	confocal	microscopy.	Images	were	taken	using	a	Leica	TCS	SP5	and	processed	using	ImageJ	(NIH).	
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Western	blot	analyses	
		 Detection	of	endogenous	and	de	novo	MyBP-C	protein	in	cardiomyocytes	was	determined	by	immunoblotting.	Adenovirus	infected	cardiomyocytes	were	rinsed	with	sterile	PBS	to	remove	culture	media,	followed	by	the	addition	of	60uL	of	urea	buffer.	Cardiomyocytes	were	scraped	off	using	a	cell	lifter	(Fisher	Scientific)	and	pipetted	into	0.6mL	tubes.	25uL	of	4x	loading	dye	(0.4%	bromophenol	blue,	10%	ß-mercaptoethanol)	was	then	added.	Samples	were	heated	at	100°C	for	5	minutes,	separated	by	gel	electrophoresis	in	10%	SDS-PAGE	gels,	and	blotted	onto	nitrocellulose	membrane	at	300	mA	for	3	hours.	Detection	of	protein	was	determined	by	using	antibodies	for	c-Myc,	ssMyBP-C,	fsMyBP-C,	and	cMyBP-C	(Sigma	C3956,	ProSci	6679,	ProSci	5651,	Santa	Cruz	sc-137180,	respectively)(B.	Lin	et	al.,	2013)	(Figure	26).	Quantification	of	replacement	levels	was	determined	by	densitometry	analysis	normalized	to	ß-actin	loading	controls,	using	ImageJ	(NIH).	Replacement	levels	were	calculated	by	signal	of	cMyc/(cMyc	+	cMyBP-C),	as	previously	described(Metzger,	Michele,	Rust,	Borton,	&	Westfall,	2003).	
Unloaded	shortening	in	cultured	adult	rat	ventricular	cardiomyocytes	
		 After	48	hours	in	culture,	HMEM	media	was	incrementally	replaced	with	Tyrode’s	solution	(135	mM	NaCl,	4	mM	KCl,	1	mM	CaCl2,	1	mM	MgCl2,	10	mM	d-glucose,	10	mM	HEPES)	to	limit	damage	to	the	cells.	Coverslips	with	attached	cardiomyocytes	were	transferred	to	a	custom	stimulation	chamber	containing	platinum	electrodes.	The	chamber	was	then	fitted	onto	a	Nikon	microscope	stage	and	stimulated	(2.0	ms	pulse,	1	Hz,	and	20V).	Sarcomere	length	and	SL	shortening	
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were	measured	by	a	video-based	detection	system	(Ionoptix,	Milton,	MA).	Analysis	of	contractile	function	was	determined	from	an	average	of	10	contractions	of	individual	cardiomyocytes,	with	10-20	cardiomyocytes	measured	per	coverslip	preparation.		
Determination	of	fsMyBP-C	expression	in	heart	failure	samples	
		 Surgical	procedures	for	TAC	(transverse	aortic	constriction)	and	sham	FVB/N	mice	were	performed(Verma	et	al.,	2012),	and	TAC	mice	developing	pressure-overload	hypertrophy.	The	transverse	aorta	was	constricted	by	7-0	silk	suture,	with	a	blunt	27	GA	needle	to	standardize	the	size	of	constriction.	After	12	weeks,	RNA	from	hearts	of	TAC	and	sham	mice	(n=3	per	group)	were	isolated	and	purified	to	make	cDNA	using	the	iScript	cDNA	synthesis	kit	(BioRad	1708891).	cDNA	libraries	were	generated,	sequenced,	and	aligned(Christodoulou,	Gorham,	Herman,	&	Seidman,	2011).		Number	of	reads	aligned	were	normalized	per	million.	Significant	changes	in	gene	expression	was	determined	as	≥	1.5-fold	increase	for	upregulation	and	≤	0.6	fold	decrease	for	downregulation,	using	the	Benjamini-Hochberg	false	discovery	rate	test	at	p	<	0.001.	Validation	of	RNA-Seq	data	was	determined	by	analysis	of	mRNA	levels	using	qPCR.	Samples	for	qPCR	used	TaqMan	primers	against	MYBPC2	with	GAPDH	as	a	reference	gene	(Applied	Biosystems	Mm00525419m1	and	Mm00486742m1,	respectively).	The	qPCR	analysis	was	performed	on	a	thermocycler	(BioRad	CFX96)	with	the	following	protocol:	10	minutes	at	94oC,	40	cycles	of	15	seconds	at	94°C	and	60	seconds	at	60°C.	Analysis	of	normalized	gene	expression	was	then	computed	with	an	amplification	efficiency	
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corrected	ΔΔCq	equation(Pfaffl,	2001).	(see	Figure	5)	
Statistical	Analysis		
		 Data	were	analyzed	using	Benjamini-Hochberg	False	Discovery-Rate	Test(Reiner,	Yekutieli,	&	Benjamini,	2003).	For	this	test,	a	fold	change	0.6	fold	down	or	1.5	fold	up,	and	p	<	0.001	was	considered	significant.	TPA	experiments	were	analyzed	using	an	unpaired	t–test.	All	other	data	are	presented	as	means	±	SEM,	unless	otherwise	indicated.	Statistical	significance	for	all	other	experiments	were	set	at	p<0.05.		
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